



Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of
Epidemiology and Population Health

Medicine - Gastroenterology & Hepatology

CLINICAL OFFICE (PRIMARY)

- **Stanford Gastroenterology and Digestive Health Clinic**

420 Broadway St

Pav D 2nd Fl Pod 2 and 3

Redwood City, CA 94063

Tel (650) 498-7999 Fax (650) 724-9454

Bio

BIO

Dr. Nguyen is Professor of Medicine, a Stanford Cancer Institute member and specializes in the treatment and prevention of primary liver cancer such as hepatocellular carcinoma (HCC).

Dr. Nguyen is also a Professor of Epidemiology and Population Health by courtesy at Stanford. Her clinical and research focus has been liver cancer for the past 20+ years. She is a frequent lecturer for the management and prevention of liver cancer for care providers and researchers at national and international conferences. She has published several key research papers to inform clinicians of the care and treatment of patients with liver cancer.

Dr. Nguyen's clinical and research focus also include patients with cirrhosis, viral hepatitis, nonalcoholic fatty liver disease (NAFLD/NASH). Her goal is to promote early detection of liver tumors and to prevent and treat complications from chronic liver diseases and liver cancer. She has extensive experience in performing clinical trials on liver cancer, fatty liver, cirrhosis, and viral hepatitis. She has lead several multi-center US and international studies.

Dr. Nguyen is clinically active, seeing patients three full days a week, with a large and comprehensive practice of general liver, liver cancer, and transplant patients at Stanford University Medical Center, as well as weekly outreach clinics in the San Jose area.

Dr. Nguyen has served as Director of the Hepatology Fellowship Program in the Division of Gastroenterology and Hepatology and the Liver Transplant Program . Currently, she is Director of the Hepatology Clerkship, a member of Stanford Bio-X, and Stanford Population Science, a member of the Appointments and Promotions Committee and a Diversity LENS Advocate for the Department of Medicine, assisting in the promotion of equity and diversity in the professoriate search process.

Dr. Nguyen has mentored over 150 trainees of diverse racial, ethnic, and economic backgrounds and levels of training. Her research lab includes trainees who are high school students, undergraduate students, medical students, graduate students in the Master's in Epidemiology or Public Health, PhD students in Epidemiology, clinical interns and residents, clinical gastroenterology and hepatology fellows, postdoctoral research fellows, early and mid-career faculty, and international visiting scholars. She has also served as Pre-Major Academic Advisor for the undergraduate school. Her mentees are from Stanford as well as other institutions in the US and overseas.

Dr. Nguyen is a Fellow of the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA), and a member of the American College of Gastroenterology (ACG), the European Association for the Study of Liver Diseases (EASL), and the Asia Pacific Association for the Study of Liver (APASL). She is also currently the President of the International Association for the Study of Liver Diseases (IASL).

Dr. Nguyen is active in national and international professional society service and community outreach efforts locally, including service as an executive board of director for nonprofit organizations. She is very active in AASLD, having served as Chair of the Hepatitis B Special Interest Group and in the Education and Hepatology Associate Committees, as member of the Steering Committee for the Hepatobiliary Neoplasia and Hepatitis B Special Interest Group, and as a member of the Practice Guideline Committee. She is a member of the Research Award Panel for the AGA, and a member of the Practice Management Committee for the ACG.

Dr. Nguyen has served in the editorial and advisory boards for several journals, including Gastroenterology, Hepatology, Lancet GI Hepatology, and as ad hoc reviewer for over thirty scientific journals including JAMA, AIM and the Lancet Group.

CLINICAL FOCUS

- Liver cancer and tumors
- Hepatocellular Carcinoma
- Cirrhosis
- Non-alcoholic fatty liver disease
- Chronic hepatitis B and C
- Hepatology and Liver Transplantation
- End-stage liver disease
- Evaluation of abnormal liver tests
- Community Outreach
- Liver tumors
- Transplant Hepatology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Gastroenterology & Hepatology
- Professor - University Medical Line (By courtesy), Epidemiology and Population Health
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Vice Chair, Professoriate Appointments and Promotions Committee (DoM A&P Committee), Department of Medicine, Stanford, (2025-2027)
- Academic Editor, PLOS Medicine, (2024- present)
- Member, Advisory Task Force SIG, American Association for the Study of Liver Disease (AASLD), (2023-2025)
- President, International Association for the Study of Liver Diseases (IASL), (2023-2025)
- Steering Committee, HBV Special Interest Group, American Association for the Study of Liver Disease (AASLD), (2023-2025)
- Steering Committee, Hepatobiliary Neoplasia Special Interest Group, American Association for the Study of Liver Disease (AASLD), (2023-2025)
- Chair, Abstract Review Committee, Liver and Biliary Carcinoma (Treatment, Diagnosis, Nat Hx), Digestive Disease Week (American Gastroenterological Association), (2022- present)
- Associate Editor, Portal Hypertension & Cirrhosis, (2022-2024)
- Faculty Search Diversity Advisor, Department of Medicine, Stanford University, (2019- present)
- Governing Council and Treasurer, International Association for the Study of Liver Diseases (IASL), (2019- present)
- Clinical Practice Guideline Committee, AASLD, (2019-2022)
- Practice Management Committee, American College of Gastroenterology (ACG), (2019-2022)
- Research Award Panel, American Gastroenterological Association (AGA), (2019-2021)
- Chair, Hepatitis B SIG, American Association for the Study of Liver Disease (AASLD), (2019-2020)
- Chair, Global Outreach Subcommittee, Hepatitis B Special Interest Group, American Association for the Study of Liver Disease (AASLD), (2018-present)
- International Advisory Board, Lancet Gastroenterology and Hepatology, (2018- present)
- Professoriate Appointments and Promotions Committee (DoM A&P Committee), Department of Medicine, Stanford University, (2018- present)
- International Editorial Board, Alimentary Pharmacology and Therapeutics, (2018-2023)
- Vice-Chair, Hepatitis B SIG, American Association for the Study of Liver Disease (AASLD), (2018-2019)
- Editorial Board, Hepatology, (2017-2019)
- CIGH Faculty Fellow, Center for Innovation in Global Health (CIGH), Stanford University, (2015- present)
- Steering Committee, HBV Special Interest Group, American Association for the Study of Liver Diseases (AASLD), (2015- present)
- Director of Hepatology Fellowship, <http://med.stanford.edu/gastrohepfellows/>, Stanford University Medical Center, (2014-2023)
- Steering Committee, Hepatobiliary Neoplasia Special Interest Group, American Association for the Study of Liver Diseases (AASLD), (2014-2016)
- Director of Hepatology Clerkship, Stanford University School of Medicine, (2013- present)
- Executive Board of Director, Asian Health Foundation, (2013- present)
- Medical Advisory Board, American Liver Foundation, (2013- present)
- Committee Chair, Abstract Review for Chronic Hepatitis B, American Association for the Study of Liver Diseases (AASLD), (2013-2019)
- Education Committee, American Association for the Study of Liver Diseases (AASLD), (2013-2016)
- Hepatology Associates Committee , MD Liaison, American Association for the Study of Liver Diseases (AASLD), (2013-2016)
- Liver Section Editor, Journal of Clinical Gastroenterology, (2013-2016)
- Editorial Board, Gastroenterology, (2011-2023)
- Abstract review member for the Hepatitis B : Epidemiology/Prevention/Control review group, American Association for the Study of Liver Diseases (AASLD), (2011-2016)
- Editorial Board, Digestive Diseases and Sciences, (2008- present)
- Director of Continuing Medical Education, Pacific Health Foundation, (2005-2012)
- Director of Clinical Research, Pacific Health Foundation, (2004-2010)

- Training and Workforce Committee, Member, American Association for the Study of Liver Diseases (AASLD), (2002-2004)

HONORS AND AWARDS

- The Professor Mindie H. Nguyen Award for Excellent Clinical Research by Young Investigators, American Asso for the Study of Liver Diseases, www.aasldfoundation.org/named-travel-awards (2020-current)
- Senior Fellow at the Center for Innovation in Global Health, Center for Innovation in Global Helath, Stanford University, Stanford, CA (2015 Oct)
- Stanford Asian American Faculty Awards, The Asian American Activities Center, Stanford University, Stanford, CA (2015 May)
- 2015 Stanford Teaching Award for GI Fellows, Department of Medicine, Stanford University Medical Center, Palo Alto, CA (2015 Dec)
- Pacific Free Clinic Physician Service Award, Cardinal Free Clinics, Stanford University School of Medicine (2013 April)
- The Franklin Edbaugh Advising Award for Faculty, Stanford University School of Medicine (2013 May)
- Chief Fellow in Gastroenterology and Hepatology, Stanford University Medical Center (2002)
- Advanced Hepatology Research Fellow Award, American Association for the Study of Liver Diseases (2001)
- Chief Resident, University of California, San Diego Medical Center (1996)
- Excellence in Teaching Award for Medical Students, University of California, San Diego, School of Medicine (1996)
- Magna Cum Laude, University of California, Irvine (1988)
- Phi Beta Kappa, University of California, Irvine (1985)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- See Administrative Appointment Section above, See above (2013 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Division of Gastroenterology and Hepatology (2002) CA
- Board Certification: Gastroenterology, American Board of Internal Medicine (2020)
- Residency: UCSD Internal Medicine Residency (1995) CA
- Medical Education: University of California San Diego School of Medicine (1992) CA
- Board Certification, American Board of Internal Medicine , Gastroenterology (2018)
- Board Certification: Transplant Hepatology, American Board of Internal Medicine (2010)
- B.S., University of California, Irvine , Biological Sciences (1988)
- M.D., Univ. of California, San Diego , Medicine (1992)
- M.A.S., Univ. of Calif., San Francisco , Masters of Advanced Studies in Clinical Research (2004)

COMMUNITY AND INTERNATIONAL WORK

- Governing Council
- Board of Directors
- Board of Directors
- Scientific Chair, Myanmar Liver Symposium 2018, Yangon
- Scientific Chair, Health Needs Assessment and Liver Symposium, Yangon
- Scientific Chair, Viral Hepatitis and Liver Cancer 2015: Mongolia National Training Workshop
- Linkage to care, epidmiology of hepatitis B, hepatitis C, and/or liver cancer in Asia Pacific region, Mainland China, South Korea, Taiwan, Hong Kong, Japan, New Zealand, Myanmar
- Pacific Free Clinic
- Outreach Liver Clinics, San Jose and San Francisco, San Jose, 231 O'Connor Drive and 200 Jose Figueres Avenue; San Francisco and Daly city
- Epidemiology and treatment outcomes of Asian patients with chronic hepatitis B and C, San Jose, CA and Dallas, Texas

- Colon cancer screening in Asian Americans, San Jose
- Updates in Hepatology, Vietnam

LINKS

- Nguyen Lab: <http://med.stanford.edu/nguyenlab.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

1. Clinical trials in fatty liver (NASH/NAFLD), liver cancer (HCC), hepatitis B and hepatitis C.
2. Epidemiology and population health of people with liver cancer, fatty liver, hepatitis B, hepatitis C, and liver cirrhosis.
3. Real-world studies of liver cancer, fatty liver, hepatitis B, hepatitis C, liver cirrhosis, and liver transplant.
4. Health disparities - sex differences, socioeconomic factors, and race/ethnicity-related issues
5. Translational studies of liver cancer, hepatitis B, and fatty liver.
6. Global health: medical education, public health, and research. Areas with current/prior work/collaboration: Spain, Romania, United Kingdom, Germany, Italy, Argentina, Brazil, Japan, Australia, New Zealand, Mainland China, Taiwan, Hong Kong, South Korea, Mongolia, Myanmar, Thailand, and Singapore.
7. Large databases used in prior published works: U.S. National Health and Nutrition Examination Survey (NHANES), Optum, Truven, Surveillance Epidemiology and End Results (SEER), UK Biobank, American Census Bureau, National Death Index (NDI), National Vital Statistic System (NVSS) from the CDC WONDER platform, National Inpatient Sample Database (NIS), United Network for Organ Sharing (UNOS), California inpatient database from the Office of Statewide Health Planning and Development (OSPHD), Taiwan National Health Insurance Research Database (NHIRD), Japan Medical Data Vision Database, Korea Health Insurance Review & Assessment Service Database (HIRA).

For more information, please contact my lab at 650-498-6084.

CLINICAL TRIALS

- ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk, Recruiting
- A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response, Not Recruiting
- Clinical Trial Multi-analyte Blood Test, Not Recruiting
- Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6, Not Recruiting
- Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α -2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B, Not Recruiting
- Epidemiologic Study of Hepatocellular Carcinoma in the US, Not Recruiting
- Gilead Sustained Virologic Response (SVR) Registry, Not Recruiting
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection, Not Recruiting
- GS-US-320-0110, Not Recruiting
- GS-US-367-1168, Not Recruiting
- GS-US-367-1169, Not Recruiting
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders, Not Recruiting
- MIRNA Study, Not Recruiting
- Phase II CaseControl Glycotest HCC Panel vs AFP in Detection of EarlyStage Hepatocellular Carcinoma, Not Recruiting
- Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy, Not Recruiting

- Risk Factors and Molecular Genomics of U.S. Patients with Chronic Liver Disease & Hepatocellular CA, Not Recruiting
- Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects, Not Recruiting
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV, Not Recruiting
- Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection, Not Recruiting
- Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia, Not Recruiting
- Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005), Not Recruiting
- Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen, Not Recruiting
- Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C, Not Recruiting
- Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF), Not Recruiting
- Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1, Not Specified

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Hong Fan, Xianhua Mao

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Epidemiology (Masters Program)
- Epidemiology (Phd Program)
- Gastroenterology & Hepatology (Fellowship Program)

Publications

PUBLICATIONS

- **A Multi-Analyte cfDNA-based Blood Test for Early Detection of Hepatocellular Carcinoma.** *Journal of hepatology*
Taggart, D. J., Mahajan, S., Gallant, M. A., Pinkoviezky, I., Xu, J., Sorg, A. J., Roberts, C. C., Slinkov, D., Gorospe, E. C., Mubarak, A., Bhandari, B. R., Freilich, B., Gunn, et al
2026
- **GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.** *Hepatology (Baltimore, Md.)*
Mao, X., Fan, H., Yuen, M. F., Cheung, R., Seto, W. K., Nguyen, M. H.
2026
- **Gestational diabetes and subsequent risk of type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in a commercially insured U.S. Pregnancy cohort.** *Diabetes research and clinical practice*
Liu, L., Velasquez, E. E., Ananth, C. V., Nadeau, K. C., Bondy, M. L., Nguyen, M. H., Williams, M. A.
2026: 113240
- **Differential Mortality Risk by Age in Males and Females With Steatotic Liver Disease.** *MedComm*
Yan, T., Chien, N., Nguyen, V. H., Le, I., Gudapati, S. T., Chau, A., Zhang, X., Barnett, S., Linden, S., Henry, L., Cheung, R., Nguyen, M. H.
2026; 7 (4): e70677
- **Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study.** *The American journal of gastroenterology*
Li, J., Liu, J. K., Chau, A., Linden, S., Tsai, P. C., Nozaki, A., Vutien, P., Uojima, H., Toyoda, H., Honda, T., Trinh, H., Abe, H., Ishikawa, et al
2025

- **Technical systematic review supporting 2025 AASLD Practice Guidelines on management of chronic hepatitis B.** *Hepatology (Baltimore, Md.)*
Pan, C. Q., Saadi, S., Ghany, M. G., Feld, J. J., Lim, J. K., Kim, A. Y., Tang, A. S., Nguyen, M. H., Sulkowski, M. S., Terrault, N. A., Lok, A. S., Hegazi, M., Hasan, et al
2025
- **AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B.** *Hepatology (Baltimore, Md.)*
Ghany, M. G., Pan, C. Q., Lok, A. S., Feld, J. J., Lim, J. K., Wang, S. H., Kim, A. Y., Tang, A. S., Nguyen, M. H., Naggie, S., Sulkowski, M. S., Rodriguez-Baez, N., Chen, et al
2025
- **Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study.** *Journal of the National Cancer Institute*
Mao, X., Zhang, X., Henry, L., Cheung, K. S., Yuen, M. F., Cheung, R., Seto, W. K., Nguyen, M. H.
2025
- **MASLD may influence female-specific cancer risk indirectly through shared metabolic pathways rather than direct causation - author's reply.** *Metabolism: clinical and experimental*
Zhang, X., Nguyen, M. H.
2025: 156350
- **Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis.** *JAMA network open*
Shi, Y., Zhang, X., Wong, T., Yan, T., Henry, L., Cheung, R., Nguyen, M. H.
2025; 8 (7): e2523674
- **Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis.** *Hepatology (Baltimore, Md.)*
Li, J., Xu, L., Rui, F., Tran, S., Tsai, P. C., Tan, Y., Toyoda, H., Zeng, Q. L., Trinh, H., Hsu, Y. C., Watanabe, T., Abe, H., Motoyama, et al
2025
- **Differential HCC risk among HBV indeterminate types at baseline and by phase transition.** *Gut*
Huang, R., Trinh, H. N., Yasuda, S., Chau, A., Maeda, M., Do, A. T., Huang, D. Q., Ito, T., Honda, T., Ishigami, M., Kozuka, R., Preda, C. M., Tseng, et al
2025
- **Projected Trends in Metabolic Dysfunction-Associated Steatotic Liver Disease Mortality Through 2040.** *JAMA network open*
Zhang, X., Linden, S., Levesley, C. R., He, X., Yang, Z., Barnet, S. D., Cheung, R., Ji, F., Nguyen, M. H.
2025; 8 (6): e2516367
- **Global Burden of Chronic Liver Disease and Temporal Trends: A Population-Based Analysis From 1990 to 2021 With Projections to 2050.** *Liver international : official journal of the International Association for the Study of the Liver*
Zhao, Y., Bo, Y., Zu, J., Xing, Z., Yang, Z., Zhang, Y., Deng, Y., Liu, Y., Zhang, L., Yuan, X., Wang, Y., Henry, L., Ji, et al
2025; 45 (6): e70155
- **Superior Diagnostic Efficacy of N-Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients.** *MedComm*
Chen, Q., Zheng, M. H., Zhu, L., Rui, F., Ni, W., Xiong, Y., Hu, X., Issa, R., Zhu, Y., Jia, L., Barnett, S., Yin, S., Zhu, et al
2025; 6 (6): e70236
- **Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study.** *Alimentary pharmacology & therapeutics*
Huang, R., Do, A. T., Toyoda, H., Li, J., Yasuda, S., Tsai, P. C., Yeh, M. L., Trinh, H., Chau, A., Huang, D. Q., Ogawa, E., Ito, T., Kozuka, et al
2025
- **GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study.** *Clinical and molecular hepatology*
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M. F., Cheung, R., Seto, W. K., Nguyen, M. H.
2025
- **Enhanced long-term outcomes with laparoscopic bariatric surgery in patients with severe obesity and metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study** *HEPATOBIILIARY SURGERY AND NUTRITION*

- Zhang, X., Rouillard, N., Mao, X., Lat, R., Cheung, R., Sasaki, K., Nguyen, M. H.
2025
- **Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment.** *Clinical and molecular hepatology*
Huang, R., Jun, D. W., Toyoda, H., Hsu, Y. C., Trinh, H., Nozaki, A., Ishikawa, T., Watanabe, T., Uojima, H., Huang, D. Q., Honda, T., Tanaka, Y., Vutien, et al
2025
 - **Metabolic dysfunction-associated steatotic liver disease: A sexually dimorphic disease and breast and gynecological cancer.** *Metabolism: clinical and experimental*
Zhang, X., Nguyen, M. H.
2025: 156190
 - **The Diagnosis and Staging of Hepatocellular Carcinoma: A Review of Current Practices.** *Clinics in liver disease*
Vutien, P., Kim, N. J., Nguyen, M. H.
2025; 29 (1): 33-48
 - **AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.** *Gastroenterology*
Ali, F. S., Nguyen, M. H., Hernaez, R., Huang, D. Q., Wilder, J., Piscocoy, A., Simon, T. G., Falck-Ytter, Y.
2025; 168 (2): 267-284
 - **Sex Differences in Adverse Liver and Nonliver Outcomes in Steatotic Liver Disease.** *JAMA network open*
Yan, T., Zhang, X., Wong, T., Cheung, R., Nguyen, M. H.
2024; 7 (12): e2448946
 - **Bariatric Surgery Reduced Long-Term Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis.** *Clinical and molecular hepatology*
Rouillard, N. A., Barnett, S. D., Zhang, X., Kam, L., Manikat, R., Cheung, R., Nguyen, M. H.
2024
 - **Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.** *JAMA network open*
Qiu, S., Cai, J., Yang, Z., He, X., Xing, Z., Zu, J., Xie, E., Henry, L., Chong, C. R., John, E. M., Cheung, R., Ji, F., Nguyen, et al
2024; 7 (11): e2445525
 - **A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis.** *Gastroenterology*
Marsh, T. L., Parikh, N. D., Roberts, L. R., Schwartz, M. E., Nguyen, M. H., Befeler, A., Page-Lester, S., Tayob, N., Srivastava, S., Rinaudo, J. A., Singal, A. G., Reddy, K. R., Marrero, et al
2024
 - **Global epidemiology, natural history, maternal-to-child transmission, and treatment of pregnant women with hepatitis C: a systematic review and meta-analysis of 311,905,738 women**
Quek, J., Loo, J., Lim, E., Chung, A., Bin Othman, A., Tan, J., Barnett, S., Nguyen, M. H., Wong, Y.
WILEY.2024: 81
 - **Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.** *Gut*
Mao, X., Zhang, X., Kam, L., Chien, N., Lai, R., Cheung, K. S., Yuen, M. F., Cheung, R., Seto, W. K., Nguyen, M. H.
2024
 - **Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.** *Journal of hepatology*
Kudaravalli, S., Huang, D. Q., Yeh, M., Trinh, L., Tsai, P. C., Hsu, Y., Kam, L. Y., Nguyen, V. H., Ogawa, E., Lee, D. H., Ito, T., Watanabe, T., Enomoto, et al
2024; 81 (1): 33-41
 - **MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.** *Hepatology international*
Chan, W. K., Wong, V. W., Adams, L. A., Nguyen, M. H.
2024
 - **Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021.** *Alimentary pharmacology & therapeutics*

- Tran, S., Zou, B., Lee, K., Kam, L., Yeo, Y., Henry, L., Cheung, R., Nguyen, M. H.
2024
- **Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.** *Hepatology (Baltimore, Md.)*
Hassan, M. M., Li, D., Han, Y., Byun, J., Hatia, R. I., Long, E., Choi, J., Kelley, R. K., Cleary, S. P., Lok, A. S., Bracci, P., Permuth, J. B., Bucur, et al
2024
 - **Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis.** *Clinical and molecular hepatology*
Le, M. H., Le, D. M., Baez, T. C., Dang, H., Nguyen, V. H., Lee, K., Stave, C. D., Ito, T., Wu, Y., Yeo, Y. H., Ji, F., Cheung, R., Nguyen, et al
2024
 - **Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Huang, D. Q., Hoang, J. K., Kamal, R., Tsai, P. C., Toyoda, H., Yeh, M. L., Yasuda, S., Leong, J., Maeda, M., Huang, C. F., Won Jun, D., Ishigami, M., Tanaka, et al
2024: JCO2300757
 - **Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.** *Hepatology international*
Huang, D. Q., Tran, S., Barnett, S., Zou, B., Yeo, Y. H., Cheung, R., Nguyen, M. H.
2023
 - **Updates in Characteristics and Survival Rates of Hepatocellular Carcinoma in a Nationwide Cohort of Real-World US Patients, 2003-2021.** *Journal of hepatocellular carcinoma*
Tran, S., Zou, B., Kam, L., Lee, K., Huang, D. Q., Henry, L., Cheung, R., Nguyen, M. H.
2023; 10: 2147-2158
 - **Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.** *Alimentary pharmacology & therapeutics*
Kam, L. Y., Yeo, Y. H., Ji, F., Henry, L., Cheung, R., Nguyen, M. H.
2023
 - **Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.** *Nature reviews. Gastroenterology & hepatology*
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., Loomba, R.
2023
 - **Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.** *JAMA network open*
Park, H., Yoon, E. L., Ito, T., Jo, A. J., Kim, M., Lee, J., Kim, H. L., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, H., Ishigami, M., Yu, et al
2023; 6 (8): e2329568
 - **Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.** *Hepatology (Baltimore, Md.)*
Huang, D. Q., Tran, A., Yeh, M., Yasuda, S., Tsai, P., Huang, C., Dai, C. Y., Ogawa, E., Ishigami, M., Ito, T., Kozuka, R., Enomoto, M., Suzuki, et al
2023
 - **Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Kudaravalli, S., Kam, L. Y., Huang, D. Q., Cheung, R., Nguyen, M. H.
2023
 - **Development and validation of a REcurrent Liver cAnCer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: analysis of the us multicenter hcc transplant consortium.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Tran, B. V., Moris, D., Markovic, D., Zaribafzadeh, H., Henao, R., Lai, Q., Florman, S. S., Tabrizian, P., Haydel, B., Ruiz, R. M., Klintmalm, G. B., Lee, D. D., Taner, et al
2023

- **Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons.** *Journal of hepatology*
Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., Cheung, R., Nguyen, M. H.
2023
- **Global burden of hepatitis B virus: current status, missed opportunities and a call for action.** *Nature reviews. Gastroenterology & hepatology*
Hsu, Y. C., Huang, D. Q., Nguyen, M. H.
2023
- **Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.** *Journal of hepatocellular carcinoma*
Ito, T., Nguyen, M. H.
2023; 10: 413-428
- **Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.** *Cancer immunology, immunotherapy : CII*
Li, T., Guo, J., Liu, Y., Du, Z., Guo, Z., Fan, Y., Cheng, L., Zhang, Y., Gao, X., Zhao, Y., He, X., Wu, W., Gao, et al
2023
- **Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin.** *Alimentary pharmacology & therapeutics*
Zeng, R. W., Yong, J. N., Tan, D. J., Fu, C. E., Lim, W. H., Xiao, J., Chan, K. E., Tan, C., Goh, X. L., Chee, D., Syn, N., Tan, E. X., Muthiah, et al
2023
- **NAFLD and Non-Liver Comorbidities.** *Clinical and molecular hepatology*
Manikat, R., Nguyen, M. H.
2023
- **Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Verna, E. C., Phipps, M. M., Halazun, K. J., Markovic, D., Florman, S. S., Haydel, B. M., Ruiz, R., Klintmalm, G., Lee, D. D., Taner, B., Hoteit, M. A., Tevar, A. D., Humar, et al
2023; 29 (1): 34-47
- **Characteristics and outcomes of hepatocellular carcinoma patients with macrovascular invasion following surgical resection: a meta-analysis of 40 studies and 8,218 patients.** *Hepatobiliary surgery and nutrition*
Huang, D. Q., Tran, A., Tan, E. X., Nerurkar, S. N., Teh, R., Teng, M. L., Yeo, E. J., Zou, B., Wong, C., Esquivel, C. O., Bonham, C. A., Nguyen, M. H.
2022; 11 (6): 848-860
- **Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States.** *Hepatology international*
Dao, A. D., Nguyen, V. H., Ito, T., Cheung, R., Nguyen, M. H.
2022
- **Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States.** *Hepatology communications*
Nguyen, M. H., Roberts, L. R., Engel-Nitz, N. M., Bancroft, T., Ozbay, A. B., Singal, A. G.
2022
- **Forecasted 2040 Global Prevalence of NAFLD using Hierarchical Bayesian Approach.** *Clinical and molecular hepatology*
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., Nguyen, M. H.
2022
- **Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis.** *Current medical research and opinion*
Nguyen, M. H., Roberts, L. R., Engel-Nitz, N. M., Bancroft, T., Ozbay, A. B., Singal, A. G.
2022: 1-35
- **Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy.** *The Lancet. Oncology*
Ji, F., Nguyen, M. H.
2022

- **Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021.** *Alimentary pharmacology & therapeutics*
Li, J., Ha, A., Rui, F., Zou, B., Yang, H., Xue, Q., Hu, X., Xu, Y., Henry, L., Barakhat, M., Stave, C. D., Shi, J., Wu, et al
2022
- **Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Ito, T., Nguyen, V. H., Tanaka, T., Park, H., Yeh, M. L., Kawanaka, M., Arai, T., Atsukawa, M., Yoon, E. L., Tsai, P. C., Toyoda, H., Huang, J. F., Henry, et al
2022
- **NAFLD versus MAFLD: Prevalence, Outcomes and Implications of a Change in Name.** *Clinical and molecular hepatology*
Ng, C. H., Huang, D. Q., Nguyen, M. H.
2022
- **Characteristics and outcomes of hepatocellular carcinoma patients with macrovascular invasion following surgical resection: a meta-analysis of 40 studies and 8,218 patients** *HEPATOBIILIARY SURGERY AND NUTRITION*
Huang, D. Q., Tran, A., Tan, E. X., Nerurkar, S. N., Teh, R., Teng, M. L. P., Yeo, E., Zou, B., Wong, C., Esquivel, C. O., Bonham, C., Nguyen, M. H.
2022
- **Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies.** *Hepatology communications*
Reveron-Thornton, R. F., Teng, M. L., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, E. X., Nerurkar, S. N., Ng, R. X., Teh, R., Tripathy, D. P., Ito, T., Tanaka, T., Miyake, et al
2022
- **Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations with Implications on Host Gene Dysregulation.** *Gastroenterology*
Hsu, Y. C., Suri, V., Nguyen, M. H., Huang, Y. T., Chen, C. Y., Chang, I. W., Tseng, C. H., Wu, C. Y., Lin, J. T., Pan, D. Z., Gaggar, A., Podlaha, O.
2022
- **Global multi-stakeholder endorsement of the MAFLD definition.** *The lancet. Gastroenterology & hepatology*
Méndez-Sánchez, N., Bugianesi, E., Gish, R. G., Lammert, F., Tilg, H., Nguyen, M. H., Sarin, S. K., Fabrellas, N., Zelber-Sagi, S., Fan, J. G., Shiha, G., Targher, G., Zheng, et al
2022
- **Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?** *Journal of hepatology*
Wong, Y. J., Nguyen, M. H.
2022
- **Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Wong, V. W., Tak, W. Y., Goh, G. B., Cheng, P. N., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Younes, Z., Alkhouri, N., Wang, L., Liu, J., Kersey, K., Myers, et al
2022
- **County-Level Variation in Cirrhosis-Related Mortality in the US, 1999-2019.** *JAMA network open*
Ha, A. Y., Le, M. H., Henry, L., Yeo, Y. H., Cheung, R. C., Nguyen, M. H.
2022; 5 (2): e2146427
- **Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients with Non-alcoholic Fatty Liver Disease.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Zou, B., Odden, M. C., Nguyen, M. H.
2022
- **Clinical profiles of Asians with NAFLD: A systematic review and meta-analysis.** *Digestive diseases (Basel, Switzerland)*
Kam, L., Huang, D. Q., Teng, M. L., Takahashi, H., Tanaka, K., Yasuda, S., Fung, J., Lee, T. Y., Hyogo, H., Ono, M., Saruwatari, J., Oniki, K., Yeo, et al
2021
- **2019 global NAFLD prevalence - A systematic review and meta-analysis.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*

- Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., Liu, C., Chang, N., Xing, et al
2021
- **Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B Reply** *LANCET GASTROENTEROLOGY & HEPATOLOGY*
Tseng, C., Hsu, Y., Nguyen, M. H.
2021; 6 (2): 87–88
 - **Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.** *Journal of hepatology*
Ye, Q., Kam, L. Y., Yeo, Y. H., Dang, N., Huang, D. Q., Cheung, R., Nguyen, M. H.
2021
 - **Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.** *The Journal of infectious diseases*
Hsu, Y. C., Yeh, M. L., Wong, G. L., Chen, C. H., Peng, C. Y., Buti, M. n., Enomoto, M. n., Xie, Q. n., Trinh, H. n., Preda, C. n., Liu, L. n., Cheung, K. S., Yeo, et al
2021
 - **Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.** *Journal of hepatology*
Tantai, X., Liu, Y., Yeo, Y. H., Praktiknjo, M., Mauro, E., Hamaguchi, Y., Engelmann, C., Zhang, P., Jeong, J. Y., van Vugt, J. L., Xiao, H., Deng, H., Gao, et al
2021
 - **Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Nguyen, V. H., Le, M. H., Cheung, R. C., Nguyen, M. H.
2021
 - **Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Martin, P., Nguyen, M. H., Dieterich, D. T., Lau, D. T., Janssen, H. L., Peters, M. G., Jacobson, I.
2021
 - **ALT levels in Treatment-Naïve, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A U.S. Nationwide Study.** *Digestive diseases (Basel, Switzerland)*
Chang, C. Y., Kam, L., Dang, N., Cheung, R., Nguyen, M. H.
2021
 - **Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Park, J., Le, A. K., Tseng, T. C., Yeh, M. L., Jun, D. W., Trinh, H., Wong, G. L., Chen, C. H., Peng, C. Y., Kim, S. E., Oh, H., Kwak, M. S., Cheung, et al
2021
 - **The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016.** *The American journal of gastroenterology*
Li, J., Le, M. H., Barakat, M. T., Cheung, R. C., Nguyen, M. H.
2021
 - **Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank.** *Digestive diseases and sciences*
Zou, B. n., Yeo, Y. H., Cheung, R. n., Ingelsson, E. n., Nguyen, M. H.
2021
 - **Surveillance of patients with cirrhosis remains suboptimal in the United States.** *Journal of hepatology*
Yeo, Y. H., Hwang, J. n., Jeong, D. n., Dang, N. n., Kam, L. Y., Henry, L. n., Park, H. n., Cheung, R. n., Nguyen, M. H.
2021
 - **Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.** *Hepatology (Baltimore, Md.)*
Ramrakhiani, N. S., Chen, V. L., Le, M., Yeo, Y. H., Barnett, S. D., Waljee, A. K., Zhu, J., Nguyen, M. H.
2021

- **Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.** *The American journal of gastroenterology*
Tran, S. n., Jeong, D. n., Henry, L. n., Cheung, R. C., Nguyen, M. H.
2021
- **Prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B.** *Alimentary pharmacology & therapeutics*
Zheng, Q., Zou, B., Wu, Y., Yeo, Y., Wu, H., Stave, C. D., Cheung, R. C., Nguyen, M. H.
2021
- **Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.** *Hepatology communications*
Chen, V. L., Yeh, M. L., Yang, J. D., Leong, J., Huang, D. Q., Toyoda, H., Chen, Y. L., Guy, J., Maeda, M., Tsai, P. C., Huang, C. F., Yasuda, S., Le, et al
2021; 5 (1): 122-132
- **Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.** *The lancet. Gastroenterology & hepatology*
Tseng, C. H., Hsu, Y. C., Nguyen, M. H.
2021; 6 (2): 87-88
- **Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice.** *Hepatology (Baltimore, Md.)*
Toyoda, H. n., Leong, J. n., Landis, C. n., Atsukawa, M. n., Watanabe, T. n., Huang, D. Q., Liu, J. n., Quek, S. X., Ishikawa, T. n., Arai, T. n., Yokohama, K. n., Chuma, M. n., Takaguchi, et al
2021
- **Characteristics and healthcare costs in the aging hepatitis B population of Japan: A nationwide real-world analysis.** *Digestive diseases (Basel, Switzerland)*
Yotsuyanagi, H. n., Kurosaki, M. n., Yatsushashi, H. n., Lee, I. H., Ng, A. n., Brooks-Rooney, C. n., Nguyen, M. H.
2021
- **Chronic hepatitis, osteoporosis, and men: under-recognised and underdiagnosed.** *The lancet. Diabetes & endocrinology*
Prasad, D. n., Nguyen, M. H.
2021; 9 (3): 141
- **The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.** *Hepatology international*
Ito, T. n., Ishigami, M. n., Zou, B. n., Tanaka, T. n., Takahashi, H. n., Kurosaki, M. n., Maeda, M. n., Thin, K. N., Tanaka, K. n., Takahashi, Y. n., Itoh, Y. n., Oniki, K. n., Seko, et al
2021
- **Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.** *Hepatology international*
Liu, M. n., Tseng, T. C., Jun, D. W., Yeh, M. L., Trinh, H. n., Wong, G. L., Chen, C. H., Peng, C. Y., Kim, S. E., Oh, H. n., Kwak, M. S., Cheung, M. n., Toyoda, et al
2021
- **Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients with Indeterminate Phase (117/120).** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Huang, D. Q., Li, X. n., Le, M. H., Le, A. K., Yeo, Y. H., Trinh, H. N., Zhang, J. n., Li, J. n., Wong, C. n., Wong, C. n., Cheung, R. C., Yang, H. I., Nguyen, et al
2021
- **Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016.** *JAMA network open*
Le, M. H., Yeo, Y. H., So, S., Gane, E., Cheung, R. C., Nguyen, M. H.
2020; 3 (11): e2022388
- **Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.** *Clinical and translational gastroenterology*
Yeo, Y. H., Tseng, T. C., Hosaka, T., Cunningham, C., Fung, J. Y., Ho, H. J., Kwak, M. S., Trinh, H. N., Ungtrakul, T., Yu, M. L., Kobayashi, M., Le, A. K., Henry, et al

2020; 11 (9): e00196

- **Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients** *CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY*
Yeo, Y., Tseng, T., Hosaka, T., Cunningham, C., Fung, J., Ho, H. J., Kwak, M., Trinh, H. N., Ungtrakul, T., Yu, M., Kobayashi, M., Le, A. K., Henry, et al
2020; 11 (9)
- **Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma Analysis From the US Multicenter HCC Transplant Consortium** *ANNALS OF SURGERY*
DiNorcia, J., Florman, S. S., Haydel, B., Tabrizian, P., Ruiz, R. M., Klintmalm, G. B., Senguttuvan, S., Lee, D. D., Taner, C., Verna, E. C., Halazun, K. J., Hoteit, M., Levine, et al
2020; 271 (4): 616–24
- **Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016.** *Journal of internal medicine*
Zou, B. n., Yeo, Y. H., Nguyen, V. H., Cheung, R. n., Ingelsson, E. n., Nguyen, M. H.
2020
- **Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.** *Clinical microbiology reviews*
Nguyen, M. H., Wong, G. n., Gane, E. n., Kao, J. H., Dusheiko, G. n.
2020; 33 (2)
- **Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B.** *The Journal of infectious diseases*
Li, J. n., Yang, H. I., Yeh, M. L., Le, M. H., Le, A. K., Yeo, Y. H., Dai, C. Y., Barnett, S. n., Zhang, J. Q., Huang, J. F., Trinh, H. N., Wong, C. n., Wong, et al
2020
- **HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.** *Hepatology international*
Tanaka, Y. n., Ogawa, E. n., Huang, C. F., Toyoda, H. n., Jun, D. W., Tseng, C. H., Hsu, Y. C., Enomoto, M. n., Takahashi, H. n., Furusyo, N. n., Yeh, M. L., Iio, E. n., Yasuda, et al
2020
- **Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.** *The lancet. Gastroenterology & hepatology*
Tseng, C. H., Hsu, Y. C., Chen, T. H., Ji, F. n., Chen, I. S., Tsai, Y. N., Hai, H. n., Thuy, L. T., Hosaka, T. n., Sezaki, H. n., Borghi, J. A., Cheung, R. n., Enomoto, et al
2020
- **Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.** *The lancet. Gastroenterology & hepatology*
Ye, Q. n., Zou, B. n., Yeo, Y. H., Li, J. n., Huang, D. Q., Wu, Y. n., Yang, H. n., Liu, C. n., Kam, L. Y., Tan, X. X., Chien, N. n., Trinh, S. n., Henry, et al
2020
- **Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B.** *The Journal of infectious diseases*
Li, J. n., Yang, H. I., Yeh, M. L., Le, M. H., Le, A. K., Yeo, Y. H., Dai, C. Y., Barnett, S. n., Zhang, J. Q., Huang, J. F., Trinh, H. N., Wong, C. n., Wong, et al
2020
- **HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.** *Hepatology international*
Tanaka, Y. n., Ogawa, E. n., Huang, C. F., Toyoda, H. n., Jun, D. W., Tseng, C. H., Hsu, Y. C., Enomoto, M. n., Takahashi, H. n., Furusyo, N. n., Yeh, M. L., Iio, E. n., Yasuda, et al
2020
- **Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.** *The lancet. Gastroenterology & hepatology*
Tseng, C. H., Hsu, Y. C., Chen, T. H., Ji, F. n., Chen, I. S., Tsai, Y. N., Hai, H. n., Thuy, L. T., Hosaka, T. n., Sezaki, H. n., Borghi, J. A., Cheung, R. n., Enomoto, et al
2020

- **Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.** *The lancet. Gastroenterology & hepatology*
Ye, Q. n., Zou, B. n., Yeo, Y. H., Li, J. n., Huang, D. Q., Wu, Y. n., Yang, H. n., Liu, C. n., Kam, L. Y., Tan, X. X., Chien, N. n., Trinh, S. n., Henry, et al
2020
- **Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999-2016.** *Hepatology (Baltimore, Md.)*
Le, M. H., Yeo, Y. H., Cheung, R., Henry, L., Lok, A. S., Nguyen, M. H.
2019
- **Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis** *LANCET GASTROENTEROLOGY & HEPATOLOGY*
Li, J., Zou, B., Yeo, Y., Feng, Y., Xie, X., Lee, D., Fujii, H., Wu, Y., Kam, L. Y., Ji, F., Li, X., Chien, N., Wei, et al
2019; 4 (5): 389–98
- **Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis** *GASTROENTEROLOGY*
Yeo, Y., Ho, H. J., Yang, H., Tseng, T., Hosaka, T., Trinh, H. N., Kwak, M., Park, Y., Fung, J., Buti, M., Rodriguez, M., Treeprasertsuk, S., Preda, et al
2019; 156 (3): 635+
- **Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.** *Hepatology (Baltimore, Md.)*
Dang, H. n., Yeo, Y. H., Yasuda, S. n., Huang, C. F., Iio, E. n., Landis, C. n., Jun, D. W., Enomoto, M. n., Ogawa, E. n., Tsai, P. C., Le, A. n., Liu, M. n., Maeda, et al
2019
- **Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.** *The American journal of gastroenterology*
Hsu, Y. C., Wong, G. L., Chen, C. H., Peng, C. Y., Yeh, M. L., Cheung, K. S., Toyoda, H. n., Huang, C. F., Trinh, H. n., Xie, Q. n., Enomoto, M. n., Liu, L. n., Yasuda, et al
2019
- **The Phosphatidylethanolamine Biosynthesis Pathway Provides a New Target for Cancer Chemotherapy.** *Journal of hepatology*
Guan, Y. n., Chen, X. n., Wu, M. n., Zhu, W. n., Arslan, A. n., Takeda, S. n., Nguyen, M. H., Majeti, R. n., Thomas, D. n., Zheng, M. n., Peltz, G. n.
2019
- **REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy.** *The Journal of infectious diseases*
Yang, H. I., Yeh, M. L., Wong, G. L., Peng, C. Y., Chen, C. H., Trinh, H. N., Cheung, K. S., Xie, Q. n., Su, T. H., Kozuka, R. n., Lee, D. H., Ogawa, E. n., Zhao, et al
2019
- **Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study** *JOURNAL OF INFECTIOUS DISEASES*
Nguyen, M. H., Yang, H., Le, A., Henry, L., Nguyen, N., Lee, M., Zhang, J., Wong, C., Wong, C., Huy Trinh
2019; 219 (1): 10–18
- **HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Ogawa, E. n., Toyoda, H. n., Iio, E. n., Jun, D. W., Huang, C. F., Enomoto, M. n., Hsu, Y. C., Haga, H. n., Iwane, S. n., Wong, G. n., Lee, D. H., Tada, T. n., Liu, et al
2019
- **Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.** *The lancet. Gastroenterology & hepatology*
2018; 3 (6): 383–403
- **Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma.** *The American journal of gastroenterology*
Estevez, J. n., Yang, J. D., Leong, J. n., Nguyen, P. n., Giama, N. H., Zhang, N. n., Ali, H. A., Lee, M. H., Cheung, R. n., Roberts, L. n., Schwartz, M. n., Nguyen, M. H.
2018

- **Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States.** *Journal of the National Cancer Institute*
Han, S. S., Kelly, S. P., Li, Y. n., Yang, B. n., Nguyen, M. n., So, S. n., Rosenberg, P. S., Hsing, A. W.
2018
- **Factors Associated with Rates of HBsAg Seroclearance in Adults with Chronic HBV Infection: A systematic review and meta-analysis.** *Gastroenterology*
Yeo, Y. H., Ho, H. J., Yang, H. I., Tseng, T. C., Hosaka, T. n., Trinh, H. N., Kwak, M. S., Park, Y. M., Fung, J. Y., Buti, M. n., Rodriguez, M. n., Treeprasertsuk, S. n., Preda, et al
2018
- **HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis.** *American journal of gastroenterology*
Lee, M., Hsiao, T. I., Subramaniam, S. R., Le, A. K., Vu, V. D., Trinh, H. N., Zhang, J., Jin, M., Wong, V. W., Wong, G. L., Nguyen, M. H.
2017
- **Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients from the US Multicenter HCC Transplant Consortium.** *Annals of surgery*
Agopian, V. G., Harlander-Locke, M. P., Ruiz, R. M., Klintmalm, G. B., Senguttuvan, S. n., Florman, S. S., Haydel, B. n., Hoteit, M. n., Levine, M. H., Lee, D. D., Taner, C. B., Verna, E. C., Halazun, et al
2017
- **Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.** *Gastroenterology*
Gane, E., Kowdley, K. V., Pound, D., Stedman, C. A., Davis, M., Etzkorn, K., Gordon, S. C., Bernstein, D., Everson, G., Rodriguez-Torres, M., Tsai, N., Khalid, O., Yang, et al
2016
- **Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.** *The New England journal of medicine*
Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., Shiffman, M. L., Schiff, E., Ghalib, R., Ryan, M., Rustgi, V., Chojkier, M., Herring, et al
2014; 370 (20): 1879-88
- **Treating hepatitis C in lower-income countries.** *New England journal of medicine*
Jayasekera, C. R., Barry, M., Roberts, L. R., Nguyen, M. H.
2014; 370 (20): 1869-1871
- **Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.** *The New England journal of medicine*
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J. P., Agarwal, K., Buggisch, P., Foster, G. R., Bräu, N., Buti, et al
2014; 370 (20): 1889-98
- **Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.** *New England journal of medicine*
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., Lalezari, J., Younes, Z. H., Pockros, et al
2014; 370 (16): 1483-1493
- **Transarterial Chemoinfusion for Hepatocellular Carcinoma as Downstaging Therapy and a Bridge toward Liver Transplantation** *AMERICAN JOURNAL OF TRANSPLANTATION*
De Luna, W., Sze, D. Y., Ahmed, A., Ha, B. Y., Ayoub, W., Keeffe, E. B., Cooper, A., Esquivel, C., Nguyen, M. H.
2009; 9 (5): 1158-1168
- **Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis** *HEPATOLOGY*
Nguyen, M. H., Garcia, R. T., Simpson, P. W., Wright, T. L., Keeffe, E. B.
2002; 36 (2): 410-417
- **Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss.** *Alimentary pharmacology & therapeutics*
Tsai, Y. N., Wu, J. L., Tseng, C. H., Chen, T. H., Chung, Y. C., Nguyen, M. H., Lin, J. T., Nagaoka, K., Tanaka, Y., Hsu, Y. C.
2026

- **Prevalence, Clinical Presentation and Outcome of Hepatitis B Patients With Indeterminate Phase: A Systematic Review and Meta-Analysis.** *Journal of viral hepatitis*
Li, J., Xu, X., Liu, J., Li, M., Issa, R., Bai, X., Kam, L. Y., Stave, C. D., Ni, W., Rui, F., Zhu, Y., Ma, X., Gu, et al
2026; 33 (4): e70161
- **Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort.** *Liver international : official journal of the International Association for the Study of the Liver*
Ji, F., Tran, S., Toyoda, H., Enomoto, M., Ogawa, E., Suzuki, T., Huang, C. F., Wong, Y. J., Chuma, M., Uojima, H., Atsukawa, M., Hsu, Y. C., Jun, et al
2026; 46 (3): e70561
- **Traditional and Novel Virologic Markers for Functional Cure and HBeAg Loss with Pegylated Interferon in Chronic Hepatitis B: A Systematic Review and Meta-analysis.** *Journal of clinical and translational hepatology*
Zhang, Y., Wang, L. F., Chen, J., Nguyen, M. H., Zheng, Q.
2026; 14 (2): 159-167
- **Social determinants disadvantage score and liver health in the All of Us Research Program.** *European journal of epidemiology*
Zhang, X., Zhao, L., Zhang, K., Vlahov, D., Chen, Y., Hsing, A., Nguyen, M. H., McGlynn, K. A., Taddei, T., Hou, L., Zhang, X.
2026
- **Traditional and Novel Virologic Markers for Functional Cure and HBeAg Loss with Pegylated Interferon in Chronic Hepatitis B: A Systematic Review and Meta-analysis** *JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY*
Zhang, Y., Wang, L., Chen, J., Nguyen, M. H., Zheng, Q.
2025
- **A contemporary review of care gaps in hepatocellular carcinoma surveillance.** *Expert review of gastroenterology & hepatology*
Duong, N., Nguyen, V., Nguyen, M.
2025
- **Reply: Methodological refinements needed in assessing metabolic-viral fibrosis interactions.** *Hepatology (Baltimore, Md.)*
Li, J., Rui, F., Nguyen, M. H.
2025
- **Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs.** *Journal of viral hepatitis*
Chau, A., Li, J., Jun, D. W., Hsu, Y. C., Toyoda, H., Yeh, M. L., Watanabe, T., Honda, T., Trinh, H., Nozaki, A., Uojima, H., Ishikawa, T., Huang, et al
2025; 32 (10): e70081
- **Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits.** *International journal of cancer*
Han, Y., Shaw, V. R., Byun, J., Thrift, A. P., Zhu, C., Li, D., Hatia, R. I., Kelley, R. K., Cleary, S. P., Lok, A. S., Bracci, P. M., Permut, J. B., Bucur, et al
2025
- **Delayed Diagnosis of Hepatitis C Infection: Results of a Nationwide US Study.** *Digestive diseases (Basel, Switzerland)*
Levesley, C. R., Zhang, X., Manikat, R., Cheung, R., Nguyen, M. H.
2025: 1-11
- **Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study.** *EClinicalMedicine*
Huang, R., Jun, D. W., Toyoda, H., Hsu, Y. C., Trinh, H., Nozaki, A., Ishikawa, T., Watanabe, T., Uojima, H., Huang, D. Q., Honda, T., Tanaka, Y., Vutien, et al
2025; 87: 103407
- **Reply: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes.** *Clinical and molecular hepatology*
Mao, X., Nguyen, M. H.
2025
- **Peri-Complication Diagnosis of Nonalcoholic Fatty Liver Disease: A US Population-Based Retrospective Analysis.** *Digestive diseases (Basel, Switzerland)*
Manikat, R., Tran, S., Kam, L. Y., Dronamraju, D., Cheung, R., Nguyen, M. H.
2025: 1-11

- **Reply: Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias?** *Clinical and molecular hepatology*
Mao, X., Nguyen, M. H.
2025
- **Correspondence to editorial on "GLP-1RA may open a new era for MASLD treatment".** *Clinical and molecular hepatology*
Mao, X., Nguyen, M. H.
2025
- **Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks-Authors' Reply.** *Alimentary pharmacology & therapeutics*
Huang, R., Nguyen, M. H.
2025
- **Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus-Related Hepatocellular Carcinoma.** *Alimentary pharmacology & therapeutics*
Wu, J. L., Tsai, Y. N., Tseng, C. H., Tseng, S. C., Lin, C. W., Hung, C. L., Nguyen, M. H., Lin, J. T., Hsu, Y. C.
2025
- **Projected Tumor Characteristics and Survival of Patients with Nonviral Hepatocellular Carcinoma in the USA.** *Digestive diseases (Basel, Switzerland)*
Liu, J. K., Chien, N., Chong, C., Barnett, S., Henry, L., John, E. M., Cheung, R., Nguyen, M. H.
2025: 1-14
- **Late Diagnosis of Chronic Hepatitis B in the United States: A Population-Based, Retrospective Cohort Study From 2007 to 2021.** *Alimentary pharmacology & therapeutics*
Le, M. H., Liu, J. K., Lee, K., Cheung, R., Nguyen, M. H.
2025
- **Correspondence to editorial "Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B".** *Clinical and molecular hepatology*
Huang, R., Nguyen, M. H.
2025
- **Correspondence to editorial "Metabolic health in antiviral era of chronic hepatitis B".** *Clinical and molecular hepatology*
Huang, R., Nguyen, M. H.
2025
- **Comparative performance of highly sensitive HBcrAg and HBsAg assays in predicting clinical flares and HBsAg loss after nucleos(t) ide analogues withdrawal in patients with chronic hepatitis B**
Hsu, Y., Tsai, Y., Wu, J., Tseng, C., Chen, T., Lin, J., Nguyen, M., Tanaka, Y.
ELSEVIER.2025
- **Limited use of FIB-4 index in patients under 65 years of age with type 2 diabetes mellitus.** *Hepatology research : the official journal of the Japan Society of Hepatology*
Kim, M., Yoon, E. L., Park, H., Ito, T., Ishigami, M., Jo, A. J., Lee, C. M., Kang, B. K., Kim, H. L., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, et al
2025; 55 (4): 505-514
- **HBV Reactivation in Immunosuppressed Patients: Screening, Prevention, and Management Including Solid Organ Transplant Recipients.** *Viruses*
Vutien, P., Nguyen, M. H.
2025; 17 (3)
- **Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology.** *Alimentary pharmacology & therapeutics*
Shi, Y., Chien, N., Fong, A., Nguyen, V. H., Gudapati, S. T., Chau, A., Tran, S., Henry, L., Cheung, R., Zhao, C., Jin, M., Nguyen, M. H.
2025
- **Long-Term Immunity and Anamnestic Response Following Hepatitis B Vaccination: A Systematic Review and Meta-Analysis.** *Journal of viral hepatitis*
Ramrakhiani, H., Le, M. H., Kam, L., Nguyen, B., Yeo, Y. H., Levesley, C. R., Gudapati, S., Barnett, S., Cheung, R., Nguyen, M. H.
2025; 32 (2): e70003

- **Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal.** *Alimentary pharmacology & therapeutics*
Tsai, Y. N., Wu, J. L., Tseng, C. H., Tseng, S. C., Hung, C. L., Nguyen, M. H., Lin, J. T., Hsu, Y. C.
2025
- **Correspondence to Editorial on "Bariatric Surgery Reduces Long-Term Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Cirrhosis".** *Clinical and molecular hepatology*
Rouillard, N. A., Henry, L., Nguyen, M. H.
2025
- **Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy.** *Journal of viral hepatitis*
Tsai, Y. N., Lo, J. C., Tseng, C. H., Hsieh, S. C., Chiu, W. C., Tai, C. M., Chang, C. Y., Lee, F. J., Nguyen, M. H., Lin, J. T., Hsu, Y. C.
2025; 32 (1): 1-8
- **Limited use of FIB-4 index in patients under 65 years of age with type 2 diabetes mellitus** *HEPATOLOGY RESEARCH*
Kim, M., Yoon, E. L., Park, H., Ito, T., Ishigami, M., Jo, A., Lee, C., Kang, B., Kim, H., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, et al
2024
- **Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B.** *The Journal of infectious diseases*
Zhang, X., Nguyen, V. H., Kam, L. Y., Barnett, S. D., Henry, L., Cheung, R., Nguyen, M. H.
2024
- **Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis.** *Diagnostics (Basel, Switzerland)*
Kim, J., Ito, T., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, H., Honda, T., Yu, M. L., Yoon, E. L., Jun, D. W., Cha, K., Nguyen, M. H.
2024; 14 (22)
- **Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis.** *Gastroenterology*
Fujiwara, N., Lopez, C., Marsh, T. L., Raman, I., Marquez, C. A., Paul, S., Mishra, S. K., Kubota, N., Katz, C., Kanzaki, H., Gonzalez, M., Quirk, L., Deodhar, et al
2024
- **ASO Visual Abstract: Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.** *Annals of surgical oncology*
Bennett, F. J., Keilson, J. M., Turgeon, M. K., Oppat, K. M., Warren, E. A., Shah, S. A., Agopian, V. G., Magliocca, J. F., Cameron, A., Orloff, S. L., Kubal, C. A., Cannon, R. M., Akoad, et al
2024
- **ASO Visual Abstract: Hepatic Resection as the Primary Treatment Modality for Hepatocellular Carcinoma Following Orthotopic Liver Transplantation.** *Annals of surgical oncology*
Matar, A. J., Oppat, K. M., Bennett, F. J., Warren, E. A., Wehrle, C. J., Li, Z., Rajendran, L., Rokop, Z. P., Kubal, C., Biesterveld, B. E., Foley, D. P., Maeda, M., Nguyen, et al
2024
- **Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study.** *PLoS medicine*
Lai, R., Barnett, S., Zhang, X., Kam, L. Y., Cheung, R., Xie, Q., Nguyen, M. H.
2024; 21 (10): e1004479
- **Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease-Author's Reply.** *Alimentary pharmacology & therapeutics*
Lee, E. Y., Henry, L., Nguyen, M. H.
2024
- **Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease-Author's Reply.** *Alimentary pharmacology & therapeutics*
Lee, E. Y., Henry, L., Nguyen, M. H.
2024

- **Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.** *Annals of surgical oncology*
Bennett, F. J., Keilson, J. M., Turgeon, M. K., Oppat, K. M., Warren, E. A., Shah, S. A., Agopian, V. G., Magliocca, J. F., Cameron, A., Orloff, S. L., Kubal, C. A., Cannon, R. M., Akoad, et al
2024
- **Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study.** *Digestive diseases (Basel, Switzerland)*
Zhang, X., Kam, L. Y., Barnett, S. D., Henry, L., Cheung, R., Nguyen, M. H.
2024: 1-10
- **SUBOPTIMAL DIAGNOSIS RATE AND PERI-COMPLICATION DIAGNOSIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN THE US: A POPULATION-BASED STUDY**
Nguyen, V., Barnett, S., Zhang, X., Cheung, R., Nguyen, M.
LIPPINCOTT WILLIAMS & WILKINS.2024: S900-S901
- **DEVELOPING A BRIEF EVALUATION INDEX TO DIAGNOSIS METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE**
He, X., Yang, Z., Ito, T., Hyogo, H., Ono, M., Oniki, K., Kojima, T., Yang, Z., Tran, S., Xing, Z., Liu, Y., Kariya, N., Yokoyama, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S604-S605
- **SUPERIOR DIAGNOSTIC EFFICACY OF PRO-C3 AND GP73 COMPARED WITH FIB-4, FAST, AGILE 3+, AND LSM FOR DETECTION OF FIBROSIS IN CHRONIC HEPATITIS B**
Chen, Q., Yeo, Y., Zheng, M., Zhu, L., Hu, X., Ni, W., Rui, F., Issa, R., Jia, L., Barnett, S., Yin, S., Wu, C., Zhu, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S303-S304
- **IRON REGULATORY PROTEIN 2 CONTRIBUTES TO ANTIMICROBIAL IMMUNITY BY PRESERVING LYSOSOMAL FUNCTION IN MACROPHAGES**
Fan, Z., Li, J., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2024: S791-S792
- **GLOBAL PREVALENCE AND OUTCOME OF CHB PATIENTS WITH INDETERMINATE PHASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 35 STUDIES AND 27,529 PATIENTS**
Li, J., Xu, X., Li, M., Liu, J., Issa, R., Kam, L., Rui, F., Ni, W., Zhu, Y., Ma, X., Gu, Q., Pan, Y., Wu, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S332-S333
- **RELATIONSHIP BETWEEN ALCOHOL CONSUMPTION AND ALL-CAUSE MORTALITY IN PATIENTS WITH STEATOTIC LIVER DISEASE: FINDINGS FROM NHANES III**
Li, J., Rui, F., Geng, N., Goujoul, A., Zhu, Y., Issa, R., Ni, W., Zhou, S., Jia, L., Fan, Z., Wu, C., Shi, J., Yeo, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S917-S918
- **ASSOCIATION BETWEEN RETREATMENT AND HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE IN PATIENTS WITH CLINICAL RELAPSES FOLLOWING WITHDRAWAL OF NUCLEOS(T) IDE ANALOGUES**
Hsu, Y., Wu, C., Wu, J., Tsai, Y., Tseng, C., Lin, C., Hung, C., Nguyen, M., Lin, J.
LIPPINCOTT WILLIAMS & WILKINS.2024: S57
- **THE CHARACTERISTICS AND LONG-TERM OUTCOMES OF ETIOLOGY-SPECIFIC CIRRHOSIS: A 15-YEAR STUDY OF STANFORD CIRRHOSIS COHORT**
Shi, Y., Chien, N., Fong, A., Vy Nguyen, Gudapati, S., Park, J., Le, I., Chau, A., Tran, S., Zhang, X., Cheung, R., Zhao, C., Jin, M., et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S1684-S1685
- **IMPACT OF METABOLIC DISEASE ON TREATMENT RESPONSE IN CHRONIC HEPATITIS B PATIENTS WITH NUCLEOS(T) IDE ANALOGUES THERAPY: A MULTICENTER REAL- B STUDY**
Huang, R., Jun, D., Toyoda, H., Hsu, Y., Huy Trinh, Nozaki, A., Ishikawa, T., Watanabe, T., Uojima, H., Huang, D., Honda, T., Tanaka, Y., Vutien, P., et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S316-S318
- **SUBGROUP DISPARITIES IN PATIENTS WITH CIRRHOSIS THAT RECEIVED PALLIATIVE/HOSPICE CARE AND DISCUSSION: FINDINGS FROM A LARGE, SINGLE-CENTER STUDY**
Fung, A., Fong, A., Gudapati, S., Nguyen, V., Park, J., Le, I., Lee, K., Chau, A., Tran, S., Zhang, X., Maeda, M., Cheung, R., Zhao, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S723-S724
- **SIGNIFICANT DIFFERENCES IN THE OVERALL AND CAUSE-SPECIFIC SURVIVAL RATES ACROSS SUBGROUPS OF PATIENTS WITH CIRRHOSIS**

- Fong, A., Liu, J., Maeda, M., Vy Nguyen, Le, I., Fung, A., Gudapati, S., Tran, S., Chau, A., Zhang, X., Park, J., Cheung, R., Zhao, C., et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S1694-S1695
- **ASSOCIATION OF GLUCAGON-LIKE PEPTIDASE 1 RECEPTOR AGONIST WITH LIVER AND NON-LIVER COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE**
Nguyen, M., Mao, X., Zhang, X., Lai, R., Cheung, K., Yuen, M., Cheung, R., Seto, W.
LIPPINCOTT WILLIAMS & WILKINS.2024: S884
 - **EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND WITH OVERWEIGHT OR OBESITY: A TARGET TRIAL EMULATION STUDY**
Nguyen, M., Mao, X., Zhang, X., Lai, R., Yuen, M., Cheung, R., Cheung, K., Seto, W.
LIPPINCOTT WILLIAMS & WILKINS.2024: S885-S886
 - **FORECASTED CHANGES IN TUMOR CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH NONVIRAL HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: A MODELING STUDY BASED ON THE SEER-MEDICARE DATABASE**
Liu, J., Chien, N., Chong, C., Barnett, S., Cheung, R., Nguyen, M.
LIPPINCOTT WILLIAMS & WILKINS.2024: S898-S899
 - **SEX DISPARITIES IN THE RATE OF DELAYED HEPATITIS C DIAGNOSIS IN PATIENTS WITH A LIVER COMPLICATION- RESULTS OF A POPULATION- BASED ANALYSIS**
Levesley, C., Zhang, X., Kam, L., Manikat, R., Cheung, R., Nguyen, M.
LIPPINCOTT WILLIAMS & WILKINS.2024: S409-S410
 - **IMPACT OF CONCURRENT FATTY LIVER (FL) AND CHRONIC HEPATITIS B (CHB) ON VIROLOGIC (VR), BIOCHEMICAL (BR), AND COMPLETE RESPONSE (CR) AMONG PATIENTS TREATED WITH NUCLEOS (T) IDE ANALOGS (NA): A REAL- B STUDY**
Chau, A., Jun, D., Hsu, Y., Toyoda, H., Yeh, M., Watanabe, T., Honda, T., Trinh, H., Nozaki, A., Uojima, H., Ishikawa, T., Huang, D., Vutien, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S279-S281
 - **LATE DIAGNOSIS OF CHRONIC HEPATITIS B IS ASSOCIATED WITH INCREASED LIVER- RELATED COMPLICATIONS A POPULATION- BASED, RETROSPECTIVE COHORT STUDY**
Le, M., Liu, J., Cheung, R., Nguyen, M.
LIPPINCOTT WILLIAMS & WILKINS.2024: S274-S275
 - **ANTIVIRAL EFFICACY OF TENOFOVIR ALAFENAMIDE VERSUS ENTECAVIR IN TREATMENT-NAÏVE CHRONIC HEPATITIS B: A MULTICENTER LONGITUDINAL STUDY**
Nguyen, M., Li, J., Jun, D., Chau, A., Huy Trinh, Hsu, Y., Watanabe, T., Honda, T., Xu, X., Ni, W., Nozaki, A., Uojima, H., Ishikawa, T., et al
LIPPINCOTT WILLIAMS & WILKINS.2024: S337-S338
 - **TEMPORAL CHANGES IN DEMOGRAPHICS AND COMPLICATIONS/ COMORBIDITIES OF PATIENT WITH CHRONIC HEPATITIS B: RESULTS OF A REALWORLD U. S. COHORT**
Nguyen, M., Ono, H., Zhang, X., Cheung, R.
LIPPINCOTT WILLIAMS & WILKINS.2024: S319
 - **NONVIRAL HCC IS INDEPENDENTLY ASSOCIATED WITH POORER SURVIVAL AS COMPARED TO VIRAL HCC: A US POPULATION-BASED STUDY**
Garcia, E., Chien, N., Yeo, Y., Nguyen, M., Cheung, R.
LIPPINCOTT WILLIAMS & WILKINS.2024: S1499-S1500
 - **THE DIAGNOSTIC UTILITY OF THE UNITED STATES FATTY LIVER INDEX FOR METABOLIC DYSFUNCTION ASSOCIATED LIVER DISEASE**
Bradford, T., Brian Nguyen, Vy Nguyen, Le, M., Manikat, R., Cheung, R., Mindie Nguyen
LIPPINCOTT WILLIAMS & WILKINS.2024: S666-S667
 - **ASO Author Reflections: Hepatic Resection as the Primary Treatment Modality for Hepatocellular Carcinoma After Orthotopic Liver Transplantation.** *Annals of surgical oncology*
Matar, A. J., Oppat, K. M., Bennett, F. J., Warren, E. A., Wehrle, C. J., Li, Z., Rajendran, L., Rokop, Z. P., Kubal, C., Biesterveld, B. E., Foley, D. P., Maeda, M., Nguyen, et al
2024
 - **Letter: Enhancing cirrhosis management-The critical role of social workers in supporting NAFLD surveillance: Authors' reply.** *Alimentary pharmacology & therapeutics*
Tran, S., Henry, L., Nguyen, M. H.

2024

- **Trends of chronic liver diseases by income level and socioeconomic factors in the United States: A population-based study.** *Alimentary pharmacology & therapeutics*
Lee, E. Y., Nguyen, V. H., Cheung, R., Nguyen, M. H.
2024
- **Integrating Strategic, Equity, and Socioeconomic Perspectives: A Holistic Approach to Advancing Hepatitis B Management and Outcomes.** *Journal of hepatology*
Kudaravalli, S., Henry, L., Nguyen, M. H.
2024
- **Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.** *Scientific reports*
Danpanichkul, P., Suparan, K., Sukphutanan, B., Kaeosri, C., Tothananarungroj, P., Sirimangklanurak, S., Kalligeros, M., Polpichai, N., Pang, Y., Wijarnpreecha, K., Sripongpan, P., Chamroonkul, N., Nguyen, et al
2024; 14 (1): 19544
- **Hepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation.** *Annals of surgical oncology*
Matar, A. J., Oppat, K. M., Bennett, F. J., Warren, E. A., Wehrle, C. J., Li, Z., Rajendran, L., Rokop, Z. P., Kubal, C., Biesterveld, B. E., Foley, D. P., Maeda, M., Nguyen, et al
2024
- **Correspondence to editorial on "Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study".** *Clinical and molecular hepatology*
Nguyen, V. H., Nguyen, M. H.
2024
- **Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis.** *EClinicalMedicine*
Quek, J. W., Loo, J. H., Lim, E. Q., Chung, A. H., Othman, A. B., Tan, J. J., Barnett, S., Nguyen, M. H., Wong, Y. J.
2024; 74: 102727
- **Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis** *ECLINICALMEDICINE*
Quek, J., Loo, J., Lim, E., Chung, A., Othman, A., Tan, J., Barnett, S., Nguyen, M. H., Wong, Y.
2024; 74
- **Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.** *Journal of clinical and translational hepatology*
Ji, F., Tran, S., Ogawa, E., Huang, C. F., Suzuki, T., Wong, Y. J., Toyoda, H., Jun, D. W., Li, L., Uojima, H., Nozaki, A., Chuma, M., Tseng, et al
2024; 12 (7): 646-658
- **Impact of Income-to-Poverty Ratio on Long-Term Mortality of Persons with Chronic Liver Disease in the USA, 1999-2018.** *Digestive diseases (Basel, Switzerland)*
Nguyen, B. T., Nguyen, V. H., Le, M., Henry, L., Cheung, R., Nguyen, M. H.
2024: 1-13
- **Editorial: Redefining liver health-Personalised approach to assessment of serum ALT in clinical practice. Authors' reply.** *Alimentary pharmacology & therapeutics*
Tan, E. X., Huang, D. Q., Nguyen, M. H.
2024
- **N-terminal type III collagen propeptide, golgi protein 73 and their combination accurately assess significant and advanced fibrosis in chronic hepatitis B patients**
Chen, Q., Yeo, Y., Hu, X., Zhu, L., Rui, F., Yin, S., Zhu, C., Wu, C., Nguyen, M., Li, J.
ELSEVIER.2024: S625
- **Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts** *CURRENT HEPATOLOGY REPORTS*
Vutien, P., Nguyen, M. H.
2024; 23 (2): 227-240

- **A prospective, blinded, multicenter US evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis**
Taggart, D., Mahajan, S., Gallant, M., Pinkoviezky, I., Xu, J., Sorg, A., Roberts, C., Slinkov, D., Gorospe, E., Mubarak, A., Bhandari, B., Freilich, B., Gunn, et al
ELSEVIER.2024: S11
- **Editorial: Revisit the causes and long-term outcomes in cirrhosis patients-Authors' reply.** *Alimentary pharmacology & therapeutics*
Henry, L., Tran, S., Nguyen, M. H.
2024
- **An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.** *Med (New York, N.Y.)*
Zhang, L., El-Shabrawi, M., Baur, L. A., Byrne, C. D., Targher, G., Kehar, M., Porta, G., Lee, W. S., Lefere, S., Turan, S., Alisi, A., Weiss, R., Faienza, et al
2024
- **Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis.** *Journal of viral hepatitis*
Rui, F., Garcia, E., Hu, X., Ni, W., Xue, Q., Xu, Y., Xu, X., Shi, J., Nguyen, M. H., Cheung, R. C., Li, J.
2024
- **Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.** *Journal of gastroenterology and hepatology*
Jang, T. Y., Liang, P. C., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C. W., Yuen, M. F., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, et al
2024
- **Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling.** *Alimentary pharmacology & therapeutics*
Tan, E. X., Huang, D. Q., Yee, N. T., Wan, Z. H., Nerurkar, S. N., Kai, J. C., Goh, K. S., Ng, C. H., Muthiah, M., Zhou, Y., Woodward, A., Le, M. H., Yeo, et al
2024
- **Reply to Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC.** *Hepatology (Baltimore, Md.)*
Huang, D. Q., Nguyen, M. H.
2024
- **In Response to: Steatotic Liver Disease-Know Your Enemies.** *Clinical and molecular hepatology*
Le, M., Henry, L., Nguyen, M. H.
2024
- **Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.** *Alimentary pharmacology & therapeutics*
Park, J. E., Nguyen, V. H., Tsai, P. C., Toyoda, H., Leong, J., Guy, J. E., Yeh, M. L., Huang, C. F., Yasuda, S., Abe, H., Hsu, Y. C., Tseng, C. H., Liu, et al
2024
- **Thick Data Analytics (TDA): An Iterative and Inductive Framework for Algorithmic Improvement** *The American Statistician*
Nguyen, M., Eulalio, T., Marafino, B. J., Rose, C., Chen, J. H., Baiocchi, M.
2024
- **Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease.** *Journal of clinical and translational hepatology*
Nguyen, V. H., Ha, A., Rouillard, N. A., Le, R. H., Fong, A., Gudapati, S., Park, J. E., Maeda, M., Barnett, S., Cheung, R., Nguyen, M. H.
2023; 11 (7): 1448-1454
- **Hepatitis B Core-Related Antigen Dynamics and Risk of Subsequent Clinical Relapses after Nucleos(t)ide Analog Cessation.** *Clinical and molecular hepatology*
Tsai, Y., Wu, J., Tseng, C., Chen, T., Wu, Y., Chen, C., Fang, Y., Yang, T., Nguyen, M. H., Lin, J., Hsu, Y.
2023

- **Chronic Hepatitis B and Steatotic Liver Disease: a Blessing in Disguise?** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Xu, X., Nguyen, M. H., Li, J.
2023
- **Collaborating with AI in literature search-An important frontier.** *Hepatology communications*
Enomoto, M., Tseng, C., Hsu, Y., Thuy, L. T., Nguyen, M. H.
2023; 7 (12)
- **Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease** *JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY*
Nguyen, V. H., Ha, A., Rouillard, N., Le, R., Fong, A., Gudapati, S., Park, J., Maeda, M., Barnett, S., Cheung, R., Nguyen, M. H.
2023
- **Use and Outcomes of Hepatitis B Virus-Positive Grafts for Kidney or Heart Transplantation in the United States From 1999 to 2021.** *Transplantation*
Singal, A. K., Reddy, K. R., Nguyen, M. H., Younossi, Z., Kwo, P., Kuo, Y. F.
2023
- **Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.** *The Kaohsiung journal of medical sciences*
Jang, T., Liang, P., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C., Yuen, M., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, et al
2023
- **Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.** *Alimentary pharmacology & therapeutics*
Ogawa, E., Jun, D. W., Toyoda, H., Hsu, Y. C., Yoon, E. L., Ahn, S. B., Yeh, M. L., Do, S., Trinh, H. N., Takahashi, H., Enomoto, M., Kawada, N., Yasuda, et al
2023
- **Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection-Authors' reply.** *Alimentary pharmacology & therapeutics*
Hsu, Y. C., Nguyen, M. H., Wu, C. Y.
2023; 58 (7): 733-734
- **DIABETES MELLITUS IS AN INDEPENDENT PREDICTOR OF SIGNIFICANT INFLAMMATION AND FIBROSIS IN CHRONIC HEPATITIS B PATIENTS CONCURRENT WITH HEPATIC STEATOSIS**
Li, J., Rui, F., Nguyen, B., Zheng, Q., Zeng, Q., He, Z., Shi, J., Wu, C., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S424-S425
- **ACUTE HEPATITIS FLARES AFTER CESSATION OF NUCLEOS(T) IDE ANALOGUES ARE ASSOCIATED WITH LOWER RATES OF HBsAg SEROCLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS**
Tsai, Y., Wu, J., Tseng, C., Wu, Y., Lin, J., Nguyen, M. H., Hsu, Y.
LIPPINCOTT WILLIAMS & WILKINS.2023: S501-S502
- **INCIDENCE OF NAFLDRELATED HEPATOCELLULAR CARCINOMA WITH DETAILED STRATIFICATION BY RISK FACTORS: A NATIONWIDE UNITED STATES COHORT STUDY**
Lai, R., Barnett, S. D., Kam, L., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S984
- **LOW ANTIVIRAL TREATMENT RATE FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)-A REAL-WORLD NATIONWIDE U. S. STUDY**
Kam, L., Yeo, Y., Ji, F., Henry, L., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S62
- **DIFFERENCES BETWEEN BIOPSY-PROVEN NASH PATIENTS WITH AND WITHOUT DIABETES MELLITUS**
Dang, H., Nguyen, V. H., Tsai, P., Ito, T., Kawanaka, M., Atsukawa, M., Arai, T., Hayama, K., Yeh, M., Maeda, M., Chuang, W., Huang, C., Dai, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S947-S948
- **DISPARITIES IN SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) BY LIVER DISEASE ETIOLOGY AND TIME PERIODS: A U. S. POPULATION- BASED STUDY FROM 2000 TO 2017**

Garcia, E., Chien, N., Yeo, Y., Nguyen, M. H., Cheung, R.
LIPPINCOTT WILLIAMS & WILKINS.2023: S1829-S1830

- **IMPACT OF SEX AND DIABETES ON LONG- TERM OUTCOMES OF PATIENTS WITH NAFLD**
Hand, C., Nguyen, V. H., Kam, L., Park, J., Le, R., Rouillard, N., Fong, A., Gudapati, S., Ha, A., Maeda, M., Barnett, S. D., Henry, L., Cheung, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S978-S979
- **IMPACT OF FATTY LIVER (FL) ON VIROLOGIC (VR), BIOCHEMICAL (BR), AND COMPLETE RESPONSE (CR) AMONG PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH NUCLEOS(T) IDE ANALOGS (NA): A REAL- B STUDY**
Chau, A., Yeh, M., Tsai, P., Trinh, H. N., Tseng, C., Hsu, Y., Ito, T., Kawashima, K., Suzuki, T., Ishikawa, T., Nozaki, A., Inoue, K., Eguchi, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S471-S472
- **LONG- TERM ALLCAUSE AND LIVER- RELATED MORTALITY OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)-RELATED LIVER CIRRHOSIS WHO UNDERWENT BARIATRIC SURGERY: A POPULATION- BASED STUDY**
Rouillard, N., Kam, L., Barnett, S. D., Manikat, R., Cheung, R. C., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S1237-S1238
- **DIFFERENCES IN INCIDENCE OF ADVERSE CLINICAL EVENTS AMONG NAFLD PARTICIPANTS WITH LIVER BIOPSY PROVEN NAFLD STRATIFIED BY NASH: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Le, D. M., Baez, T., Le, M. H., Dang, H., Nguyen, V. H., Lee, K., Ito, T., Wu, Y., Yeo, Y., Ji, F., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S949-S950
- **INCIDENCE OF ADVERSE CLINICAL EVENTS IN PERSONS WITH NAFLD: A SYSTEMATIC REVIEW AND META- ANALYSIS**
Le, D. M., Baez, T., Le, M. H., Dang, H., Nguyen, V. H., Lee, K., Ito, T., Wu, Y., Yeo, Y., Ji, F., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S983
- **TRENDS OF CHRONIC LIVER DISEASES BY INCOME LEVEL AND SOCIOECONOMIC FACTORS IN THE US NATIONAL POPULATION**
Lee, E., Nguyen, V. H., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S1303-S1304
- **DEVELOPMENT AND VALIDATION OF A RISK SCORE FOR FIBROSIS STAGE 2 OR HIGHER: A REAL-NAFLD STUDY OF 1902 REAL- WORLD PATIENTS WITH BIOPSY**
Nguyen, V. H., Ito, T., Dang, H., Tsai, P., Kawanaka, M., Atsukawa, M., Arai, T., Hayama, K., Yeh, M., Maeda, M., Barnett, S. D., Chuang, W., Huang, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S943-S944
- **REGIONAL AND SEX DIFFERENCES IN INCIDENCE OF ADVERSE CLINICAL EVENTS IN PERSONS WITH NAFLD: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Baez, T., Le, D. M., Le, M. H., Dang, H., Nguyen, V. H., Lee, K., Ito, T., Wu, Y., Yeo, Y., Ji, F., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S1039
- **IMPACT OF FAMILY INCOME-TO-POVERTY RATIO ON LONG-TERM MORTALITY OF PERSONS WITH CHRONIC LIVER DISEASE IN THE UNITED STATES, 1999-2018**
Nguyen, B., Nguyen, V. H., Le, M. H., Henry, L., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S1286-S1287
- **DIAGNOSIS IS DELAYED: PERICOMPLICATION DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE**
Manikat, R., Tran, S., Kam, L., Dronamraju, D., Cheung, R. C., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S945-S946
- **GLOBAL DIFFERENCES IN THE EVALUATION AND TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B: A REAL- B STUDY**
Kudaravalli, S., Huang, D. Q., Kam, L., Nguyen, V. H., Trinh, H. N., Hsu, Y., Li, J., Zhang, J., Ogawa, E., Lee, D., Ito, T., Watanabe, T., Enomoto, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S464-S466
- **COMPARISON OF CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO DID OR DIDN'T RECEIVE LIVER BIOPSY**
Zhang, X., Kam, L., Barnett, S. D., Henry, L., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S931
- **UPPER LIMIT OF NORMAL ALT LEVELS IN HEALTH AND METABOLIC DISEASES: POOLED ANALYSIS OF 484,177 INDIVIDUALS WITH BOOTSTRAP MODELLING**

- Tan, E., Huang, D. Q., Yee, N., Hui, W., Nerurkar, S., Chua, J., Goh, K., Ng, C., Muthiah, M., Zhou, Y., Woodward, A., Le, M. H., Yeo, et al
LIPPINCOTT WILLIAMS & WILKINS.2023: S1676-S1677
- **Sex differences in treatment response to nucleos(t)ide therapy in chronic hepatitis B: a multicenter longitudinal study.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Chau, A., Yeh, M. L., Tsai, P. C., Huang, D. Q., Kim, S. E., Trinh, H., Yoon, E. L., Oh, H., Jeong, J. Y., Ahn, S. B., An, J., Tseng, C. H., Hsu, et al
2023
 - **Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: a longitudinal real-world study.** *Clinical and molecular hepatology*
Nguyen, V. H., Le, I., Ha, A., Le, R. H., Rouillard, N. A., Fong, A., Gudapati, S., Park, J. E., Maeda, M., Barnett, S., Cheung, R., Nguyen, M. H.
2023
 - **Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multi-center Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.** *Gastroenterology*
Reddy, K. R., McLerran, D., Marsh, T., Parikh, N., Roberts, L. R., Schwartz, M., Nguyen, M. H., Befeler, A., Page-Lester, S., Tang, R., Srivastava, S., Rinaudo, J. A., Feng, et al
2023
 - **Trends of Cirrhosis-related Mortality in the USA during the COVID-19 Pandemic.** *Journal of clinical and translational hepatology*
Yeo, Y. H., He, X., Lv, F., Zhao, Y., Liu, Y., Yang, J. D., Zu, J., Ji, F., Nguyen, M. H.
2023; 11 (3): 751-756
 - **Reply: Proper monitoring instead of expanding treatment for improving prognosis of indeterminate phase hepatitis B patients.** *Hepatology (Baltimore, Md.)*
Huang, D. Q., Nguyen, M. H.
2023
 - **Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study.** *Alimentary pharmacology & therapeutics*
Hsu, Y. C., Lin, Y. H., Lee, T. Y., Nguyen, M. H., Tseng, C. H., Ho, H. J., Kao, F. Y., Lin, J. T., Wu, C. Y., Wu, C. Y.
2023
 - **Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.** *Hepatology international*
Wong, Y. J., Tran, S., Huang, C. F., Hsu, Y. C., Preda, C., Toyoda, H., Liu, J., Jun, D. W., Landis, C., Huang, D. Q., Gila, A., Negoita, L., Yasuda, et al
2023
 - **An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.** *Hepatobiliary surgery and nutrition*
Sun, D. Q., Targher, G., Byrne, C. D., Wheeler, D. C., Wong, V. W., Fan, J. G., Tilg, H., Yuan, W. J., Wanner, C., Gao, X., Long, M. T., Kanbay, M., Nguyen, et al
2023; 12 (3): 386-403
 - **Effectiveness of HCC surveillance programs using multitarget blood test: A modeling study.** *Hepatology communications*
Chhatwal, J., Samur, S., Yang, J. D., Roberts, L. R., Nguyen, M. H., Ozbay, A. B., Ayer, T., Parikh, N. D., Singal, A. G.
2023; 7 (6)
 - **COST OF LIVER CANCER SCREENING IN PATIENTS WITH CIRRHOSIS**
Samur, S., Rustgi, V. K., Parikh, N. D., Yang, J. D., Roberts, L. R., Nguyen, M. H., Ozbay, A. B., Ayer, T., Singal, A. G., Chhatwal, J.
ELSEVIER SCIENCE INC.2023: S152
 - **Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis**
Wong, Y., Nguyen, V. H., Yang, H., Li, J., Le, M., Wu, W., Han, N., Fong, K., Chen, E., Wong, C., Rui, F., Xu, X., Xue, et al
ELSEVIER.2023: S1096-S1097
 - **Effectiveness of HCC surveillance programs using multitarget blood test: A modeling study.** *Hepatology communications*
Chhatwal, J., Samur, S., Yang, J. D., Roberts, L. R., Nguyen, M. H., Ozbay, A. B., Ayer, T., Parikh, N. D., Singal, A. G.
2023; 7 (6)

- **COST OF LIVER CANCER SCREENING IN PATIENTS WITH CIRRHOSIS**
Samur, S., Rustgi, V. K., Parikh, N. D., Yang, J. D., Roberts, L. R., Nguyen, M. H., Ozbay, A. B., Ayer, T., Singal, A. G., Chhatwal, J.
ELSEVIER SCIENCE INC.2023: S152
- **An international multidisciplinary consensus statement on MAFLD and the risk of CVD.** *Hepatology international*
Zhou, X. D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A., Wong, V. W., Cai, J., Shapiro, M. D., Eslam, M., Steg, P. G., Sung, K. C., Misra, et al
2023
- **Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.** *Clinical and molecular hepatology*
Wong, Y. J., Nguyen, V. H., Yang, H. I., Li, J., Le, M. H., Wu, W. J., Han, N. X., Fong, K. Y., Chen, E., Kumar, R., Wong, C., Rui, F., Xu, et al
2023
- **Letter: grouping traditional biomarkers that are within reach has great utility - further validation is needed.** *Alimentary pharmacology & therapeutics*
Lai, R., Nguyen, M. H.
2023; 57 (9): 1050-1051
- **Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis.** *Current opinion in gastroenterology*
Liu, Y., Ji, F., Nguyen, M. H.
2023; 39 (3): 131-139
- **Immortal Time and Selection Biases in Study of Direct-Acting Antiviral Treatment and Hepatitis C Outcomes-Reply.** *JAMA internal medicine*
Ogawa, E., Yeo, Y. H., Nguyen, M. H.
2023
- **Nonalcoholic fatty liver disease (NAFLD) detection and deep learning in a Chinese community-based population.** *European radiology*
Yang, Y., Liu, J., Sun, C., Shi, Y., Hsing, J. C., Kamyra, A., Keller, C. A., Antil, N., Rubin, D., Wang, H., Ying, H., Zhao, X., Wu, et al
2023
- **Global treatment rate and barriers to DAA therapy: A systematic review and meta-analysis of 146 studies and 1,760,352 HCV patients.** *Liver international : official journal of the International Association for the Study of the Liver*
Nguyen, V. H., Huang, D. Q., Le, M. H., Jin, M., Lee, E. Y., Henry, L., Nerurkar, S. N., Ogawa, E., Thin, K. N., Teng, M. L., Goh, K. S., Kai, J. C., Wong, et al
2023
- **Letter to the Editor: Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Lai, R., Nguyen, M. H.
2023
- **An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease** *HEPATOBIILIARY SURGERY AND NUTRITION*
Sun, D., Targher, G., Byrne, C. D., Wheeler, D. C., Wong, V., Fan, J., Tilg, H., Yuan, W., Wanner, C., Gao, X., Long, M. T., Kanbay, M., Nguyen, et al
2023
- **Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Liu, J., Kam, L. Y., Huang, D. Q., Henry, L., Cheung, R., Nguyen, M. H.
2023
- **A prospective clinical trial to evaluate the performance of a multi-analyte blood test for early detection of hepatocellular carcinoma among at-risk patients with liver cirrhosis: The CLiMB study.**
Roy, D., Xu, J., Taggart, D. J., Gallant, M. A., Bush, K., Reed, O., Akhtar, A., Yang, J., Nguyen, M., Li, W., Van Etten, R. A.
LIPPINCOTT WILLIAMS & WILKINS.2023: TPS617
- **Letter: rising incidence and poor survival in patients with nonviral HCC-better HCC surveillance and treatment for alcohol-associated and non-alcohol fatty liver diseases are needed.** *Alimentary pharmacology & therapeutics*
Manikat, R., Nguyen, M. H.
2023; 57 (3): 361-362

- **Racial and ethnic disparities in years of potential life loss among patients with cirrhosis during the COVID-19 pandemic in the United States.** *The American journal of gastroenterology*
Zhao, Y., Yeo, Y. H., Samaan, J., Lv, F., He, X., Liu, J., Li, M., Gao, N., Park, J., Yang, J. D., Ayoub, W. S., Zhang, L., Odden, et al
2023
- **Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis.** *JHEP reports : innovation in hepatology*
Tseng, C. H., Chen, T. H., Wu, J. L., Lee, T. Y., Borghi, J. A., Lin, J. T., Nguyen, M. H., Hsu, Y. C.
2023; 5 (1): 100617
- **Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States** *JOURNAL OF HEPATOLOGY*
Gao, X., Lv, F., He, X., Zhao, Y., Liu, Y., Zu, J., Henry, L., Wang, J., Yeo, Y., Ji, F., Nguyen, M. H.
2023; 78 (1): 16-27
- **Liver-Related Mortality in Hepatitis B Virus Core Antibody+/Hepatitis B Virus Surface Antigen- Patients: Occult Hepatitis B Virus, Hepatitis B Virus Reactivation, and Hepatocellular Carcinoma Development.** *The American journal of gastroenterology*
Jung, J., Nguyen, M. H.
2023; 118 (1): 24-25
- **Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.** *JAMA internal medicine*
Ogawa, E., Chien, N., Kam, L., Yeo, Y. H., Ji, F., Huang, D. Q., Cheung, R., Nguyen, M. H.
2022
- **Curing chronic hepatitis B virus infection.** *The Lancet. Infectious diseases*
Hsu, Y. C., Nguyen, M. H.
2022
- **Recognizing skin conditions in patients with cirrhosis: a narrative review.** *Annals of medicine*
Liu, Y., Zhao, Y., Gao, X., Liu, J., Ji, F., Hsu, Y. C., Li, Z., Nguyen, M. H.
2022; 54 (1): 3017-3029
- **Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.** *JAMA network open*
Nguyen, V. H., Kam, L., Yeo, Y. H., Huang, D. Q., Henry, L., Cheung, R., Nguyen, M. H.
2022; 5 (12): e2245424
- **A Reappraisal of the Diagnostic Performance of B-Mode Ultrasonography for Mild Liver Steatosis.** *The American journal of gastroenterology*
Lee, C. M., Yoon, E. L., Nakajima, A., Yoneda, M., Toyoda, H., Yasuda, S., Lee, J., Kim, M., Kang, B. K., Nguyen, M. H., Jun, D. W., Sumida, Y.
2022
- **Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B.** *Alimentary pharmacology & therapeutics*
Kam, L. Y., Huang, D. Q., Tobias, A. F., Poon, K., Henry, L., Kwo, P., Cheung, R., Nguyen, M. H.
2022
- **ANTIVIRAL THERAPY IS SEVERELY UNDERUTILIZED IN HEPATITIS B-AND HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA AFTER LIVER RESECTION: A REAL-HCC STUDY**
Huang, D., Kamal, R., Bonham, C., Tsai, P., Toyoda, H., Yeh, M., Yeh, M., Yasuda, S., Leong, J., Hoang, J., Maeda, M., Huang, C., Jun, et al
WILEY.2022: S1423-S1424
- **RACIAL AND ETHNIC DISPARITIES IN YEARS OF POTENTIAL LIFE LOST ASSOCIATED WITH CIRRHOSIS IN THE UNITED STATES BEFORE AND DURING THE COVID-19 PANDEMIC**
Yeo, Y., Zhao, Y., Samaan, J., Lv, F., He, X., Liu, Y., Gao, N., Odden, M. C., Ji, F., Nguyen, M. H.
WILEY.2022: S1074-S1075
- **IMPACT OF THE COVID-19 PANDEMIC ON MORTALITY RATE OF LIVER DISEASE IN THE UNITED STATES: A POPULATION-BASED STUDY, 2010-2021**
Gao, X., Lv, F., He, X., Zhao, Y., Liu, Y., Zu, J., Henry, L., Wang, J., Yeo, Y., Ji, F., Nguyen, M. H.
WILEY.2022: S117

- **RACIAL AND ETHNIC DISPARITIES IN CLINICAL PRESENTATION AND OUTCOMES AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES: A REAL-WORLD STUDY OF 10,135 PATIENTS**
Nguyen, V. H., Ha, A., Park, J., Rouillard, N., Le, R. H. X., Fong, A., Maeda, M., Nguyen, M. H.
WILEY.2022: S707-S708
- **GLOBAL INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Le, M., Le, D. M., Baez, T., Wu, Y., Lee, E. Y., Ito, T., Nguyen, M. H.
WILEY.2022: S850
- **SERIOUS ADVERSE CLINICAL EVENTS AFTER CESSATION OF NUCLEOS(T) IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Tseng, C., Chen, T., Wu, J., Lee, T., Borghi, J. A., Lin, J., Nguyen, M. H., Hsu, Y.
WILEY.2022: S237-S238
- **EXCESS CIRRHOSIS-RELATED MORTALITY AND RELEVANT DISPARITIES DURING THE COVID-19 PANDEMIC**
Yeo, Y., Zhao, Y., Samaan, J., Lv, F., He, X., Park, J., Liu, Y., Ji, F., Nguyen, M. H.
WILEY.2022: S129-S130
- **INCIDENCE AND PREDICTORS OF OFF-THERAPY RELAPSES AFTER CESSATION OF TENOFOVIR ALAFENAMIDE IN PATIENTS WITH CHRONIC HEPATITIS B**
Tseng, C., Chen, C., Huang, C., Chen, P., Jang, T., Yang, T., Nguyen, M. H., Hsu, Y.
WILEY.2022: S280
- **PREDICTION OF CLINICAL RELAPSE AFTER DISCONTINUATION OF NUCLEOS(T) IDE ANALOGS FOR CHRONIC HEPATITIS B USING DYNAMIC HBV CORE-RELATED ANTIGEN MEASUREMENTS**
Tsai, Y., Wu, J., Tseng, C., Chen, T., Wu, Y., Chen, C., Fang, Y., Yang, T., Nguyen, M. H., Hsu, Y.
WILEY.2022: S295
- **THE TREND OF YEARS OF POTENTIAL LIFE LOST ASSOCIATED WITH CIRRHOSIS BEFORE AND DURING THE COVID-19 PANDEMIC: A POPULATION-BASED STUDY**
Zhao, Y., Yeo, Y., Samaan, J., Lv, F., He, X., Gao, N., Park, J., Yang, J., Ayoub, W. S., Odden, M. C., Ji, F., Nguyen, M. H.
WILEY.2022: S74-S75
- **RACIAL AND ETHNIC DISPARITIES IN CLINICAL PRESENTATION, TREATMENT, AND OVERALL SURVIVAL IN PATIENTS WITH HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA (HCV-HCC): A REAL-WORLD EXPERIENCE FROM THE REAL-HCC REGISTRY**
Park, J., Nguyen, V. H., Tsai, P., Toyoda, H., Leong, J., Guy, J. E., Yeh, M., Huang, C., Yasuda, S., Abe, H., Hsu, Y., Tseng, C., Liu, et al
WILEY.2022: S403-S405
- **HIGHER HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN CHRONIC HEPATITIS C (CHC) PATIENTS AFTER HEPATITIS C VIRUS (HCV) CURE COMPARED TO TREATED CHRONIC HEPATITIS B (CHB): RESULTS FROM A MULTINATIONAL REAL-WORLD COHORT OF PATIENTS WITH CIRRHOSIS**
Park, J., Tran, S., Ogawa, E., Huang, C., Toyoda, H., Chen, C., Yeh, M., Tseng, C., Hsu, Y., Kawashima, K., Preda, C., Istratescu, D., Yasuda, et al
WILEY.2022: S377-S379
- **SEX DIFFERENCES IN CLINICAL PRESENTATION AND SURVIVAL IN PATIENTS WITH CIRRHOSIS**
Fong, A., Tran, A., Ha, A., Nguyen, V. H., Zhao, C., Jin, M., Gao, K., Cheung, R., Nguyen, M. H.
WILEY.2022: S1174-S1175
- **DIFFERENTIAL CHARACTERISTICS AND SURVIVAL BY CHRONIC LIVER DISEASE (CLD) ETIOLOGY IN A NATIONWIDE REAL-WORLD COHORT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), 2003-2021**
Tran, S., Zou, B., Kam, L., Huang, D., Henry, L., Hsing, A., Cheung, R., Nguyen, M. H.
WILEY.2022: S1422-S1423
- **PREDICTING HEPATOCELLULAR CARCINOMA DEVELOPMENT IN NAFLD PATIENTS WITHOUT CIRRHOSIS**
Huang, D., Lin, Y., Tran, S., Zou, B., Yeo, Y., Cheung, R., Nguyen, M. H.
WILEY.2022: S1430
- **REAL-WORLD TREATMENT OUTCOME WITH PROTEASE INHIBITOR (PI) VERSUS NON-PI DIRECT ACTING ANTIVIRAL (DAA) IN DECOMPENSATED HEPATITIS C (HCV) CIRRHOSIS: A REAL-C STUDY WITH INVERSE PROBABILITY OF TREATMENT WEIGHTING (IPTW) ANALYSIS**
Wong, Y., Tran, S., Huang, C., Hsu, Y., Preda, C., Toyoda, H., Liu, J., Jun, D., Landis, C., Huang, D., Gila, A., Negoita, L., Yasuda, et al

WILEY.2022: S45-S47

- **UTILIZATION OF ANTIVIRAL THERAPY AND ITS IMPACT ON SURVIVAL RATES IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS-RELATED HEPATOCELLULAR CARCINOMA (HBV-HCC) IN THE UNITED STATES**
Kudaravalli, S., Kam, L., Huang, D., Cheung, R., Nguyen, M. H.
WILEY.2022: S282-S283
- **DIFFERENTIAL HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE AND SURVIVAL RATES BY ETIOLOGY OF CHRONIC LIVER DISEASE (CLD) IN A NATIONWIDE REAL-WORLD COHORT OF UNITED STATES PATIENTS WITH CIRRHOSIS, 2003-2021**
Tran, S., Zou, B., Kam, L., Huang, D., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2022: S1222-S1223
- **NATIONWIDE POPULATION-LEVEL REAL-WORLD EVIDENCE OF LONG-TERM MORTALITY, LIVER AND NON-LIVER BENEFITS OF DAA THERAPY IN PATIENTS WITH CHRONIC HEPATITIS (CHC) TREATED WITH DIRECT-ACTING ANTIVIRALS (DAA)**
Ogawa, E., Chien, N., Kam, L., Tran, S., Huang, D., Yeo, Y., Ji, F., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2022: S373-S374
- **ANTIVIRAL THERAPY REDUCES HEPATOCELLULAR CARCINOMA RISK AMONG HBV PATIENTS IN THE INDETERMINATE PHASE**
Huang, D., Tran, A., Yeh, M., Tsai, P., Chuang, W., Huang, C., Dai, C., Toyoda, H., Yasuda, S., Trinh, H., Ogawa, E., Ishigami, M., Ito, et al
WILEY.2022: S34-S35
- **CHARACTERISTICS AND TREATMENT RATE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN THE DAA AND COVID-19 ERAS IN THE UNITED STATES**
Nguyen, V. H., Kam, L., Yeo, Y., Huang, D., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2022: S370-S371
- **INCREASED TREATMENT RESPONSE AND BONE DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B SWITCHED TO TENOFOVIR ALAFENAMIDE FROM OTHER NUCLEOS(T) IDE ANALOGUE: 96-WEEK RESULTS FROM A PROSPECTIVE MULTINATIONAL STUDY**
Ogawa, E., Jun, D., Toyoda, H., Hsu, Y., Yoon, E., Ahn, S., Do, S. T., Trinh, H. N., Takahashi, H., Enomoto, M., Kawada, N., Yasuda, S., Tseng, et al
WILEY.2022: S281-S282
- **RACIAL AND ETHNIC DISPARITIES IN CHARACTERISTICS AND CARE PATTERNS OF CHRONIC HEPATITIS B (CHB) PATIENTS IN THE UNITED STATES (US): RESULTS OF A NATIONWIDE COHORT**
Liu, J., Kam, L., Huang, D., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2022: S292
- **A NOVEL EDUCATIONAL PROGRAM TO ADDRESS MISUNDERSTANDINGS IN APPLYING AASLD HBV TREATMENT GUIDELINES**
Ahn, J., Anderson, S., Dela Cruz, A., Kwo, P., Nguyen, M. H., Schwartz, Z.
WILEY.2022: S296-S297
- **CHARACTERISTICS AND CARE OF CHRONIC HEPATITIS B PATIENTS WITH ADVANCED PRACTICE PROVIDERS**
Kam, L., Huang, D., Tobias, A. F., Poon, K., Henry, L., Kwo, P., Cheung, R., Nguyen, M. H.
WILEY.2022: S279-S280
- **A NOVEL EDUCATIONAL PROGRAM TO ADDRESS MISUNDERSTANDINGS IN APPLYING AASLD HBV TREATMENT GUIDELINES**
Ahn, J., Anderson, S., Dela Cruz, A., Kwo, P., Nguyen, M. H., Schwartz, Z.
WILEY.2022: S296-S297
- **CHARACTERISTICS AND CARE OF CHRONIC HEPATITIS B PATIENTS WITH ADVANCED PRACTICE PROVIDERS**
Kam, L., Huang, D., Tobias, A. F., Poon, K., Henry, L., Kwo, P., Cheung, R., Nguyen, M. H.
WILEY.2022: S279-S280
- **Trends of Cirrhosis-related Mortality in the USA during the COVID-19 Pandemic** *JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY*
Yeo, Y., He, X., Lv, F., Zhao, Y., Liu, Y., Yang, J., Zu, J., Ji, F., Nguyen, M. H.
2022
- **Bulevirtide and tenofovir combination therapy for hepatitis D virus infection: longer treatment and more diverse trial populations are needed.** *The Lancet. Infectious diseases*
Ito, T., Nguyen, M. H.
2022

- **Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.** *Hepatology international*
Hsu, Y. C., Jun, D. W., Peng, C. Y., Yeh, M. L., Trinh, H., Wong, G. L., Kim, S. E., Chen, C. H., Oh, H., Lin, C. H., Trinh, L., Wong, V. W., Yoon, et al
2022
- **Liver complications in untreated treatment-ineligible versus treated treatment-eligible patients with hepatitis B.** *Digestive diseases (Basel, Switzerland)*
Huang, D. Q., Lee, D. H., Le, M. H., Le, A., Yeo, Y. H., Trinh, H. N., Chung, M., Nguyen, V., Johnson, T., Zhang, J. Q., Wong, C., Wong, C., Li, et al
2022
- **Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.** *BMC gastroenterology*
Alshuwaykh, O., Cheung, A., Goel, A., Kwong, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Nguyen, M., Kim, W. R., Kwo, et al
2022; 22 (1): 410
- **Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19** *GUT*
Zhao, Y., Yeo, Y., Samaan, J., Lv, F., He, X., Gao, N., Park, J., Yang, J., Ayoub, W., Odden, M. C., Ji, F., Nguyen, M. H.
2022
- **Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.** *Hepatology communications*
Alshuwaykh, O., Daugherty, T., Cheung, A., Goel, A., Dhanasekaran, R., Ghaziani, T. T., Ahmed, A., Dronamraju, D., Kumari, R., Kwong, A., Nguyen, M., Kim, W. R., Kwo, et al
2022
- **Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.** *Journal of hepatology*
Gao, X., Lv, F., He, X., Zhao, Y., Liu, Y., Zu, J., Henry, L., Wang, J., Yeo, Y. H., Ji, F., Nguyen, M. H.
2022
- **Transient Elastography and Serum-based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort- a Cross Sectional Analysis.** *Digestive diseases (Basel, Switzerland)*
Le, M. H., Henry, L., Cheung, R., Nguyen, M. H.
2022
- **Letter to the editor: Screening for fatty liver disease and fibrosis in the elderly population: A call for action.** *Hepatology (Baltimore, Md.)*
Li, J., Nguyen, M. H.
2022
- **Increased mortality of patients with alcohol-related liver diseases during the COVID-19 pandemic in the United States.** *Journal of internal medicine*
Yeo, Y. H., Zou, B., Cheung, R., Nguyen, M. H.
2022
- **Utilization and outcomes of hepatitis B-positive grafts in orthotopic liver transplantation in the United States, 1999-2021.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Ali, S. E., Vutien, P., Bonham, C. A., Landis, C., Kwo, P., Esquivel, C., Nguyen, M. H.
2022
- **Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos (t)ide analogue: 96-week results from a prospective multinational study**
Ogawa, E., Jun, D., Toyoda, H., Hsu, Y., Yoon, E., Ahn, S., Do, S., Huy Trinh, Takahashi, H., Enomoto, M., Yasuda, S., Tseng, C., Yeh, M., et al
ELSEVIER.2022: S875-S876
- **Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial**
Chhatwal, J., Samur, S., Yang, J., Roberts, L., Nguyen, M., Ozbay, A., Ayer, T., Parikh, N. D., Singal, A.
ELSEVIER.2022: S214-S215
- **The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis**
Tantai, X., Liu, Y., Yeo, Y., Praktiknjo, M., Mauro, E., Hamaguchi, Y., Engelmann, C., Zhang, P., Jeong, J., van Vugt, J., Xiao, H., Deng, H., Gao, et al
ELSEVIER.2022: S883-S884

- **Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.** *JAMA network open*
Tan, D. J., Ng, C. H., Tay, P. W., Syn, N., Muthiah, M. D., Lim, W. H., Tang, A. S., Lim, K. E., Lim, G. E., Tamaki, N., Kim, B. K., Teng, M. L., Fung, et al
2022; 5 (6): e2219407
- **Machine Learning Can Predict Recurrence Patterns After Liver Transplantation in Hepatocellular Carcinoma Patients: Analysis from the US Multicenter HCC Transplant Consortium**
Narayan, R. R., Safarnejad, L., Tran, B., Nguyen, M., Ross, E., Agopian, V., Melcher, M.
SPRINGER.2022: 348-349
- **Response to "Does NAFLD prevalence data expire?"** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Yeo, Y. H., Le, M. H., Nguyen, M. H.
2022
- **Metabolic abnormalities play a crucial role in non-obese people suffering from non-alcoholic fatty liver disease (NAFLD).** *Hepatobiliary surgery and nutrition*
Ye, Q., Ito, T., Henry, L., Nguyen, M. H.
2022; 11 (2): 333-334
- **Defining Age-Related Thresholds for ALT and the Risk of Confounders** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Huang, D. Q., Nguyen, M. H.
2022; 20 (3): 715-716
- **Renal outcomes with tenofovir alafenamide in liver transplant recipients.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Liu, J. K., Vutien, P., Huang, D. Q., Ishigami, M., Landis, C., Nguyen, M. H., REAL-B Liver Transplant Study Group, Nikhil Daniel, P. C., Ito, T., Dang, H., Mayumi, M., Leong, J.
2022
- **Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial**
Chhatwal, J., Samur, S., Yang, J., Roberts, L. R., Nguyen, M., Ozbay, A., Ayer, T., Parikh, N., Singal, A. G.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Increased risk of liver-related outcomes in chronic hepatitis B patients with metabolic syndrome: A systematic review and meta-analysis.** *Digestive diseases (Basel, Switzerland)*
Thin, K. N., Tran, A., Li, J., Lee, E. Y., Yang, H., Rui, F., Liu, C., Stave, C. D., Cheung, R. C., Nguyen, M. H.
2022
- **A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.** *Hepatology communications*
Lin, N., Lin, Y., Xu, J., Liu, D., Li, D., Meng, H., Gallant, M. A., Kubota, N., Roy, D., Li, J. S., Gorospe, E. C., Sherman, M., Gish, et al
2022
- **Chronic hepatitis B and fatty liver -weal or woe?** *The American journal of gastroenterology*
Li, J., Henry, L., Nguyen, M. H.
2022
- **Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B.** *Alimentary pharmacology & therapeutics*
Hu, H. H., Jeng, W. J., Pan, M. H., Luo, W. S., Chang, C. L., Huang, Y. T., Su, C. Y., Chiang, C. T., Jen, C. L., Chien, Y. C., Lu, S. N., Wang, L. Y., Huang, et al
2022
- **MAFLD and pregnancy- What are the consequences?** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Nakanishi, A., Henry, L., Nguyen, M. H.
2022
- **Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?** *Liver international : official journal of the International Association for the Study of the Liver*

Wong, Y. J., Nguyen, M. H.
2022

- **Letter: hepatic steatosis and fibrosis in chronic hepatitis B-the chicken-and-egg conundrum. Authors' reply.** *Alimentary pharmacology & therapeutics*
Zheng, Q., Nguyen, M. H.
2022; 55 (1): 145-146
- **Letter: hepatic steatosis in chronic hepatitis B-viral, metabolic or treatment-related? Authors' reply.** *Alimentary pharmacology & therapeutics*
Zheng, Q., Nguyen, M. H.
2022; 55 (1): 149
- **Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.** *Hepatology (Baltimore, Md.)*
Chen, V. L., Ramrakhiani, N. S., Nguyen, M. H.
1800
- **A MULTI-ANALYTE BLOOD TEST FOR ACCURATE AND EARLY DETECTION OF HEPATOCELLULAR CARCINOMA**
Lin, N., Lin, Y., Xu, J., Li, M., Liu, D., Gallant, M. A., Kubota, N., Roy, D., Li, J., Gorospe, E., Sherman, M., Gish, R. G., Abou-Alfa, et al
WILEY.2021: 1418A
- **Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome-wide association study.** *JGH open : an open access journal of gastroenterology and hepatology*
Wang, Z., Budhu, A. S., Shen, Y., Wong, L. L., Hernandez, B. Y., Tiirikainen, M., Ma, X., Irwin, M. L., Lu, L., Zhao, H., Lim, J. K., Taddei, T., Mishra, et al
2021; 5 (12): 1363-1372
- **Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome-wide association study** *JGH OPEN*
Wang, Z., Budhu, A. S., Shen, Y., Wong, L., Hernandez, B. Y., Tiirikainen, M., Ma, X., Irwin, M. L., Lu, L., Zhao, H., Lim, J. K., Taddei, T., Mishra, et al
2021
- **On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.** *Liver international : official journal of the International Association for the Study of the Liver*
Huang, C., Tyng-Yuan, J., Jun, D. W., Ahn, S. B., An, J., Enomoto, M., Takahashi, H., Ogawa, E., Yoon, E., Jeong, S. W., Shim, J., Jeong, J. Y., Kim, et al
2021
- **Lurking in acute hepatitis B flares following treatment cessation were inescapable uncertainty and potential irreversibility.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Hsu, Y., Tseng, C., Nguyen, M. H.
2021
- **Nationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in Korea.** *Journal of clinical medicine*
Ju, Y. C., Jun, D. W., Yoon, E. L., Ahn, S. B., Kim, Y. J., Nguyen, M. H.
2021; 10 (20)
- **ON-TREATMENT GAMMA-GLUTAMYL TRANSFERASE PREDICTS THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS**
Huang, C., Jang, T., Yu, M.
WILEY.2021: 440A-441A
- **CHANGE OF PREDICTIVE ABILITY IN NON-INVASIVE FIBROSIS MARKERS AMONG ASIAN NON-ALCOHOLIC FATTY LIVER DISEASE BY AGE, OBESITY, AND A PRESENCE OF TYPE 2 DIABETES**
Ito, T., Nguyen, V. H., Tanaka, T., Park, H., Yeh, M., Kawanaka, M., Arai, T., Atsukawa, M., Yoon, E., Tsai, P., Toyoda, H., Fujishiro, M., Huang, et al
WILEY.2021: 936A-937A
- **ALT LEVELS IN HEPATITIS B PATIENTS WITH CONCURRENT FATTY LIVER DISEASE: A US NATIONWIDE STUDY**
Chang, C., Kam, L., Dang, N., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 444A
- **TREATMENT EVALUATION, TREATMENT ELIGIBILITY, AND ANTIVIRAL THERAPY AMONG ASIAN AND NON-ASIAN PATIENTS WITH CHRONIC HEPATITIS B (CHB)**

- Huang, D., Nguyen, V. H., Trinh, H. N., Ogawa, E., Enomoto, M., Kozuka, R., Marciano, S., Suzuki, T., Yoshimaru, Y., Ko, K., Hui, R., Lee, D., Go, et al
WILEY.2021: 467A-468A
- **COMPARATIVE DIAGNOSTIC PERFORMANCE OF NONINVASIVE TESTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ADVANCED FIBROSIS: A UNITED STATES POPULATION-BASED STUDY IN 2017-2018**
Le, M., Yeo, Y., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 942A-943A
 - **DISPARITIES IN CIRRHOSIS-RELATED MORTALITY AMONG URBAN AND RURAL AREAS IN THE UNITED STATES: A POPULATION-BASED STUDY FROM 1999-2019**
Ha, A., Le, M., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 117A-118A
 - **LONG-TERM OVERALL AND RECURRENCE-FREE SURVIVAL FOLLOWING CURATIVE SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA IN THE RECENT DECADE: A META-ANALYSIS OF 110 STUDIES AND 82,392 PATIENTS**
Reveron-Thornton, R., Teng, M., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, X., Nerurkar, S. N., Ng, R., Teh, R., Prasad, D., Ito, T., Tanaka, T., Miyake, et al
WILEY.2021: 655A-656A
 - **UTILIZATION AND OUTCOMES OF HEPATITIS B-POSITIVE GRAFTS IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT) IN THE UNITED STATES, 1987-2020**
Ali, S., Vutien, P., Bonham, C., Landis, C., Kwo, P., Esquivel, C. O., Nguyen, M. H.
WILEY.2021: 919A-920A
 - **OVERALL (OS) AND RECURRENCE-FREE SURVIVAL (RFS) FOLLOWING SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA (HCC) WITH MACROVASCULAR INVASION (MVI): A META-ANALYSIS OF 40 STUDIES AND 8,218 PATIENTS**
Huang, D., Tran, A., Tan, X., Quek, S., Nerurkar, S., Teh, R., Teng, M., Yeo, E., Zou, B., Wong, C., Cheung, R. C., Esquivel, C. O., Bonham, et al
WILEY.2021: 861A
 - **META-ANALYSIS: REGIONAL DIFFERENCES IN OUTCOMES OF SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA**
Teng, M., Reveron-Thornton, R., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, X., Nerurkar, S. N., Ng, R., Teh, R., Prasad, D., Ito, T., Tanaka, T., Miyake, et al
WILEY.2021: 859A
 - **OPTIMIZING HEPATITIS B VIRUS SCREENING IN THE UNITED STATES USING A SIMPLE DEMOGRAPHICS-BASED MODEL**
Ramrakhiani, N., Chen, V., Le, M., Yeo, Y., Barnett, S. D., Waljee, A., Zhu, J., Nguyen, M. H.
WILEY.2021: 461A-462A
 - **GLOBAL NAFLD PREVALENCE NOW AND IN THE FUTURE- A META-ANALYSIS WITH TREND AND FORECASTING**
Le, M., Yeo, Y., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D., Zhao, C., Zhang, J., Liu, C., Chang, N., Xing, et al
WILEY.2021: 1011A-1012A
 - **ENTECAVIR VERSUS TENOFOVIR DISOPROXIL FUMARATE FOR SEROCLEARANCE OF HEPATITIS B SURFACE ANTIGEN IN AN INTERNATIONAL REAL-WORLD COHORT**
Hsu, Y., Jun, D., Peng, C., Yeh, M., Trinh, H. N., Wong, G. L. H., Kim, S., Chen, C., Oh, H., Lin, C., Yoon, E., Ahn, S., Huang, et al
WILEY.2021: 434A-436A
 - **DECLINING HBV IMMUNITY FOLLOWING HBV VACCINATION DURING CHILDHOOD/ADOLESCENCE AND AMNESTIC RESPONSE RATES TO BOOSTER: A SYSTEMATIC REVIEW AND META-ANALYSIS.**
Le, D. M., Le, M., Yeo, Y., Lee, E. Y., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 451A
 - **CHANGE OF PREDICTIVE ABILITY IN NON-INVASIVE FIBROSIS MARKERS AMONG ASIAN NON-ALCOHOLIC FATTY LIVER DISEASE BY AGE, OBESITY, AND A PRESENCE OF TYPE 2 DIABETES**
Ito, T., Nguyen, V. H., Tanaka, T., Park, H., Yeh, M., Kawanaka, M., Arai, T., Atsukawa, M., Yoon, E., Tsai, P., Toyoda, H., Fujishiro, M., Huang, et al
WILEY.2021: 936A-937A
 - **ALT LEVELS IN HEPATITIS B PATIENTS WITH CONCURRENT FATTY LIVER DISEASE: A US NATIONWIDE STUDY**
Chang, C., Kam, L., Dang, N., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 444A

- **TREATMENT EVALUATION, TREATMENT ELIGIBILITY, AND ANTIVIRAL THERAPY AMONG ASIAN AND NON-ASIAN PATIENTS WITH CHRONIC HEPATITIS B (CHB)**
Huang, D., Nguyen, V. H., Trinh, H. N., Ogawa, E., Enomoto, M., Kozuka, R., Marciano, S., Suzuki, T., Yoshimaru, Y., Ko, K., Hui, R., Lee, D., Go, et al
WILEY.2021: 467A-468A
- **COMPARATIVE DIAGNOSTIC PERFORMANCE OF NONINVASIVE TESTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ADVANCED FIBROSIS: A UNITED STATES POPULATION-BASED STUDY IN 2017-2018**
Le, M., Yeo, Y., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 942A-943A
- **DISPARITIES IN CIRRHOSIS-RELATED MORTALITY AMONG URBAN AND RURAL AREAS IN THE UNITED STATES: A POPULATION-BASED STUDY FROM 1999-2019**
Ha, A., Le, M., Cheung, R. C., Nguyen, M. H.
WILEY.2021: 117A-118A
- **LONG-TERM OVERALL AND RECURRENCE-FREE SURVIVAL FOLLOWING CURATIVE SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA IN THE RECENT DECADE: A META-ANALYSIS OF 110 STUDIES AND 82,392 PATIENTS**
Reveron-Thornton, R., Teng, M., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, X., Nerurkar, S. N., Ng, R., Teh, R., Prasad, D., Ito, T., Tanaka, T., Miyake, et al
WILEY.2021: 655A-656A
- **UTILIZATION AND OUTCOMES OF HEPATITIS B-POSITIVE GRAFTS IN ORTHOTOPIC LIVER TRANSPLANTATION (OLT) IN THE UNITED STATES, 1987-2020**
Ali, S., Vutien, P., Bonham, C., Landis, C., Kwo, P., Esquivel, C. O., Nguyen, M. H.
WILEY.2021: 919A-920A
- **OVERALL (OS) AND RECURRENCE-FREE SURVIVAL (RFS) FOLLOWING SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA (HCC) WITH MACROVASCULAR INVASION (MVI): A META-ANALYSIS OF 40 STUDIES AND 8,218 PATIENTS**
Huang, D., Tran, A., Tan, X., Quek, S., Nerurkar, S., Teh, R., Teng, M., Yeo, E., Zou, B., Wong, C., Cheung, R. C., Esquivel, C. O., Bonham, et al
WILEY.2021: 861A
- **META-ANALYSIS: REGIONAL DIFFERENCES IN OUTCOMES OF SURGICAL RESECTION FOR HEPATOCELLULAR CARCINOMA**
Teng, M., Reveron-Thornton, R., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, X., Nerurkar, S. N., Ng, R., Teh, R., Prasad, D., Ito, T., Tanaka, T., Miyake, et al
WILEY.2021: 859A
- **OPTIMIZING HEPATITIS B VIRUS SCREENING IN THE UNITED STATES USING A SIMPLE DEMOGRAPHICS-BASED MODEL**
Ramrakhiani, N., Chen, V., Le, M., Yeo, Y., Barnett, S. D., Waljee, A., Zhu, J., Nguyen, M. H.
WILEY.2021: 461A-462A
- **Provider Perspectives on HCC Surveillance in Patients With Cirrhosis: Community Provider Perspectives Matter** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
[Anonymous]
2021; 19 (9): 1991
- **Impact of non-alcoholic steatohepatitis (NASH) case definition on population characteristics identified in a US claims database**
Gallagher, K., Esposito, D., Jamal-Allial, A. A., Du, S., Patel, Y., Nguyen, M., Ness, E., Capozza, T., Titievsky, L.
WILEY.2021: 30-31
- **Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed After HCV SVR**
Yeh, M., Leong, J., Ogawa, E., Jun, D., Tseng, C., Landis, C., Tanaka, Y., Huang, C., Hayashi, J., Hsu, Y., Huang, J., Dai, C., Chuang, et al
WILEY.2021: 66
- **The incidence rates of hepatobiliary diseases among non-alcoholic steatohepatitis patients stratified by fibrosis-4 (FIB-4) index for liver fibrosis**
Jamal-Allial, A. A., Gallagher, K., Capozza, T., Du, S., Ness, E., Nguyen, M., Patel, Y., Esposito, D. B., Titievsky, L.
WILEY.2021: 360-361
- **Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR.** *Cancers*
Yeh, M., Liang, P., Tsai, P., Wang, S., Leong, J., Ogawa, E., Jun, D. W., Tseng, C., Landis, C., Tanaka, Y., Huang, C., Hayashi, J., Hsu, et al

2021; 13 (14)

- **Incidence of hepatic outcomes in patients with cirrhosis due to primary biliary cholangitis: A population-based epidemiology study**
Titievsky, L., Ness, E., Law, A., Goldman, E., Wheeler, D., Bertoia, M., Seeger, J. D., Nguyen, M., Patel, Y., Adekunle, F., Bassanelli, C.
ELSEVIER.2021: S434
- **Comorbidity and healthcare utilization burden of patients diagnosed with non-alcoholic steatohepatitis based on fibrosis-4 score severity**
Titievsky, L., Jamal-Allial, A., Gallagher, K., Capozza, T., Dodge, S., Du, S., Law, A., Natha, M., Ness, E., Nguyen, M., Patel, Y., Randhawa, A., Esposito, et al
ELSEVIER.2021: S577
- **Proportion, characteristics, and outcome of chronic hepatitis B who are 'linked to care' in Korea: A nationwide retrospective longitudinal study**
Ju, Y., Jun, D., Yoon, E., Ahn, S., Kim, Y., Nguyen, M.
ELSEVIER.2021: S675
- **Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed After HCV SVR**
Yeh, M., Liang, P., Tsai, P., Wang, S., Leong, J., Ogawa, E., Jun, D., Tseng, C., Landis, C., Tanaka, Y., Huang, C., Hayashi, J., Hsu, et al
ELSEVIER.2021: S780-S781
- **Incidence rates of hepatobiliary outcomes among patients with non-alcoholic steatohepatitis based on fibrosis-4 score severity at baseline**
Titievsky, L., Jamal-Allial, A., Gallagher, K., Capozza, T., Dodge, S., Du, S., Law, A., Natha, M., Ness, E., Nguyen, M., Patel, Y., Randhawa, A., Esposito, et al
ELSEVIER.2021: S566-S567
- **A population-based US study of hepatitis C diagnosis rate.** *European journal of gastroenterology & hepatology*
Yeo, Y. H., Kam, L. Y., Le, M. H., Jeong, D., Dang, N., Henry, L., Cheung, R., Nguyen, M. H.
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation.** *Hepatology communications*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W. R., Nguyen, M. H., Esquivel, C. O., Concepcion, et al
2021; 5 (3): 516-525
- **Treatment eligibility in hepatitis B: a call for better linkage to optimal care** *LANCET GASTROENTEROLOGY & HEPATOLOGY*
Huang, D. Q., Nguyen, M. H.
2021; 6 (3): 160
- **Chronic hepatitis, osteoporosis, and men: under-recognised and underdiagnosed** *LANCET DIABETES & ENDOCRINOLOGY*
Prasad, D., Nguyen, M. H.
2021; 9 (3): 141
- **Differential Characteristics and Outcomes of Asian and non-Asian Patients with HBV-related Hepatocellular Carcinoma.** *Liver international : official journal of the International Association for the Study of the Liver*
Huang, D. Q., Hoang, J. K., Leong, J. n., Riveiro-Barciela, M. n., Maeda, M. n., Yang, J. D., Accarino, E. V., Thin, K. n., Trinh, L. n., Cheung, R. C., Roberts, L. R., Buti, M. n., Schwartz, et al
2021
- **Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.** *Hepatology international*
Lin, C. W., Chen, Y. S., Lo, G. H., Wu, T. C., Yeh, J. H., Yeh, M. L., Dai, C. Y., Huang, J. F., Chuang, W. L., Roberts, L. n., Jun, D. W., Toyoda, H. n., Yasuda, et al
2021
- **Cost-effectiveness of HCC Surveillance among HCV patients after Sustained Virological Response with Direct-acting Antivirals.** *Liver international : official journal of the International Association for the Study of the Liver*
Huang, D. Q., Nguyen, M. H.
2021
- **Quantify the Risk of Severe Hepatitis B Flare in a Real World Where Cessation of Nucleos(t)ide Analog is Routinely Practiced.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Hsu, Y. C., Wu, J. L., Nguyen, M. H.

2021

- **Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers.** *Alimentary pharmacology & therapeutics*
Huang, D. Q., Nguyen, M. H.
2021; 54 (8): 1093-1094
- **Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.** *Hepatology international*
Mak, L. Y., Hoang, J., Jun, D. W., Chen, C. H., Peng, C. Y., Yeh, M. L., Kim, S. E., Huang, D. Q., Jeong, J. Y., Yoon, E., Oh, H., Tsai, P. C., Huang, et al
2021
- **Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.** *The lancet. Gastroenterology & hepatology*
Eslam, M., Ahmed, A., Després, J. P., Jha, V., Halford, J. C., Wei Chieh, J. T., Harris, D. C., Nangaku, M., Colagiuri, S., Targher, G., Joshi, S., Byrne, C. D., Khunti, et al
2021
- **HBV-related Hepatocellular Carcinoma: A Call to Improve Surveillance and Linkage to Care.** *Liver international : official journal of the International Association for the Study of the Liver*
Huang, D. Q., Hoang, J. K., Nguyen, M. H.
2021
- **Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.** *The American journal of gastroenterology*
Nguyen, M. H., Atsukawa, M., Ishikawa, T., Yasuda, S., Yokohama, K., Trinh, H. N., Arai, T., Fukunishi, S., Ogawa, E., Hsu, Y. C., Maeda, M., Dang, H., Tseng, et al
2021; 116 (6): 1264-1273
- **Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide#.** *Journal of the Formosan Medical Association = Taiwan yi zhi*
Yeh, M. L., Liang, P. C., Trinh, S., Huang, C. I., Huang, C. F., Hsieh, M. Y., Huang, J. F., Dai, C. Y., Chuang, W. L., Nguyen, M. H., Yu, M. L.
2021
- **Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.** *PLoS one*
Pan, C. Q., Chang, T. T., Bae, S. H., Brunetto, M. n., Seto, W. K., Coffin, C. S., Tan, S. K., Mo, S. n., Flaherty, J. F., Gaggar, A. n., Nguyen, M. H., Çelen, M. K., Thompson, et al
2021; 16 (5): e0251552
- **Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.** *Annals of surgery*
Turgeon, M. K., Shah, S. A., Delman, A. M., Tran, B. V., Agopian, V. G., Wedd, J. P., Magliocca, J. F., Kim, A., Cameron, A., Olyaei, A., Orloff, S. L., Anderson, M. P., Kubal, et al
2021; 274 (4): 613-620
- **Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities.** *Gut*
Hsu, Y. C., Tseng, C. H., Su, T. H., Kao, J. H., Nguyen, M. H.
2021
- **One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.** *Hepatology international*
Tseng, T. C., Choi, J. n., Nguyen, M. H., Peng, C. Y., Siakavellas, S. n., Papatheodoridis, G. n., Wang, C. C., Lim, Y. S., Lai, H. C., Trinh, H. N., Wong, C. n., Wong, C. n., Zhang, et al
2021
- **Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B.** *Liver international : official journal of the International Association for the Study of the Liver*
Ahn, S. B., Choi, J. n., Jun, D. W., Oh, H. n., Yoon, E. L., Kim, H. S., Jeong, S. W., Kim, S. E., Shim, J. J., Cho, Y. K., Lee, H. Y., Han, S. W., Nguyen, et al
2021

- **NASH/liver fibrosis prevalence and incidence of non-liver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidities: Lessons from South Korea.** *Digestive diseases (Basel, Switzerland)*
Park, J. n., Lee, E. Y., Li, J. n., Jun, M. J., Yoon, E. n., Ahn, S. B., Liu, C. n., Yang, H. n., Rui, F. n., Zou, B. n., Henry, L. n., Lee, D. H., Jun, et al
2021
- **Severe Acute Exacerbation after Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: a Real-world Study of Routine Practice.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Hsu, Y. C., Wu, J. L., Tseng, C. H., Nguyen, M. H., Lin, C. W., Hung, C. L.
2021
- **Treatment eligibility in hepatitis B: a call for better linkage to optimal care.** *The lancet. Gastroenterology & hepatology*
Huang, D. Q., Nguyen, M. H.
2021; 6 (3): 160
- **Sarcopenic Obesity in Non-Alcoholic Fatty Liver Disease-The Union of Two Culprits.** *Life (Basel, Switzerland)*
Emhmed Ali, S. n., Nguyen, M. H.
2021; 11 (2)
- **Improved survival and high sustained virologic response with DAA therapy in patients with HCV-related HCC: A call for expanded use.** *Journal of gastroenterology and hepatology*
Ji, F. n., Li, T. n., Nguyen, M. H.
2021
- **Defining age related thresholds for ALT and the risk of confounders.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Huang, D. Q., Nguyen, M. H.
2021
- **Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?** *Hepatology (Baltimore, Md.)*
Huang, D. Q., Yeo, Y. H., Nguyen, M. H.
2021
- **Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease.** *The Kaohsiung journal of medical sciences*
Prasad, D. n., Nguyen, M. H.
2021
- **Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease.** *The Kaohsiung journal of medical sciences*
Prasad, D. n., Nguyen, M. H.
2021
- **Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation** *HEPATOLOGY COMMUNICATIONS*
Alshuwaykh, O., Kwong, A., Goel, A., Cheung, A., Dhanasekaran, R., Ahmed, A., Daugherty, T., Dronamraju, D., Kumari, R., Kim, W., Esquivel, C. O., Concepcion, W., Melcher, et al
2020
- **ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation.** *Hepatology communications*
Huang, D. Q., Yeo, Y. H., Tan, E., Takahashi, H., Yasuda, S., Saruwatari, J., Tanaka, K., Oniki, K., Kam, L. Y., Muthiah, M. D., Hyogo, H., Ono, M., Barnett, et al
2020; 4 (11): 1624-1636
- **PRECISE MEDICINE USING A NEW SUBCLASSIFICATION AND CLINICAL MANAGEMENT FOR BARCELONA CLINIC LIVER CANCER STAGE C HEPATOCELLULAR CARCINOMA: A MULTICENTRE STUDY**
Lin, C., Chen, Y., Lo, G., Wu, T., Yeh, J., Wang, Y., Yeh, M., Dai, C., Huang, J., Chuang, W., Roberts, L. R., Jun, D., Toyoda, et al
WILEY.2020: 96A-97A
- **INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA (HCC) IN A PROSPECTIVELY FOLLOWED US COHORT OF PATIENTS AT RISK: HEPATOCELLULAR CARCINOMA EARLY DETECTION STRATEGY (HEDS) STUDY**

- Reddy, K., Parikh, N. D., Roberts, L. R., Schwartz, M. E., Nguyen, M. H., Befele, A., Page-Lester, S., McLerran, D., Srivastava, S., Rinaudo, J., Feng, Z., Marrero, J. A.
WILEY.2020: 643A
- **HCC RISK POST-SVR WITH DAAS IN EAST ASIANS: FINDINGS FROM THE REAL-C COHORT**
Tanaka, Y., Ogawa, E., Huang, C., Toyoda, H., Jun, D., Tseng, C., Hsu, Y., Enomoto, M., Takahashi, H., Furusyo, N., Yeh, M., Lio, E., Yasuda, et al
WILEY.2020: 34A–36A
 - **VIROLOGIC, BIOCHEMICAL, AND RENAL OUTCOMES OF TREATMENT-NAIVE PATIENTS WITH SEQUENTIAL THERAPY FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE PRACTICE**
Toyoda, H., Trinh, H. N., Leong, J., Atsukawa, M., Watanabe, T., Chuma, M., Liu, J., Yokohama, K., Dang, H., Maeda, M., Le, R., Thin, K., Tran, et al
WILEY.2020: 498A–499A
 - **DIFFERENTIAL CHARACTERISTICS AND OUTCOMES OF ASIAN AND NON-ASIAN PATIENTS WITH HBV-RELATED HEPATOCELLULAR CARCINOMA**
Huang, D., Hoang, J., Leong, J., Barciela, R., Maeda, M., Vargas-Accarino, E., Yang, J., Roberts, L. R., Cheung, R., Schwartz, M. E., Ferret, M., Nguyen, M. H.
WILEY.2020: 457A–458A
 - **THE EPIDEMIOLOGY OF NAFLD AND LEAN NAFLD IN JAPAN: A SYSTEMATIC REVIEW AND META-ANALYSIS WITH INDIVIDUAL PATIENT LEVEL DATA AND FORECASTING, 1995-2040**
Ito, T., Ishigami, M., Zou, B., Tanaka, T., Takahashi, H., Kurosaki, M., Maeda, M., Thin, K., Tanaka, K., Takahashi, Y., Itoh, Y., Oniki, K., Seko, et al
WILEY.2020: 999
 - **HEPATOCELLULAR CARCINOMA INCIDENCE WITH TENOFOVIR VS ENTECAVIR IN CHRONIC HEPATITIS B: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Tseng, C., Hsu, Y., Chen, T., Ji, F., Chen, I., Tsai, Y., Hai, H., Le, T., Hosaka, T., Sezaki, H., Borghi, J. A., Cheung, R., Enomoto, et al
WILEY.2020: 642A
 - **INCREASED VIRAL SUPPRESSION RATE IN REAL-WORLD CHRONIC HEPATITIS B (CHB) PATIENTS AFTER SWITCH FROM LONG-TERM ENTECAVIR (ETV) THERAPY TO TENOFOVIR ALAFENAMIDE (TAF): A MULTICENTER STUDY**
Nguyen, M. H., Atsukawa, M., Ishikawa, T., Yasuda, S., Trinh, H. N., Yokohama, K., Fukunishi, S., Ogawa, E., Hsu, Y., Maeda, M., Dang, H., Tseng, C., Takahashi, et al
WILEY.2020: 486A–487A
 - **ELASTOGRAPHY AND LIVER BIOPSY DATA FOR NASH AND FIBROSIS PREVALENCE AMONG SOUTH KOREAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A META-ANALYSIS OF 61 STUDIES AND 27,496 PARTICIPANTS**
Park, J., Lee, E., Lee, D., Li, J., Zou, B., Jun, M., Liu, C., Yang, H., Rui, F., Cheung, R., Nguyen, M. H.
WILEY.2020: 964–65
 - **SEQUENTIAL THERAPY WITH TENOFOVIR ALAFENAMIDE (TAF) IN PATIENTS WITH CHRONIC HEPATITIS B (CHB): AN INTERIM ANALYSIS OF AN ONGOING MULTINATIONAL PROSPECTIVE STUDY**
Ogawa, E., Toyoda, H., Jun, D., Hsu, Y., Yoon, E., Ahn, S., Yeh, M., Yasuda, S., Kawashima, K., Do, S. T., Trinh, H. N., Takahashi, H., Enomoto, et al
WILEY.2020: 495A–496A
 - **INCIDENCE AND FACTORS ASSOCIATED WITH FUNCTIONAL CURE (HBsAg SEROCLEARANCE) DURING ETV OR TDF THERAPY FOR CHRONIC HEPATITIS B (CHB): AN INTERNATIONAL REAL-WORLD STUDY WITH LONG-TERM FOLLOW-UP**
Hsu, Y., Yeh, M., Wong, G., Chen, C., Peng, C., Ferrets, M., Enomoto, M., Xie, Q., Trinh, H. N., Preda, C., Liu, L., Cheung, K., Hoang, et al
WILEY.2020: 463A–464A
 - **LONGITUDINAL REAL-WORLD STUDY ON ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) CHANGES IN ENTECAVIR (ETV) VERSUS TENOFOVIR DISOPROXIL FUMARATE (TDF)-TREATED CHRONIC HEPATITIS B (CHB) PATIENTS: A REAL-B STUDY**
Mak, L., Hoang, J., Jun, D., Chen, C., Peng, C., Yet, M., Kim, S., Jeong, J., Yoon, E., Oh, H., Tsai, P., Huang, C., Ahn, et al
WILEY.2020: 17A–18A
 - **THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B VIRUS INFECTION SUBJECTS NOT MEETING CRITERIA FOR ANTIVIRAL THERAPY**
Alshuwaykh, O., Goel, A., Daugherty, T., Cheung, A., Kim, W., Kwong, A. J., Ahmed, A., Ghaziani, T., Torok, N. J., Nguyen, M. H., Dronamraju, D., Dhanasekaran, R., Kumari, et al
WILEY.2020: 472A–473A

- **HIGH HCV CURE RATES WITH APPROVED INTERFERON-FREE DIRECT ACTING ANTIVIRALS AMONG DIVERSE MAINLAND CHINESE PATIENTS INCLUDING GENOTYPES 3a AND 3b**
Ji, F., Li, J., Liu, L., Jing, L., Wang, X., Liu, J., Cai, D., Huang, R., Zhang, J., Wang, Q., Nan, Y., Li, J., Ye, et al
WILEY.2020: 532A–533A
- **Clinical Response to Treatment for Acute Kidney Injury (AKI) in Patients With Cirrhosis**
John, N., Alshuwaykh, O., Goel, A., Ahmed, A., Cheung, A., Dronamraju, D., Kumari, R., Daugherty, T., Dhanasekaran, R., Kim, R. W., Nguyen, M. H., Kwo, P. Y.
LIPPINCOTT WILLIAMS & WILKINS.2020: S587–S588
- **Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma** *HEPATOLOGY COMMUNICATIONS*
Chen, V. L., Yeh, M., Yang, J., Leong, J., Huang, D. Q., Toyoda, H., Chen, Y., Guy, J., Maeda, M., Tsai, P., Huang, C., Yasuda, S., Le, et al
2020
- **ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation** *HEPATOLOGY COMMUNICATIONS*
Huang, D. Q., Yeo, Y., Tan, E., Takahashi, H., Yasuda, S., Saruwatari, J., Tanaka, K., Oniki, K., Kam, L. Y., Muthiah, M. D., Hyogo, H., Ono, M., Barnett, et al
2020
- **High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b** *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*
Ji, F., Li, J., Liu, L., Liang, J., Wang, X., Liu, J., Cai, D., Huang, R., Zhang, J., Wang, Q., Nan, Y., Li, J., Ye, et al
2020
- **Liver Care and Surveillance: The Global Impact of the COVID-19 Pandemic.** *Hepatology communications*
Toyoda, H., Huang, D. Q., Le, M. H., Nguyen, M. H.
2020
- **Liver Care and Surveillance: The Global Impact of the COVID-19 Pandemic** *HEPATOLOGY COMMUNICATIONS*
Toyoda, H., Huang, D. Q., Le, M. H., Nguyen, M. H.
2020
- **High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.** *Journal of gastroenterology and hepatology*
Ji, F., Li, J., Liu, L., Liang, J., Wang, X., Liu, J., Cai, D., Huang, R., Zhang, J., Wang, Q., Nan, Y., Li, J., Ye, et al
2020
- **Prevalence of Chronic Hepatitis B Virus Infection in the United States.** *The American journal of gastroenterology*
Lim, J. K., Nguyen, M. H., Kim, W. R., Gish, R., Perumalswami, P., Jacobson, I. M.
2020
- **Fatty liver is not independently associated with rates of complete response to oral antiviral therapy in chronic hepatitis B patients.** *Liver international : official journal of the International Association for the Study of the Liver*
Li, J., Le, A. K., Chaung, K. T., Henry, L., Hoang, J. K., Cheung, R., Nguyen, M. H.
2020
- **Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.** *The American journal of gastroenterology*
Hsu, Y. C., Nguyen, M. H.
2020
- **Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population-authors' reply.** *Alimentary pharmacology & therapeutics*
Kang, K. A., Jun, D. W., Nguyen, M. H.
2020; 51 (6): 670–71
- **Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Authors' reply.** *Alimentary pharmacology & therapeutics*
Jun, D. W., Nguyen, M. H.

2020; 51 (6): 662–63

- **The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.** *Hepatology international*
Wu, Y. n., Zheng, Q. n., Zou, B. n., Yeo, Y. H., Li, X. n., Li, J. n., Xie, X. n., Feng, Y. n., Stave, C. D., Zhu, Q. n., Cheung, R. n., Nguyen, M. H.
2020
- **Provider Perspectives on HCC Surveillance in Patients With Cirrhosis: Community Provider Perspectives Matter.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Wei, M. T., Nguyen, M. H.
2020
- **Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States-a call for action.** *Alimentary pharmacology & therapeutics*
Yeo, Y. H., Nguyen, M. H.
2020
- **Delayed Diagnosis and Disparity in Hepatitis C Virus-Infected Immigrants in North America: A Call for Action.** *Liver international : official journal of the International Association for the Study of the Liver*
Emhmed Ali, S. n., Nguyen, M. H.
2020
- **Letter: substantial under-diagnosis of NAFLD - more efforts are needed globally.** *Alimentary pharmacology & therapeutics*
Emhmed Ali, S. n., Nguyen, M. H.
2020; 52 (10): 1624
- **Is tenofovir more effective than entecavir to prevent hepatocellular carcinoma? The controversy goes on.** *Hepatology international*
Tseng, C. H., Nguyen, M. H., Hsu, Y. C.
2020
- **Development and validation of a risk score for liver cirrhosis prediction in untreated and treated chronic hepatitis B.** *The Journal of infectious diseases*
Le, A. K., Yang, H. I., Yeh, M. L., Jin, M. n., Trinh, H. N., Henry, L. n., Liu, A. n., Zhang, J. Q., Li, J. n., Wong, C. n., Wong, C. n., Cheung, R. n., Yu, et al
2020
- **Racial and Socioeconomic Disparities in Hospitalization of Pediatrics with Liver Disease from 2005 to 2015.** *Digestive diseases and sciences*
Martin, M. n., Zou, B. n., Hoang, J. n., Jeong, D. n., Bensen, R. n., Nguyen, M. H.
2020
- **Post-Transplant Outcomes in Older Patients with Hepatocellular Carcinoma (HCC) are Driven by non-HCC Factors.** *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*
Adeniji, N. n., Arjunan, V. n., Prabhakar, V. n., Mannalithara, A. n., Ghaziani, T. n., Ahmed, A. n., Kwo, P. n., Nguyen, M. n., Melcher, M. L., Busuttil, R. W., Florman, S. S., Haydel, B. n., Ruiz, et al
2020
- **Epidemiology of COVID-19: A Systematic Review and Meta-analysis of Clinical Characteristics, Risk factors and Outcomes.** *Journal of medical virology*
Li, J. n., Huang, D. Q., Zou, B. n., Yang, H. n., Hui, W. Z., Rui, F. n., Yee, N. T., Liu, C. n., Nerurkar, S. N., Kai, J. C., Teng, M. L., Li, X. n., Zeng, et al
2020
- **Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.** *Liver cancer*
Tseng, T. C., Peng, C. Y., Hsu, Y. C., Su, T. H., Wang, C. C., Liu, C. J., Yang, H. C., Yang, W. T., Lin, C. H., Yu, M. L., Lai, H. C., Tanaka, Y. n., Nguyen, et al
2020; 9 (2): 207–20
- **Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B.** *Alimentary pharmacology & therapeutics*
Oh, H. n., Jun, D. W., Lee, I. H., Ahn, H. J., Kim, B. O., Jung, S. n., Nguyen, M. H.
2020

- **Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection.** *European radiology*
Feng, Y. n., Wu, H. n., Huang, D. Q., Xu, C. n., Zheng, H. n., Maeda, M. n., Zhao, X. n., Wang, L. n., Xiao, F. n., Lv, H. n., Liu, T. n., Qi, J. n., Li, et al
2020
- **Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.** *Hepatology (Baltimore, Md.)*
Krishnan, M. S., Rajan Kd, A. n., Park, J. n., Arjunan, V. n., Garcia Marques, F. J., Bermudez, A. n., Girvan, O. A., Hoang, N. S., Yin, J. n., Nguyen, M. H., Kothary, N. n., Pitteri, S. n., Felsner, et al
2020
- **Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis.** *European journal of clinical pharmacology*
Song, H. J., Jiang, X. n., Henry, L. n., Nguyen, M. H., Park, H. n.
2020
- **Noninvasive diagnosis methods are needed in paediatric non-alcoholic fatty liver disease (NAFLD).** *Liver international : official journal of the International Association for the Study of the Liver*
Li, J. n., Nguyen, M. H.
2020
- **Editorial: comorbidities in patients with chronic hepatitis B-authors' reply.** *Alimentary pharmacology & therapeutics*
Yoon, E. L., Oh, H. n., Jun, D. W., Nguyen, M. H.
2020; 52 (5): 893–94
- **Non-alcoholic fatty liver disease (NAFLD) in Asia - More efforts are needed.** *Liver international : official journal of the International Association for the Study of the Liver*
Li, J. n., Nguyen, M. H.
2020
- **Early multiplexed detection of cirrhosis by giant magnetoresistive biosensors with protein biomarkers.** *ACS sensors*
Ng, E. n., Le, A. K., Nguyen, M. H., Wang, S. X.
2020
- **Increasing age and non-liver comorbidities in patients with chronic hepatitis B in Taiwan: A nationwide population-based analysis.** *Digestive diseases (Basel, Switzerland)*
Tseng, C. H., Hsu, Y. C., Ho, H. J., Nguyen, M. H., Wu, C. Y.
2020
- **Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population.** *Alimentary pharmacology & therapeutics*
Kang, K. A., Jun, D. W., Kim, M. S., Kwon, H. J., Nguyen, M. H.
2020; 51 (3): 388–96
- **Increasing age and non-liver comorbidities in patients with chronic hepatitis B in Taiwan: A nationwide population-based analysis.** *Digestive diseases (Basel, Switzerland)*
Tseng, C. H., Hsu, Y. C., Ho, H. J., Nguyen, M. H., Wu, C. Y.
2020
- **Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population.** *Alimentary pharmacology & therapeutics*
Kang, K. A., Jun, D. W., Kim, M. S., Kwon, H. J., Nguyen, M. H.
2020; 51 (3): 388–96
- **A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.** *Digestive diseases and sciences*
Zou, B., Yeo, Y. H., Jeong, D., Park, H., Sheen, E., Lee, D. H., Henry, L., Garcia, G., Ingelsson, E., Cheung, R., Nguyen, M. H.
2019
- **SUBSTANTIAL GAP IN ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B (CHB) PATIENTS IN THE UNITED STATES: A NATIONWIDE STUDY OF 7,124 PATIENTS**

Ye, Q., Yeo, Y., Dang, N., Kam, L., Cheung, R., Nguyen, M. H.
WILEY.2019: 566A

- **What to Do When Fecal Immunochemical Test (FIT) Is Positive Following Normal Colonoscopy? Comparison of Adenoma Detection Rate (ADR) of Standard FIT-Colonoscopy and Relook Colonoscopy**
Wei, M., Dao, A. T., Le, A., Nguyen, T., Tran, B., Trinh, L. L., Nguyen, H. A., Nguyen, K., Levitt, B. S., Shieh, E., Goyal, T., Cheung, R., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: S192
- **Sustained Decline of Noninvasive Fibrosis Index Values in Patients With Chronic Hepatitis C (CHC) With Sustained Virologic Response (SVR) After Receiving Direct-Acting Antiviral Agents (DAAs)**
Prabhakar, V., Lutchman, G., Ahmed, A., Nguyen, M. H., Daugherty, T., Kwo, P.
LIPPINCOTT WILLIAMS & WILKINS.2019: S553–S554
- **TENOFOVIR VERSUS ENTECAVIR FOR HEPATOCELLULAR CARCINOMA PREVENTION IN AN INTERNATIONAL CONSORTIUM OF CHRONIC HEPATITIS B**
Hsu, Y., Wong, G., Chen, C., Peng, C., Yeh, M., Cheung, K., Toyoda, H., Huang, C., Trinh, H. N., Xie, Q., Enomoto, M., Liu, L., Yasuda, et al
WILEY.2019: 290A–291A
- **INCREASING AGE AND NON-LIVER COMORBIDITIES IN PATIENTS WITH CHRONIC HEPATITIS B IN TAIWAN: A NATIONWIDE POPULATION-BASED ANALYSIS**
Tseng, C., Hsu, Y., Ho, H. J., Nguyen, M. H., Wu, C.
WILEY.2019: 596A–597A
- **COMORBIDITY PREVALENCE AND HEALTH CARE UTILIZATION IN A POPULATION-BASED STUDY OF CHRONIC HEPATITIS B PATIENTS FROM 2007 TO 2016 IN SOUTH KOREA**
Oh, H., Wong, G., Lee, E., Ahn, H., Kim, B., Jung, S., Jun, D., Nguyen, M. H.
WILEY.2019: 582A
- **IMPROVEMENT IN VIROLOGIC, BIOCHEMICAL AND RENAL OUTCOMES IN CHRONIC HEPATITIS B (CHB) PATIENTS SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE CLINICAL PRACTICE**
Yeh, M., Trinh, S., Huang, C., Hsieh, M., Huang, C., Liang, P., Huang, J., Dai, C., Chuang, W., Nguyen, M. H., Yu, M.
WILEY.2019: 295A–296A
- **RACE DOES NOT AFFECT THE PERFORMANCE OF ROUTINELY AVAILABLE NONINVASIVE TESTS FOR THE DISCRIMINATION OF ADVANCED FIBROSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH) IN THE PHASE 3 STELLAR TRIALS OF SELONSERTIB**
Wong, V., Tak, W., Goh, G., Cheng, P., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Bzowej, N. H., Younes, Z., Alkhoury, N., Wang, Y., Kersey, K., Li, et al
WILEY.2019: 1029A–1030A
- **HCV CURE BY ALL ORAL DAA IMPROVES 5-YEAR OVERALL AND LIVER-RELATED SURVIVAL IN HCV-RELATED HCC PATIENTS: A REAL-WORLD, PROPENSITY SCORE-MATCHED STUDY FROM BOTH EAST AND WEST**
Dang, H., Yeo, Y., Yasuda, S., Huang, C., Iio, E., Landis, C. S., Jun, D., Enomoto, M., Ogawa, E., Tsai, P., Le, A., Liu, M., Maeda, et al
WILEY.2019: 28A
- **ASSOCIATIONS BETWEEN WEIGHT PERCEPTION AND THE INTENTION TO LOSE WEIGHT AND BETWEEN THE INTENTION TO DIET/EXERCISE AND REPORTED MET/CALORIE COUNT IN PERSONS WITH NAFLD: A US POPULATION-BASED STUDY OF 11,713 PARTICIPANTS, 2001-2014**
Nguyen Hoang Vy, Yeo, Y., Zou, B., Le, M., Cheung, R., Nguyen, M. H.
WILEY.2019: 753A–754A
- **PREVALENCE AND FACTORS ASSOCIATED WITH HEPATIC STEATOSIS (HS) AND HEPATIC FIBROSIS IN CHRONIC HEPATITIS B (CHB) ASSOCIATED WITH HS: A SYSTEMATIC REVIEW AND META-ANALYTIC ASSESSMENT OF 57 STUDIES AND 268,151 PARTICIPANTS**
Zheng, Q., Wu, Y., Zou, B., Yeo, Y., Wu, H., Stave, C., Cheung, R., Nguyen, M. H.
WILEY.2019: 570A–571A
- **INCREASING PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN MAINLAND CHINA: A META-ANALYSIS OF 124 STUDIES AND 1,232,281 PARTICIPANTS**
Wu, Y., Zheng, Q., Zou, B., Yeo, Y., Li, X., Li, J., Feng, Y., Xie, X., Stave, C., Cheung, R., Zhu, Q., Nguyen, M. H.
WILEY.2019: 742A–743A
- **DISTRIBUTION OF BMI, SERUM ALT, HEPATIC STEATOSIS AND LIVER FIBROSIS IN ASIANS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A SYSTEMATIC REVIEW AND META-ANALYSIS OF 108 STUDIES WITH 2,260,207 INDIVIDUALS**

- Kam, L., Yeo, Y., Huang, D., Fung, J., Lee, T., Yasuda, S., Wong, V., Saruwatari, J., Barnett, S., Oniki, K., Li, J., Zou, B., Cheung, et al
WILEY.2019: 741A–742A
- **SYSTEMATIC REVIEW AND META-ANALYSIS: A NATURAL HISTORY STUDY TO INCLUDE NAFLD INCIDENCE, DISEASE TRANSITION AND OUTCOMES**
Wu, Y., Yeo, Y., Zou, B., Li, X., Zheng, Q., Li, J., Xie, X., Feng, Y., Stave, C., Cheung, R., Zhu, Q., Nguyen, M. H.
WILEY.2019: 743A
 - **THE IMPACT OF COEXISTING HEPATIC STEATOSIS (HS) ON DEVELOPMENT OF CIRRHOSIS, HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT AND HBsAg SEROCLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)**
Li, J., Yang, H., Le, A., Henry, L., Hoang, J., Cheung, R., Yu, M., Nguyen, M. H.
WILEY.2019: 1347A–1348A
 - **IMPACT OF SVR ON LONG-TERM LIVER-RELATED OUTCOMES: RESULTS OF THE REAL-C REGISTRY AT 23 CENTERS FROM HONG KONG, KOREA, JAPAN AND TAIWAN**
Tanaka, Y., Toyoda, H., Jun, D., Enomoto, M., Huang, C., Ogawa, E., Yasuda, S., Iio, E., Iwane, S., Haga, H., Dai, C., Jeong, J., Park, et al
WILEY.2019: 908A–909A
 - **REDEFINING THE UPPER LIMIT OR NORMAL (ULN) OF ALANINE TRANSAMINASE (ALT) LEVELS FOR ASIANS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 60 STUDIES AND 335,163 INDIVIDUALS**
Huang, D., Yeo, Y., Tan, X., Kam, L., Fung, J., Lee, T., Wong, V., Saruwatari, J., Muthiah, M., Barnett, S., Oniki, K., Li, J., Zou, et al
WILEY.2019: 1055A–1056A
 - **INCREASING PREVALENCE AND ASSOCIATION BETWEEN SEVERITY OF RENAL INSUFFICIENCY WITH MORTALITY IN PERSONS WITH NAFLD, A UNITED STATES POPULATION-BASED STUDY**
Le, M., Yeo, Y., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2019: 155A–156A
 - **Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis** *JOURNAL OF HEPATOLOGY*
Ji, F., Yeo, Y., Wei, M., Ogawa, E., Enomoto, M., Lee, D., Iio, E., Lubel, J., Wang, W., Wei, B., Ide, T., Preda, C., Conti, et al
2019; 71 (3): 473–85
 - **Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study.** *BMJ open*
Zhang, M., Wu, R., Xu, H., Uhanova, J., Gish, R., Wen, X., Jin, Q., Gerald, M. Y., Nguyen, M. H., Gao, Y., Niu, J.
2019; 9 (8): e028248
 - **Prevalence of NAFLD in China: What Did We Learn From the Recent Meta-Analysis?** *Hepatology (Baltimore, Md.)*
Wu, Y., Yeo, Y. H., Nguyen, M. H., Cheung, R. C.
2019
 - **Associations Between Body Fat, Muscle Mass, and Nonalcoholic Fatty Liver Disease: A Population-Based Study.** *Hepatology communications*
Hsing, J. C., Nguyen, M. H., Yang, B., Min, Y., Han, S. S., Pung, E., Winter, S. J., Zhao, X., Gan, D., Hsing, A. W., Zhu, S., Wang, C. J.
2019; 3 (8): 1061–72
 - **Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: A propensity-matched cohort study.** *Journal of internal medicine*
Park, H., Dawwas, G. K., Liu, X., Nguyen, M. H.
2019
 - **Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis Bn** *JOURNAL OF MEDICAL VIROLOGY*
Wei, M. T., Le, A. K., Chang, M. S., Hsu, H., Nguyen, P., Zhang, J. Q., Wong, C., Wong, C., Cheung, R., Nguyen, M. H.
2019; 91 (7): 1288–94
 - **Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4, and 6 infection.** *Journal of viral hepatitis*
Asselah, T., Shafran, S. D., Bourgeois, S., Lai, C., Mathurin, P., Willems, B., Nguyen, M. H., Davis, M. N., Huang, K. C., Svarovskaia, E., Osinusi, A., McNally, J., Brainard, et al
2019

- **Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin** *JAMA ONCOLOGY*
Chien, N., Yeo, Y., Nguyen, M. H.
2019; 5 (6): 911
- **Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Han, S. S., Kelly, S. P., Li, Y., Yang, B., Nguyen, M., So, S., Rosenberg, P. S., Hsing, A. W.
2019; 111 (6): 550–56
- **Reply.** *Gastroenterology*
Yeo, Y. H., Nguyen, M. H.
2019
- **Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California (vol 63, pg 2267, 2018)** *DIGESTIVE DISEASES AND SCIENCES*
Wei, M., Ford, J., Li, Q., Jeong, D., Kwong, A. J., Nguyen, M. H., Chang, M. S.
2019; 64 (5): 1392–94
- **Red blood cell distribution width to albumin ratio as a novel prognostic indicator for patients with chronic hepatitis B-related liver cirrhosis**
Huang, R., Wang, J., Henry, L., Zhang, Z., Zhu, C., Nguyen, M., Wu, C.
ELSEVIER SCIENCE BV.2019: E694–E695
- **Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection** *HEPATOLOGY COMMUNICATIONS*
Jun, T., Hsu, Y., Ogawa, S., Huang, Y., Yeh, M., Tseng, C., Huang, C., Tai, C., Dai, C., Huang, J., Chuang, W., Yu, M., Tanaka, et al
2019; 3 (4): 493–503
- **Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection.** *Hepatology communications*
Jun, T., Hsu, Y. C., Ogawa, S., Huang, Y. T., Yeh, M. L., Tseng, C. H., Huang, C. F., Tai, C. M., Dai, C. Y., Huang, J. F., Chuang, W. L., Yu, M. L., Tanaka, et al
2019; 3 (4): 493-503
- **Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection** *HEPATOLOGY*
Yeo, Y., Le, M. H., Chang, E. T., Henry, L., Nguyen, M. H.
2019; 69 (4): 1385–97
- **Hepatitis B and renal function: A matched study comparing non-hepatitis B, untreated, treated and cirrhotic hepatitis patients** *LIVER INTERNATIONAL*
Vinh Vu, Trinh, S., An Le, Johnson, T., Hoang, J., Jeong, D., Henry, L., Barnett, S., Cheung, R., Nguyen, M. H.
2019; 39 (4): 655–66
- **Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Trinh, S., Le, A. K., Chang, E. T., Hoang, J., Jeong, D., Chung, M., Lee, M., Wang, U., Henry, L., Cheung, R., Nguyen, M. H.
2019; 17 (5): 948+
- **Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Nguyen, V. H., Le, A. K., Trinh, H. N., Chung, M., Johnson, T., Wong, C., Wong, C., Zhang, J., Li, J., Levitt, B. S., Nguyen, H. A., Nguyen, K. K., Henry, et al
2019; 17 (5): 957+
- **Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment**
Choi, J., Liu, K., Le, A., Wong, V., Chan, S. L., Nguyen, M., Lim, Y., Wong, G.
ELSEVIER SCIENCE BV.2019: E461
- **Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis**
Liu, K., Choi, J., Le, A., Wong, V., Chan, S. L., Nguyen, M., Lim, Y., Wong, G.

ELSEVIER SCIENCE BV.2019: E475–E476

- **Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death**
Liu, K., Choi, J., Le, A., Wong, V., Chan, S. L., Nguyen, M., Lim, Y., Wong, G.
ELSEVIER SCIENCE BV.2019: E475
- **Correction to: Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California.** *Digestive diseases and sciences*
Wei, M., Ford, J., Li, Q., Jeong, D., Kwong, A. J., Nguyen, M. H., Chang, M. S.
2019
- **Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B** *HEPATOLOGY*
Nguyen, M. H., Lim, J. K., Ozbay, A., Frayssse, J., Liou, I., Meyer, N., Dusheiko, G., Gordon, S. C.
2019; 69 (3): 959–73
- **GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Yang, J., Addissie, B. D., Mara, K. C., Harmsen, W. S., Dai, J., Zhang, N., Wongjarupong, N., Ali, H. M., Ali, H. A., Hassan, F. A., Lavu, S., Cvinar, J. L., Giama, et al
2019; 28 (3): 531–38
- **Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis** *KOREAN JOURNAL OF INTERNAL MEDICINE*
Lee, H., Jun, D., Kim, H., Oh, H., Saeed, W., Ahn, H., Cheung, R. C., Nguyen, M. H.
2019; 34 (2): 296–+
- **Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA** *DIGESTIVE DISEASES AND SCIENCES*
Nguyen, A. L., Park, H., Nguyen, P., Sheen, E., Kim, Y. A., Nguyen, M. H.
2019; 64 (3): 698–707
- **A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study** *DIGESTIVE DISEASES AND SCIENCES*
Lee, H. M., Ahn, J., Kim, W., Lim, J. K., Nguyen, M., Pan, C. Q., Kim, D., Mannalithara, A., Te, H., Huy Trinh, Chu, D., Tram Tran, Woog, J., Lok, et al
2019; 64 (2): 358–66
- **Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.** *Hepatology international*
Huang, C. F., Iio, E. n., Jun, D. W., Ogawa, E. n., Toyoda, H. n., Hsu, Y. C., Haga, H. n., Iwane, S. n., Enomoto, M. n., Lee, D. H., Wong, G. n., Liu, C. H., Tada, et al
2019
- **Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.** *Annals of surgery*
DiNorcia, J. n., Florman, S. S., Haydel, B. n., Tabrizian, P. n., Ruiz, R. M., Klintmalm, G. B., Senguttuvan, S. n., Lee, D. D., Taner, C. B., Verna, E. C., Halazun, K. J., Hoteit, M. n., Levine, et al
2019
- **Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study.** *Journal of clinical medicine*
Park, J. H., Choi, J. n., Jun, D. W., Han, S. W., Yeo, Y. H., Nguyen, M. H.
2019; 8 (9)
- **An Automated, Quantitative, and Multiplexed Assay Suitable for Point-of-Care Hepatitis B Virus Diagnostics.** *Scientific reports*
Gani, A. W., Wei, W. n., Shi, R. Z., Ng, E. n., Nguyen, M. n., Chua, M. S., So, S. n., Wang, S. X.
2019; 9 (1): 15615
- **Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.** *The Journal of infectious diseases*
Zou, B. n., Yeo, Y. H., Le, M. H., Henry, L. n., Chang, E. T., Lok, A. S., Cheung, R. n., Nguyen, M. H.
2019
- **Nonliver Comorbidities in Patients With Chronic Hepatitis B.** *Clinical liver disease*
Wei, M. T., Henry, L. n., Nguyen, M. H.

2019; 14 (3): 126–30

- **Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis.** *European journal of gastroenterology & hepatology*
Zhao, C. n., Xing, F. n., Yeo, Y. H., Jin, M. n., Le, R. n., Le, M. n., Jin, M. n., Henry, L. n., Cheung, R. n., Nguyen, M. H.
2019
- **Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?** *Hepatology (Baltimore, Md.)*
Nguyen, M. H.
2019
- **Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin.** *JAMA oncology*
Chien, N. n., Yeo, Y. H., Nguyen, M. H.
2019
- **Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.** *Journal of medical virology*
Wei, M. T., Le, A. K., Chang, M. S., Hsu, H. n., Nguyen, P. n., Zhang, J. Q., Wong, C. n., Wong, C. n., Cheung, R. n., Nguyen, M. H.
2019
- **Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network** *CONTEMPORARY CLINICAL TRIALS*
Borges, K. A., Dai, J., Parikh, N. D., Schwartz, M., Nguyen, M. H., Roberts, L. R., Befeler, A. S., Srivastava, S., Rinaudo, J., Feng, Z., Marrero, J. A., Reddy, K.
2019; 76: 49–54
- **Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Estevez, J., Yang, J., Leong, J., Nguyen, P., Giama, N. H., Zhang, N., Ali, H. A., Lee, M., Cheung, R., Roberts, L., Schwartz, M., Nguyen, M. H.
2019; 114 (1): 80–88
- **Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross-Sectional Population-Based Study on Its Relationship From 1999 to 2016.** *Hepatology communications*
Le, M. H., Yeo, Y. H., Henry, L. n., Nguyen, M. H.
2019; 3 (10): 1334–46
- **Chronic hepatitis B and NASH: Is "fat" all bad?** *Hepatology (Baltimore, Md.)*
Li, J. n., Cheung, R. C., Nguyen, M. H.
2019
- **Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B** *JOURNAL OF HEPATOLOGY*
Nguyen, M. H., Ozbay, A., Liou, I., Meyer, N., Gordon, S. C., Dusheiko, G., Lim, J. K.
2019; 70 (1): 24–32
- **Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication.** *Liver international : official journal of the International Association for the Study of the Liver*
Younossi, Z. M., Stepanova, M. n., Younossi, I. n., Papatheodoridis, G. n., Janssen, H. L., Agarwal, K. n., Nguyen, M. H., Gane, E. n., Tsai, N. n., Nader, F. n.
2019
- **Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment** *JOURNAL OF HEPATOLOGY*
Ji, F., Yeo, Y., He, C., Li, J., Gao, X., Li, Z., Henry, L., Nguyen, M. H.
2019; 70 (1): 209–11
- **Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Hsu, Y., Nguyen, M. H., Mo, L., Wu, M., Yang, T., Chen, C., Tseng, C., Tai, C., Wu, C., Lin, J., Tanaka, Y., Chang, C.
2019; 49 (1): 107–15
- **Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir plus sofosbuvir or sofosbuvir plus velpatasvir** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*

- Nguyen, E., Trinh, S., Huy Trinh, Huy Nguyen, Khanh Nguyen, Do, A., Levitt, B., Do, S., My Nguyen, Purohit, T., Shieh, E., Nguyen, M. H. 2019; 49 (1): 99–106
- **Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.** *Alimentary pharmacology & therapeutics*
Liu, K. n., Choi, J. n., Le, A. n., Yip, T. C., Wong, V. W., Chan, S. L., Chan, H. L., Nguyen, M. H., Lim, Y. S., Wong, G. L. 2019
 - **Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.** *World journal of gastroenterology*
Lee, H. Y., Oh, H. n., Park, C. H., Yeo, Y. H., Nguyen, M. H., Jun, D. W. 2019; 25 (23): 2961–72
 - **Reply to LTE 19-00352.** *Gastroenterology*
Yeo, Y. H., Nguyen, M. H. 2019
 - **Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.** *Annals of surgery*
DiNorcia, J. n., Florman, S. S., Haydel, B. n., Tabrizian, P. n., Ruiz, R. M., Klintmalm, G. B., Senguttuvan, S. n., Lee, D. D., Taner, C. B., Verna, E. C., Halazun, K. J., Hoteit, M. n., Levine, et al 2019
 - **Genetic analysis reveals functions of atypical polyubiquitin chains** *ELIFE*
Gutierrez, F., Simsek, D., Mizrak, A., Deutschbauer, A., Braberg, H., Johnson, J., Xu, J., Shales, M., Nguyen, M., Tamse-Kuehn, R., Palm, C., Steinmetz, L. M., Krogan, et al 2018; 7
 - **Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia** *BMJ OPEN GASTROENTEROLOGY*
Wei, B., Ji, F., Yeo, Y., Ogawa, E., Stave, C. D., Dang, S., Li, Z., Furusyo, N., Cheung, R. C., Nguyen, M. H. 2018; 5 (1)
 - **Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations** *BMJ OPEN GASTROENTEROLOGY*
Gilman, A. J., Le, A. K., Zhao, C., Hoang, J., Yasukawa, L. A., Weber, S. C., Vierling, J. M., Nguyen, M. H. 2018; 5 (1)
 - **Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis** *BMJ OPEN GASTROENTEROLOGY*
Wei, B., Ji, F., Yeo, Y., Ogawa, E., Zou, B., Stave, C. D., Dang, S., Li, Z., Furusyo, N., Cheung, R. C., Nguyen, M. H. 2018; 5 (1)
 - **Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.** *Alimentary pharmacology & therapeutics*
Hsu, Y., Nguyen, M. H., Mo, L., Wu, M., Yang, T., Chen, C., Tseng, C., Tai, C., Wu, C., Lin, J., Tanaka, Y., Chang, C. 2018
 - **Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Hsu, Y., Jun, T., Huang, Y., Yeh, M., Lee, C., Ogawa, S., Cho, S., Lin, J., Yu, M., Nguyen, M. H., Tanaka, Y. 2018; 48 (10): 1128–37
 - **Increasing Age and Comorbidities in a Population-based Study of Chronic Hepatitis B (CHB) Patients from 2007 to 2016 in Korea**
Jun, D., Oh, H., Ahn, H., Kim, B., Nguyen, M. H. WILEY.2018: 135
 - **Healthcare Resource Utilization and Costs by Disease Severity in an Insured National Sample of US Patients with Chronic Hepatitis B.** *Journal of hepatology*
Nguyen, M. H., Ozbay, A. B., Liou, I., Meyer, N., Gordon, S. C., Dusheiko, G., Lim, J. K. 2018

- **Real-World Experience of All-Oral Directly Acting Antivirals in Asian Chronic Hepatitis C Patients-Real-World Evidence from the Asia Liver Consortium for HCV (REAL-C)**
Huang, C., Iio, E., Jun, D., Ogawa, E., Haga, H., Enomoto, M., Iwane, S., Liu, C., Lee, D., Takahashi, H., Wong, G. L. H., Yang, H., Hayashi, et al
WILEY.2018: 421A–422A
- **The Majority of Previously Uninfected High-Risk Adults in the United States Do Not Have Immunity Against Hepatitis B Virus: A Population-Based Study**
Yeo, Y., Le, M., Chang, E. T., Henry, L., Nguyen, M. H.
WILEY.2018: 134A–135A
- **Development and Validation of a Risk Score System Inclusive of Antiviral Therapy for Liver Cirrhosis Risk in Chronic Hepatitis B Infection**
Liu, A., Le, A. K., Yang, H., Jin, M., Trinh, H. N., Zhang, J., Li, J., Wong, C., Wong, C., Yu, M., Nguyen, M. H.
WILEY.2018: 1193A–1194A
- **Prevalence of NAFLD and Liver Fibrosis in Asian Americans: A Population Based US Study from Nhanes, 2011-2014**
Le, M., Yeo, Y., Tran, S., Nguyen, M. H.
WILEY.2018: 1293A
- **Incidence and Predictors of HBsAg Seroclearance in 10,614 Untreated Patients on Long-Term Follow-up: A Collaborative Study from North America and Asia Pacific**
Yeo, Y., Ho, H. J., Yang, H., Tseng, T., Trinh, H. N., Park, Y., Hosaka, T., Kwak, M., Fung, J., Ungtrakul, T., Yu, M., Li, J., Zhang, et al
WILEY.2018: 132A–133A
- **A Phenome- Wide Association Study of Patatin-like Phospholipase Domain Containing 3 (PNPLA3) I148M Variant in 337,536 Participants of the UK Biobank Study**
Yeo, Y., Rao, A., Liu, B., Nguyen, M. H., Ingelsson, E.
WILEY.2018: 65A–66A
- **Effectiveness and Safety of DAA Treatment for Chronic Hepatitis C Patients with Previous Hepatocellular Carcinoma: Results from a Real-World, Multicenter Study of Asian Countries**
Ogawa, E., Iio, E., Jun, D., Huang, C., Haga, H., Enomoto, M., Iwane, S., Lee, D., Takahashi, H., Wong, G. L. H., Yang, H., Hayashi, J., Nomura, et al
WILEY.2018: 34A–35A
- **Serial Changes in Serum Levels of Mac-2 Binding Protein Glycosylation Isomer and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues**
Hsu, Y., Jun, T., Huang, Y., Yeh, M., Lin, J., Yu, M., Nguyen, M. H., Tanaka, Y.
WILEY.2018: 230A–231A
- **Ethnic-Specific Prevalence of HBV Infection and Exposure in US-Born and Foreign-Born Persons in the United States from 2011-2016**
Le, M., Yeo, Y., Nguyen, M. H.
WILEY.2018: 1212A–1213A
- **The Impact of Nonalcoholic Fatty Liver Disease (NAFLD) on the Development of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B Infection Patients**
Li, J., Chaung, K. T., Nguyen, P., Le, A. K., Hoang, J. K., Yang, H., Nguyen, M. H.
WILEY.2018: 1189A
- **The Impact of Non-Alcoholic Fatty Liver Disease (NAFLD) on the Rates of Biochemical and Virological Responses in Chronic Hepatitis B Patients Under Antiviral Therapy**
Chaung, K. T., Li, J., Le, A. K., Hoang, J. K., Nguyen, M. H.
WILEY.2018: 259A–260A
- **Nonalcoholic Fatty Liver Disease Increases Risk of Incident Chronic Kidney Disease in a Large Cohort of U.S Population**
Park, H., Liu, X., Nguyen, M. H.
WILEY.2018: 967A–968A
- **Distribution of Etiologies in Cirrhosis Admissions and Its Year Trend Burden in California (CA): A Population-Based Study with the Office of Statewide Health Planning and Development (OSHPD)**
Wei, B., Wei, M., Jeong, D., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2018: 461A

- **Initial Evaluation, Laboratory Monitoring, and Surveillance of Chronic Hepatitis B (CHB) Patients: Results of a Real-World Analysis of 85,922 Commercially-Insured Patients**
Tran, S., Jeong, D., Yeo, Y., Le, M., Henry, L., Cheung, R., Nguyen, M. H.
WILEY.2018: 82A
- **Medical Monitoring Among Cirrhotic Patients in Real World Practice: A Nationwide US Study with 43,915 Cirrhotics**
Yeo, Y., Jeong, D., Tran, S., Cheung, R., Nguyen, M. H.
WILEY.2018: 283A
- **Sex, Time-Period and Birthplace Specific Prevalence of Hepatitis B and Hepatitis C Virus Infection in Children and Adolescents in the United States during 1999-2016**
Zou, B., Yeo, Y., Le, M., Cheung, R., Nguyen, M. H.
WILEY.2018: 1193A
- **Prevalence of Hepatitis C Infection in Ethnically Diverse US Population Including Asian Americans and US-Born Vs Foreign-Born Persons: A Population-Base Study during 2011-2016**
Zou, B., Le, M., Yeo, Y., Cheung, R., Nguyen, M. H.
WILEY.2018: 931A–932A
- **Estimations of the Total Number of Undiagnosed Patients and Antiviral Treatment Rate for Chronic Hepatitis B in the United States**
Ogawa, E., Jeong, D., Yeo, Y., Henry, L., Tran, S., Cheung, R., Nguyen, M. H., Furusyo, N.
WILEY.2018: 1214A
- **The Prevalence, Diagnosis Rate, and Treatment Rate of Hepatitis C Infection in the United States: A Nationwide Study**
Yeo, Y., Jeong, D., Sally Tran, Ogawa, E., Cheung, R., Nguyen, M. H.
WILEY.2018: 281A
- **National Estimates of Overall and Liver-Related Inpatient Care Cost in Cirrhotic Patients with Diverse Etiologies and Ethnicities in the United States (US)**
Zou, B., Yeo, Y., Jeong, D., Cheung, R., Sheen, E., Park, H., Lee, D., Garcia, G., Nguyen, M. H.
WILEY.2018: 110A
- **Prevalence of Hepatitis B Vaccination Coverage Versus Serologic Evidence of Hepatitis B Immunity in Children and Adolescents in the United States, 1999-2016**
Le, M., Yeo, Y., So, S. K., Gane, E. J., Cheung, R., Nguyen, M. H.
WILEY.2018: 1192A–1193A
- **Sex, Time-Period and Birthplace Specific Prevalence of Hepatitis B and Hepatitis C Virus Infection in Children and Adolescents in the United States during 1999-2016**
Zou, B., Yeo, Y., Le, M., Cheung, R., Nguyen, M. H.
WILEY.2018: 1193A
- **Prevalence of Hepatitis C Infection in Ethnically Diverse US Population Including Asian Americans and US-Born Vs Foreign-Born Persons: A Population-Base Study during 2011-2016**
Zou, B., Le, M., Yeo, Y., Cheung, R., Nguyen, M. H.
WILEY.2018: 931A–932A
- **Estimations of the Total Number of Undiagnosed Patients and Antiviral Treatment Rate for Chronic Hepatitis B in the United States**
Ogawa, E., Jeong, D., Yeo, Y., Henry, L., Tran, S., Cheung, R., Nguyen, M. H., Furusyo, N.
WILEY.2018: 1214A
- **The Prevalence, Diagnosis Rate, and Treatment Rate of Hepatitis C Infection in the United States: A Nationwide Study**
Yeo, Y., Jeong, D., Sally Tran, Ogawa, E., Cheung, R., Nguyen, M. H.
WILEY.2018: 281A
- **National Estimates of Overall and Liver-Related Inpatient Care Cost in Cirrhotic Patients with Diverse Etiologies and Ethnicities in the United States (US)**
Zou, B., Yeo, Y., Jeong, D., Cheung, R., Sheen, E., Park, H., Lee, D., Garcia, G., Nguyen, M. H.
WILEY.2018: 110A

- **Prevalence of Hepatitis B Vaccination Coverage Versus Serologic Evidence of Hepatitis B Immunity in Children and Adolescents in the United States, 1999-2016**
Le, M., Yeo, Y., So, S. K., Gane, E. J., Cheung, R., Nguyen, M. H.
WILEY.2018: 1192A–1193A
- **The prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection.** *Hepatology (Baltimore, Md.)*
Yeo, Y. H., Le, M. H., Chang, E. T., Henry, L., Nguyen, M. H.
2018
- **Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B.** *Hepatology (Baltimore, Md.)*
Nguyen, M. H., Lim, J. K., Ozbay, A. B., Fraysse, J., Liou, I., Meyer, N., Dusheiko, G., Gordon, S. C.
2018
- **Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California** *DIGESTIVE DISEASES AND SCIENCES*
Wei, M., Ford, J., Li, Q., Jeong, D., Kwong, A. J., Nguyen, M. H., Chang, M. S.
2018; 63 (9): 2267–74
- **Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention** *CANCER*
Yang, B., Liu, J. B., So, S. K., Han, S. S., Wang, S. S., Hertz, A., Shariff-Marco, S., Gomez, S., Rosenberg, P. S., Nguyen, M. H., Hsing, A. W.
2018; 124 (17): 3551–59
- **Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study** *SCIENTIFIC REPORTS*
Zou, B., Yeo, Y., Jeong, D., Sheen, E., Park, H., Nguyen, P., Hsu, Y., Garcia, G., Nguyen, M. H.
2018; 8
- **Temporal Trends in Disease Presentation and Survival of Patients With Hepatocellular Carcinoma: A Real-World Experience From 1998 to 2015** *CANCER*
Kim, N. G., Nguyen, P. P., Dang, H., Kumari, R., Garcia, G., Esquivel, C. O., Nguyen, M. H.
2018; 124 (12): 2588–98
- **Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California.** *Hepatology, medicine and policy*
Toy, M., Wei, B., Virdi, T. S., Le, A., Trinh, H., Li, J., Zhang, J., Hsing, A. W., So, S. K., Nguyen, M. H.
2018; 3: 6
- **Multiplexed precision genome editing with trackable genomic barcodes in yeast** *NATURE BIOTECHNOLOGY*
Roy, K. R., Smith, J. D., Vonesch, S. C., Lin, G., Tu, C., Lederer, A. R., Chu, A., Suresh, S., Nguyen, M., Horecka, J., Tripathi, A., Burnett, W. T., Morgan, et al
2018; 36 (6): 512-+
- **Author response to "Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients"** *LIVER INTERNATIONAL*
Jun, T. W., Nguyen, M. H., Yu, M.
2018; 38 (6): 1141
- **Editorial: the durability of seroconversion of hepatitis B e antigen in the treatment of chronic hepatitis B with PEG-interferon alfa-2a** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Wei, M. T., Nguyen, M. H.
2018; 47 (11): 1556–57
- **More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma** *LIVER INTERNATIONAL*
Jun, T. W., Yeh, M., Yang, J., Chen, V. L., Nguyen, P., Giama, N. H., Huang, C., Hsing, A. W., Dai, C., Huang, J., Chuang, W., Roberts, L. R., Yu, et al
2018; 38 (5): 895–902
- **Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis**
Yeo, Y. H., Ho, H. J., Yang, H., Tseng, T., Kwak, M., Park, Y. M., Fung, Y. J., Ferret, M. B., Rodriguez, M., Preda, C. M., Ungtrakul, T., Charatcharoenwitthaya, P., Li, et al
ELSEVIER SCIENCE BV.2018: S478–S479

- **Is renal impairment associated with chronic hepatitis B - a propensity score matched study of healthy non-hepatitis B patients compared to patients with untreated chronic hepatitis B**
Vu, V., Trinh, S., Le, A., Johnson, T., Hoang, J., Jeong, D., Henry, L., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S512–S513
- **Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States**
Zou, B., Yeo, Y. H., Jeong, D., Sheen, E., Park, H., Nguyen, P., Hsu, Y., Garcia, G., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S704–S705
- **Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis**
Jun, T., Tanaka, Y., Hsu, Y., Nguyen, M., Yu, M.
ELSEVIER SCIENCE BV.2018: S650–S651
- **Validation of AASLD treatment guideline eligibility based on disease outcomes of large community and clinical cohorts of chronic hepatitis B patients**
Lee, D. H., Le, A., Chung, M., Nguyen, V. H., Johnson, T., Ji, F., Ogawa, E., Trinh, H. N., Zhang, J., Wong, C., Wong, C., Li, J., Yang, et al
ELSEVIER SCIENCE BV.2018: S503
- **Validation of a clinical scoring system to predict risk of hepatocellular carcinoma in an ethnically diverse cohort of patients with chronic hepatitis C virus infection**
Wei, M. T., Le, M. H., Le, A., Trinh, H. N., Wong, G., Landis, C., Zhang, J., Nguyen, P., Lee, M., Ji, F., Lee, D. H., Ogawa, E., Chang, et al
ELSEVIER SCIENCE BV.2018: S305–S306
- **Soluble cytotoxic T-lymphocyte-associated antigen-4 and soluble programmed cell death protein-1 are predictive immune checkpoint seromarkers for spontaneous functional cure of chronic hepatitis B with opposite effects**
Yang, H., Hu, H., Pan, M., Luo, W., Jeng, R., Su, C., Chiang, C., Jen, C., Lu, S., Wang, L., Lee, M., Liu, J., Nguyen, et al
ELSEVIER SCIENCE BV.2018: S476
- **Renal outcomes in chronic hepatitis b patients treated with tenofovir disoproxil fumarate or entecavir: a propensity score matched study**
Trinh, S., Le, A., Hoang, J., Jeong, D., Chung, M., Lee, M., Wang, U., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S519–S520
- **Adherence to AASLD treatment guidelines on treatment initiation among treatment-eligible patients with chronic hepatitis B: Experiences from primary care and referral practices**
Nguyen, V. H., Le, A., Chung, M., Johnson, T., Levitt, B., Nguyen, H., Nguyen, K., Trinh, H., Wong, C., Wong, C., Zhang, J., Li, J., Garcia, et al
ELSEVIER SCIENCE BV.2018: S505–S506
- **Ethnic differences in HCV-related HCC outcomes: Report from the Real-world Evidence by the Asia Pacific Rim Liver Consortium for HCC (REAL-HCC)**
Prasad, D., Nguyen, P., Guy, J., Yeh, M., Leong, J., Yang, J., Saeed, W., Hsu, Y., Tsai, P., Dai, C., Huang, J., Chen, Y., Jun, et al
ELSEVIER SCIENCE BV.2018: S304–S305
- **Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the US based on the Truven Health MarketScan Database**
Ogawa, E., Jeong, D., Yeo, Y. H., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S481–S482
- **Performance of Wisteria floribunda agglutinin-positive Mac2-binding protein as an HCC biomarker in an ethnically diverse cohort of patients with chronic HBV and HCV**
Jun, T., Yu, M., Hsu, Y., Tanaka, Y., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S439
- **Clinical presentation and survival of Asian and non-Asian patients with HBV-related hepatocellular carcinoma (HBV-HCC): Results of 767 United States patients with long-term follow-up**
Hoang, J., Nguyen, P., Leong, J., Yang, J., Le, A., Roberts, L., Schwartz, M., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S443
- **The time trend of hospital admissions, inpatient mortality rate, and hospital cost of hospitalizations associated with cirrhosis in the United States: an analysis on the National Inpatient Sample**
Zou, B., Yeo, Y. H., Jeong, D., Sheen, E., Park, H., Lee, D. H., Garcia, G., Nguyen, M.

ELSEVIER SCIENCE BV.2018: S733

- **Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir**
Nguyen, E., Trinh, S., Trinh, H., Nguyen, H., Nguyen, K., Levitt, B., Nguyen, M., Purohit, T., Shieh, E., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S284–S285
- **Treatment of chronic hepatitis B and renal impairment in patients with and without cirrhosis**
Vu, V., Trinh, S., Le, A., Johnson, T., Hoang, J., Jeong, D., Henry, L., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S511–S512
- **Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis**
Ji, F., Wei, M. T., Yeo, Y. H., Wei, B., Ogawa, E., Lee, D. H., Enomoto, M., Toyoda, H., Bass, M. B., Lubel, J., Ide, T., Preda, C. M., Iio, et al
ELSEVIER SCIENCE BV.2018: S259–S260
- **The time trend of proportion and mortality rate of admissions associated with acute respiratory illness in cirrhotic patients with diverse ethnicity and socioeconomic status: an analysis on the US National Inpatient Sample**
Zou, B., Yeo, Y. H., Jeong, D., Sheen, E., Park, H., Lee, D. H., Garcia, G., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S146
- **Men have higher mortality in cirrhosis: outcomes by gender and etiology in a large, diverse cohort**
Yeluru, A., Le, M. H., Zhao, C., Nguyen, P., Trinh, S., Le, H., Dang, H., Pura, A., Dang, N., Alviar, B., Tran, S., Johnson, T., Le, et al
ELSEVIER SCIENCE BV.2018: S709–S710
- **Changes in serum levels of the novel mac-2 binding protein glycosylation isomer and risk of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleos(t)ide analogues**
Hsu, Y., Jun, T., Yeh, M., Huang, Y., Yu, M., Nguyen, M., Tanaka, Y.
ELSEVIER SCIENCE BV.2018: S496–S498
- **A risk score combining quantitative hepatitis B surface antigen and core-related antigen levels to predict off-therapy relapse after cessation of nucleos(t)ide analogues in patients with chronic hepatitis B**
Hsu, Y., Tanaka, Y., Nguyen, M., Chang, C., Tai, C., Tseng, C., Chen, C., Wu, M., Lin, J.
ELSEVIER SCIENCE BV.2018: S498
- **Suboptimal rates of effective hepatitis B vaccination in adults at high risk of infection in the United States from 1999-2014**
Le, M., Lee, D. H., Lee, M., Gane, E., So, S., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S480–S481
- **Effective hepatitis B vaccination by serologic results in the United States: a population-based study from 1999-2016**
Le, M., Lee, D. H., Lee, M., Gane, E., So, S., Nguyen, M.
ELSEVIER SCIENCE BV.2018: S480
- **Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. *PLoS one***
Park, H. n., Jeong, D. n., Nguyen, P. n., Henry, L. n., Hoang, J. n., Kim, Y. n., Sheen, E. n., Nguyen, M. H.
2018; 13 (4): e0196452
- **Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. *Scientific reports***
Wong, A. n., Le, A. n., Lee, M. H., Lin, Y. J., Nguyen, P. n., Trinh, S. n., Dang, H. n., Nguyen, M. H.
2018; 8 (1): 7164
- **Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association***
Younossi, Z. M., Stepanova, M. n., Janssen, H. L., Agarwal, K. n., Nguyen, M. H., Gane, E. n., Tsai, N. n., Younossi, I. n., Racila, A. n.
2018
- **Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. *The Korean journal of internal medicine***
Lee, H. Y., Jun, D. W., Kim, H. J., Oh, H. n., Saeed, W. K., Ahn, H. n., Cheung, R. C., Nguyen, M. H.
2018
- **Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. *BMJ open gastroenterology***

- Tran, S. A., Le, A. n., Zhao, C. n., Hoang, J. n., Yasukawa, L. A., Weber, S. n., Henry, L. n., Nguyen, M. H.
2018; 5 (1): e000192
- **Changes in Renal Function in Patients With Chronic HBV infection Treated with Tenofovir Disoproxil Fumarate vs Entecavir.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Trinh, S. n., Le, A. K., Chang, E. T., Hoang, J. n., Jeong, D. n., Chung, M. n., Lee, M. H., Wang, U. n., Henry, L. n., Cheung, R. n., Nguyen, M. H.
2018
 - **Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California.** *Digestive diseases and sciences*
Wei, M. n., Ford, J. n., Li, Q. n., Jeong, D. n., Kwong, A. J., Nguyen, M. H., Chang, M. S.
2018
 - **Editorial: rifaximin-a kick in the gut for spontaneous bacterial peritonitis? Authors' reply.** *Alimentary pharmacology & therapeutics*
Goel, A. n., Nguyen, M. H.
2018; 47 (2): 303
 - **Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.** *Alimentary pharmacology & therapeutics*
Ji, F. n., Wei, B. n., Yeo, Y. H., Ogawa, E. n., Zou, B. n., Stave, C. D., Li, Z. n., Dang, S. n., Furusyo, N. n., Cheung, R. C., Nguyen, M. H.
2018
 - **Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015.** *Clinical and translational gastroenterology*
Liu, A. n., Le, A. n., Zhang, J. n., Wong, C. n., Wong, C. n., Henry, L. n., Nguyen, M. H.
2018; 9 (3): 141
 - **Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.** *Journal of hepatology*
Ji, F. n., Yeo, Y. H., He, C. n., Li, J. n., Gao, X. n., Li, Z. n., Henry, L. n., Nguyen, M. H.
2018
 - **Disparities in Hepatocellular Carcinoma Incidence by Race/Ethnicity and Geographic Area in California: Implications for Prevention.** *Cancer*
Yang, B. n., Liu, J. B., So, S. K., Han, S. S., Wang, S. S., Hertz, A. n., Shariff-Marco, S. n., Lin Gomez, S. n., Rosenberg, P. S., Nguyen, M. H., Hsing, A. W.
2018
 - **Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia.** *BMJ open gastroenterology*
Wei, B. n., Ji, F. n., Yeo, Y. H., Ogawa, E. n., Stave, C. D., Dang, S. n., Li, Z. n., Furusyo, N. n., Cheung, R. C., Nguyen, M. H.
2018; 5 (1): e000209
 - **Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study.** *Scientific reports*
Zou, B. n., Yeo, Y. H., Jeong, D. n., Sheen, E. n., Park, H. n., Nguyen, P. n., Hsu, Y. C., Garcia, G. n., Nguyen, M. H.
2018; 8 (1): 9969
 - **Reduced Incidence of Hepatocellular Carcinoma with Tenofovir in Chronic Hepatitis B Patients with and without Cirrhosis - a Propensity Score Matched Study.** *The Journal of infectious diseases*
Nguyen, M. H., Yang, H. I., Le, A. n., Henry, L. n., Nguyen, N. n., Lee, M. H., Zhang, J. n., Wong, C. n., Wong, C. n., Trinh, H. n.
2018
 - **A New Conception-Pre-HCC Disease.** *Hepatology (Baltimore, Md.)*
Yang, Y. n., Feng, Y. n., Zhao, X. n., Wang, L. n., Xie, X. n., Li, J. n., Nguyen, M. H., Zhu, Q. n.
2018
 - **Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California** *Hepatology, Medicine and Policy*
Toy, M., Wei, B., Virdi, T., Le, A., Tirnh, H., Li, J., Zhang, J., Hsing, A., So, S., Nguyen, M. H.
2018; 3 (6)
 - **Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis.** *BMJ open gastroenterology*

- Wei, B. n., Ji, F. n., Yeo, Y. H., Ogawa, E. n., Zou, B. n., Stave, C. D., Dang, S. n., Li, Z. n., Furusyo, N. n., Cheung, R. C., Nguyen, M. H.
2018; 5 (1): e000207
- **Editorial: the durability of seroconversion of hepatitis B e antigen in the treatment of chronic hepatitis B with PEG-interferon alfa-2a.** *Alimentary pharmacology & therapeutics*
Wei, M. T., Nguyen, M. H.
2018; 47 (11): 1556–57
 - **Author response to "Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients".** *Liver international : official journal of the International Association for the Study of the Liver*
Jun, T. W., Nguyen, M. H., Yu, M. L.
2018; 38 (6): 1141
 - **Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.** *Cancer*
Kim, N. G., Nguyen, P. P., Dang, H. n., Kumari, R. n., Garcia, G. n., Esquivel, C. O., Nguyen, M. H.
2018
 - **Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations.** *BMJ open gastroenterology*
Gilman, A. J., Le, A. K., Zhao, C. n., Hoang, J. n., Yasukawa, L. A., Weber, S. C., Vierling, J. M., Nguyen, M. H.
2018; 5 (1): e000203
 - **Anti-viral therapy is associated with improved survival but underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience.** *Alimentary pharmacology & therapeutics*
Chen, V. L., Yeh, M. L., Le, A. K., Jun, M. n., Saeed, W. K., Yang, J. D., Huang, C. F., Lee, H. Y., Tsai, P. C., Lee, M. H., Giama, N. n., Kim, N. G., Nguyen, et al
2018
 - **Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment.** *Journal of viral hepatitis*
Agarwal, K. n., Ahn, S. H., Elkhashab, M. n., Lau, A. H., Gaggar, A. n., Bulusu, A. n., Tian, X. n., Cathcart, A. L., Woo, J. n., Subramanian, G. M., Andreone, P. n., Kim, H. J., Chuang, et al
2018
 - **Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors.** *Scientific reports*
Wong, A. n., Le, A. n., Lee, M. H., Lin, Y. J., Nguyen, P. n., Trinh, S. n., Dang, H. n., Nguyen, M. H.
2018; 8 (1): 7164
 - **Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Younossi, Z. M., Stepanova, M. n., Janssen, H. L., Agarwal, K. n., Nguyen, M. H., Gane, E. n., Tsai, N. n., Younossi, I. n., Racila, A. n.
2018
 - **Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.** *The Korean journal of internal medicine*
Lee, H. Y., Jun, D. W., Kim, H. J., Oh, H. n., Saeed, W. K., Ahn, H. n., Cheung, R. C., Nguyen, M. H.
2018
 - **Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis.** *BMJ open gastroenterology*
Tran, S. A., Le, A. n., Zhao, C. n., Hoang, J. n., Yasukawa, L. A., Weber, S. n., Henry, L. n., Nguyen, M. H.
2018; 5 (1): e000192
 - **Changes in Renal Function in Patients With Chronic HBV infection Treated with Tenofovir Disoproxil Fumarate vs Entecavir.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Trinh, S. n., Le, A. K., Chang, E. T., Hoang, J. n., Jeong, D. n., Chung, M. n., Lee, M. H., Wang, U. n., Henry, L. n., Cheung, R. n., Nguyen, M. H.
2018
 - **Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California.** *Digestive diseases and sciences*
Wei, M. n., Ford, J. n., Li, Q. n., Jeong, D. n., Kwong, A. J., Nguyen, M. H., Chang, M. S.
2018

- **Editorial: rifaximin-a kick in the gut for spontaneous bacterial peritonitis? Authors' reply.** *Alimentary pharmacology & therapeutics*
Goel, A. n., Nguyen, M. H.
2018; 47 (2): 303
- **Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.** *Alimentary pharmacology & therapeutics*
Ji, F. n., Wei, B. n., Yeo, Y. H., Ogawa, E. n., Zou, B. n., Stave, C. D., Li, Z. n., Dang, S. n., Furusyo, N. n., Cheung, R. C., Nguyen, M. H.
2018
- **Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015.** *Clinical and translational gastroenterology*
Liu, A. n., Le, A. n., Zhang, J. n., Wong, C. n., Wong, C. n., Henry, L. n., Nguyen, M. H.
2018; 9 (3): 141
- **Hepatitis B DNA level for guidance of antiviral initiation timing in pregnant women for MTCT reduction**
Aziz, N., Chang, C. Y., Poongkunran, M., Javaid, A., Trinh, H. N., Lau, D., Nguyen, M. H.
MOSBY-ELSEVIER.2017: 720
- **Real-world Effectiveness (RWE) and Adverse Events with Sofosbuvir plus Ribavirin (SOF plus RBV) Based Therapies in Chronic Hepatitis C Genotype 3 (CHC GT 3) Patients in Asia-A Systematic Review of 8 Studies and 3510 Patient**
Wei, B., Ji, F., Yeo, Y., Ogawa, E., Henry, L., Li, Z., Dang, S., Furusyo, N., Cheung, R., Nguyen, M. H.
WILEY.2017: 857A–858A
- **Association of different types of chronic liver diseases with hepatocellular carcinoma in the United States**
Park, H., Jeong, D., Nguyen, P., Kim, Y., Nguyen, M. H.
WILEY.2017: 541A–542A
- **The impact of treatment of chronic hepatitis B (CHB) on patient-reported outcomes (PROs)**
Younossi, Z. M., Stepanova, M., Janssen, H. L., Agarwal, K., Nguyen, M. H., Gane, E. J., Tsai, N. C., Younossi, I., Hunt, S.
WILEY.2017: 1020A
- **Recurrence-Free Survival in Liver Transplant Recipients with Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Results from the US Multicenter HCC Transplant Consortium**
Verna, E. C., Abdelmessih, R. M., Florman, S. S., Haydel, B. M., Ruiz, R., Klintmalm, G., Lee, D. D., Taner, B., Hoteit, M. A., Halazun, K. J., Tevar, A. D., Humar, A., Chapman, et al
WILEY.2017: 900A–901A
- **Is antiviral treatment for chronic hepatitis B (CHB) in Asian patients associated with osteopenia/osteoporosis? A comparison study of tenofovir (TDF), entecavir (ETV) and untreated (UTx) patients**
Wei, M., Le, A. K., Nguyen, P., Zhang, J. Q., Wong, C., Wong, C., Chang, M., Nguyen, M. H.
WILEY.2017: 516A–517A
- **Suboptimal rates, trends and predictors of hepatitis B vaccination in a population-based sample of children and adolescents in the United States (US) between 1999 and 2014**
Le, M. H., Toy, M., Gane, E. J., So, S., Nguyen, M. H.
WILEY.2017: 1003A
- **Prevalence and predictors of hepatitis B immunization in adults without immunity for hepatitis B from 1999-2014: a population-based study of 27,713 adults in the US**
Le, M. H., Toy, M., Gane, E. J., So, S., Nguyen, M. H.
WILEY.2017: 1004A
- **Safety and Efficacy of Vesatolimod (GS-9620) in Patients with Chronic Hepatitis B (CHB) Who Are Not Currently on Antiviral Treatment**
Agarwal, K., Ahn, S., Elkhatab, M., Kim, K., Lau, A. H., Gaggar, A., Subramanian, M., McHutchison, J. G., Andreone, P., Kim, H. J., Chuang, W., Nguyen, M. H.
WILEY.2017: 497A–498A
- **REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) - A Risk Score for the Prediction of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis (CHB) Patients Treated with Oral Anti-HBV Therapy**
Nguyen, M. H., Yang, H., Yeh, M., Wong, G. L., Peng, C., Chen, C., Trinh, H. N., Cheung, K., Su, T., Kozuka, R., Ogawa, E., Li, J., Zhang, et al
WILEY.2017: 98A–99A

- **Serum Biomarkers Improve Prognostic Ability of BCLC Staging System**
Bangaru, S., Wei, W., Schwartz, M. E., Parikh, N., Nguyen, M. H., Roberts, L. R., Reddy, K., Befeler, A., Harnois, D. M., Srivastava, S., Rinaudo, J., Feng, Z., Marrero, et al
WILEY.2017: 754A–755A
- **Progression to advanced liver disease in nonalcoholic fatty liver disease (NAFLD) differs among Asians compared to Caucasians and Hispanics**
Ha, N. B., Trinh, S., Le, R. H., Hoang, J. K., Lee, M., Henry, L., Yasukawa, L., Nguyen, M. H.
WILEY.2017: 1172A–1173A
- **Age and gender-specific disease progression rates to cirrhosis and hepatocellular carcinoma (HCC) in treated and untreated patients with chronic hepatitis B**
Le, A. K., Toy, M., Yang, H., Trinh, H. N., Zhang, J. Q., Wong, C., Wong, C., Li, J., Nguyen, M. H.
WILEY.2017: 994A
- **Cirrhotic patients with acute respiratory illness in the United States encounter substantial hospital charge burden**
Zou, B., Yeo, Y., Jeong, D., Henry, L., Park, H., Nguyen, M. H.
WILEY.2017: 408A
- **Effect of Tenofovir Disoproxil (TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB) compared to Untreated Patients: a Multicenter Study with Propensity Score Matching (PSM)**
Nguyen, M. H., Yang, H., Le, A. K., Nguyen, N. H., Zhang, J. Q., Wong, C., Wong, C., Trinh, H. N.
WILEY.2017: 482A–483A
- **A multicenter study revealing chronic hepatitis B comorbidity trends over the last 15 years in the United States**
Liu, A. F., Le, A. K., Zhang, J. Q., Wong, C., Wong, C., Nguyen, M. H.
WILEY.2017: 990A
- **Long-Term Follow-Up of Patient-Reported Outcomes (PROs) in Chronic Hepatitis C (HCV) Patients with Compensated and Decompensated Cirrhosis with Sustained Virologic Response (SVR)**
Younossi, Z. M., Stepanova, M., Tapper, E. B., Henry, L., Sheikh, A. M., Nguyen, M. H., Reau, N., Lawitz, E.
WILEY.2017: 599A
- **Real Life Effectiveness of Direct-Acting Antivirals (DAAs) in Asian Patients with Chronic Hepatitis C Genotype 1: Systematic Review and Meta-analysis of 33 Published Articles and 7942 patients**
Ji, F., Wei, B., Yeo, Y., Zou, B., Ogawa, E., Henry, L., Li, Z., Cheung, R., Furusyo, N., Dang, S., Nguyen, M. H.
WILEY.2017: 596A–597A
- **Sustained Virological Response 12 Weeks after Therapy (SVR12) with Direct-Acting Antivirals (DAA) in Select Asian Populations with Chronic Hepatitis C Genotype 1 (HCV GT 1): A Meta-Analysis of Real-World Effectiveness from Asia**
Ji, F., Wei, B., Yeo, Y., Zou, B., Ogawa, E., Henry, L., Dang, S., Cheung, R., Furusyo, N., Li, Z., Nguyen, M. H.
WILEY.2017: 812A–813A
- **Real-world Effectiveness (RWE) of Sofosbuvir plus Ribavirin (SOF plus RBV) Chronic Hepatitis C Genotype 2 (CHC GT 2) in Asia: A Systemic Review and Meta-analysis of Pooled SVR12**
Wei, B., Ji, F., Yeo, Y., Zou, B., Ogawa, E., Henry, L., Cheung, R., Li, Z., Dang, S., Furusyo, N., Nguyen, M. H.
WILEY.2017: 811A
- **Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience** *BMJ OPEN GASTROENTEROLOGY*
Peter Nguyen, Vutien, P., Hoang, J., Trinh, S., Le, A., Yasukawa, L., Weber, S., Henry, L., Nguyen, M. H.
2017; 4 (1)
- **COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE ADMINISTRATION OF TENOFOVIR ALAFENAMIDE (TAF), A NOVEL NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI), FOR THE MANAGEMENT OF CHRONIC HEPATITIS B (CHB) IN THE UNITED STATES (US)**
Dusheiko, G., Lim, J., Liou, Tafazzoli, A., Deniz, B., Thibault, S. C., Gordon, S., Nguyen, M. H.
ELSEVIER SCIENCE INC.2017: A78
- **Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma.** *Journal of clinical gastroenterology*
Kutsenko, A., Ladenheim, M. R., Kim, N., Nguyen, P., Chen, V., Jayasekera, C., Yang, J. D., Kumari, R., Roberts, L., Nguyen, M. H.
2017; 51 (4): 384-390

- **Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States** *PLOS ONE*
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., Nguyen, M. H.
2017; 12 (3)
- **Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.** *European journal of gastroenterology & hepatology*
Ji, F., Tian, C., Li, Z., Deng, H., Nguyen, M. H.
2017
- **Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B.** *Journal of clinical gastroenterology*
Chang, C. Y., Aziz, N., Poongkunran, M., Javaid, A., Trinh, H. N., Lau, D. T., Nguyen, M. H.
2017
- **Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.** *Medicine*
Chang, C. Y., Nguyen, P., Le, A., Zhao, C., Ahmed, A., Daugherty, T., Garcia, G., Lutchman, G., Kumari, R., Nguyen, M. H.
2017; 96 (6)
- **HCV Prevalence in Asian Americans in California** *JOURNAL OF IMMIGRANT AND MINORITY HEALTH*
Lin, O. N., Chang, C., Lee, J., Ailinh Do, A., Martin, M., Martin, A., Nguyen, M. H.
2017; 19 (1): 91-97
- **Letter: reduction in chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low-risk patients - more questions than answers. Authors' reply.** *Alimentary pharmacology & therapeutics*
Lin, D. n., Yang, H. I., Hoang, J. n., Nguyen, M. H.
2017; 45 (1): 186-87
- **Black hepatocellular carcinoma patients diagnosed after 2010 have worse long-term survival than white patients**
Estevez, J., Yang, J. D., Leong, J., Nguyen, P., Giama, N., Roberts, L., Schwartz, M., Nguyen, M.
ELSEVIER SCIENCE BV.2017: S447-S448
- **Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology**
Kim, N. G., Yeh, M., Yang, J. D., Leong, J., Jun, M., Saeed, W., Nguyen, P., Tsai, P., Lee, H. Y., Dai, C., Huang, J., Chuang, W., Yang, et al
ELSEVIER SCIENCE BV.2017: S458
- **Advancing age and comorbidities in chronic hepatitis B patients: results of 10-year longitudinal analysis of a diverse population-based cohort of 44,026 chronic hepatitis B patients in the United States**
Nguyen, M. H., Lim, J., Ozbay, A. B., Frayssse, J., Liou, I., Meyer, N., Dusheiko, G., Gordon, S.
ELSEVIER SCIENCE BV.2017: S60
- **Prevalence of osteoporosis and bone fracture was 2-fold higher in chronic hepatitis B compared to non-chronic hepatitis B patients and continued to increase in the last decade: results of a United States population-based cohort study**
Gordon, S. C., Lim, J., Liou, I., Ozbay, A. B., Moore-Schiltz, L., Dusheiko, G., Nguyen, M. H.
ELSEVIER SCIENCE BV.2017: S61
- **Metabolic risk factors increase the risk of hepatocellular carcinoma in patients with hepatitis C cirrhosis**
Kutsenko, A., Le, A., Trinh, S., Dang, H., Nguyen, M.
ELSEVIER SCIENCE BV.2017: S125-S126
- **Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States**
Lim, J., Nguyen, M., Liou, I., Ozbay, A. B., Moore-Schiltz, L., Dusheiko, G., Gordon, S.
ELSEVIER SCIENCE BV.2017: S266-S267
- **SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C**
Le, A. K., Zhao, C., Hoang, J., Yasukawa, L. A., Zhang, J., Weber, S. C., Nguyen, M.
ELSEVIER SCIENCE BV.2017: S283-S284
- **3 times higher healthcare cost in chronic hepatitis B patients compared to non-chronic hepatitis B controls especially those with decompensated liver disease: United States real world healthcare utilization and cost analysis**

Nguyen, M. H., Lim, J., Ozbay, A. B., Shreay, S., Liou, I., Meyer, N., Dusheiko, G., Gordon, S.
ELSEVIER SCIENCE BV.2017: S369–S370

- **High rate of progression to cirrhosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver (FL)**
Li, J., Chaung, K. T., Le, A. K., Hoang, J. K., Nguyen, M. H.
ELSEVIER SCIENCE BV.2017: S488
- **Higher and rising prevalence and incidence of renal impairment and chronic kidney disease in chronic hepatitis B patients compared to matched non-chronic hepatitis B controls in the United States: results of a real-world analysis**
Nguyen, M. H., Lim, J., Liou, I., Ozbay, A. B., Fraysse, J., Meyer, N., Dusheiko, G., Gordon, S.
ELSEVIER SCIENCE BV.2017: S677–S678
- **Integrated analysis of controlled clinical trials evaluating efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C genotype 6 (HCV GT 6)**
Nguyen, M. H., Chuang, W., Hassanein, T., Kowdley, K., Lai, C., Chan, H., Feld, J. J., Letterio, C., Hahambis, T. A., Llewellyn, J., De-Oertel, S., Brainard, D. M., Lawitz, et al
ELSEVIER SCIENCE BV.2017: S723
- **Viral kinetics in women of child bearing potential with chronic hepatitis B virus following treatment with tenofovir alafenamide or tenofovir disoproxil fumarate**
Pan, C., Chang, T., Bae, S., Brunetto, M., Coffin, C., Lau, A., Mo, S., Flaherty, J. F., Gaggar, A., Subramanian, G. M., Nguyen, M. H., Gurel, S., Thompson, et al
ELSEVIER SCIENCE BV.2017: S258–S259
- **Significantly lower rates of cirrhosis and worse long-term survival in cryptogenic hepatocellular carcinoma compared to viral etiologies: results of a multi-center international cohort**
Jun, T., Yeh, M., Chen, V., Yang, J. D., Nguyen, P., Chung, M., Nasra, G., Huang, C. F., Dai, C., Huang, J., Chuang, W., Roberts, L., Nguyen, et al
ELSEVIER SCIENCE BV.2017: S623
- **Thyroid cancer mortality higher in Filipinos in United States: an analysis using national mortality records from 2003-2012.** *Cancer*
Nguyen, M., Hu, J., Hastings, K., Daza, E., Cullen, M., Orloff, L., Palaniappan, L.
2017
- **Hepatitis B DNA level for guidance of antiviral initiation timing in pregnant women for MTCT reduction**
Aziz, N., Chang, C., Poongkunran, M., Javaid, A., Trinh, H., Lau, D., Nguyen, M.
MOSBY-ELSEVIER.2017: S242–S243
- **More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma.** *Liver international : official journal of the International Association for the Study of the Liver*
Jun, T. W., Yeh, M. L., Yang, J. D., Chen, V. L., Nguyen, P. n., Giama, N. H., Huang, C. F., Hsing, A. W., Dai, C. Y., Huang, J. F., Chuang, W. L., Roberts, L. R., Yu, et al
2017
- **Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.** *PloS one*
Vutien, P. n., Jin, M. n., Le, M. H., Nguyen, P. n., Trinh, S. n., Huang, J. F., Yu, M. L., Chuang, W. L., Nguyen, M. H.
2017; 12 (9): e0183851
- **Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.** *Expert review of gastroenterology & hepatology*
Okada, M. n., Enomoto, M. n., Kawada, N. n., Nguyen, M. H.
2017
- **Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.** *Alimentary pharmacology & therapeutics*
Goel, A. n., Rahim, U. n., Nguyen, L. H., Stave, C. n., Nguyen, M. H.
2017
- **Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers.** *Scientific reports*
Chen, V. L., Le, A. K., Podlaha, O. n., Estevez, J. n., Li, B. n., Vutien, P. n., Chang, E. T., Rosenberg-Hasson, Y. n., Pflanz, S. n., Jiang, Z. n., Ge, D. n., Gaggar, A. n., Nguyen, et al
2017; 7 (1): 11169

- **Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue.** *Liver international : official journal of the International Association for the Study of the Liver*
Zhao, C. n., Jin, M. n., Le, R. H., Le, M. H., Chen, V. L., Jin, M. n., Wong, G. L., Wong, V. W., Lim, Y. S., Chuang, W. L., Yu, M. L., Nguyen, M. H.
2017
- **Management of Chronic Hepatitis B in Pregnancy.** *Journal of clinical gastroenterology*
Li, J. n., Chang, M. S., Tran, T. T., Nguyen, M. H.
2017
- **Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.** *Expert review of gastroenterology & hepatology*
Hsu, Y. C., Wei, M. T., Nguyen, M. H.
2017
- **Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.** *Alimentary pharmacology & therapeutics*
Wong, C. R., Njei, B. n., Nguyen, M. H., Nguyen, A. n., Lim, J. K.
2017
- **Epidemiology of hepatitis B and the role of vaccination.** *Best practice & research. Clinical gastroenterology*
Chang, M. S., Nguyen, M. H.
2017; 31 (3): 239–47
- **Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.** *PloS one*
Kim, Y. A., Trinh, S. n., Thura, S. n., Kyi, K. P., Lee, T. n., Sze, S. n., Richards, A. n., Aronsohn, A. n., Wong, G. L., Tanaka, Y. n., Dusheiko, G. n., Nguyen, M. H.
2017; 12 (8): e0181603
- **Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.** *BMJ open gastroenterology*
Nguyen, P. n., Vutien, P. n., Hoang, J. n., Trinh, S. n., Le, A. n., Yasukawa, L. A., Weber, S. n., Henry, L. n., Nguyen, M. H.
2017; 4 (1): e000181
- **Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.** *Alimentary pharmacology & therapeutics*
Le, A. K., Zhao, C. n., Hoang, J. K., Tran, S. A., Chang, C. Y., Jin, M. n., Nguyen, N. H., Yasukawa, L. A., Zhang, J. Q., Weber, S. C., Garcia, G. n., Nguyen, M. H.
2017
- **Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.** *Drug design, development and therapy*
Ogawa, E. n., Furusyo, N. n., Nguyen, M. H.
2017; 11: 3197–3204
- **Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma.** *Scientific reports*
Estevez, J. n., Chen, V. L., Podlaha, O. n., Li, B. n., Le, A. n., Vutien, P. n., Chang, E. T., Rosenberg-Hasson, Y. n., Jiang, Z. n., Pflanz, S. n., Ge, D. n., Gaggar, A. n., Nguyen, et al
2017; 7 (1): 11867
- **Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?** *Hepatology (Baltimore, Md.)*
Ji, F. n., Yeo, Y. H., Wei, M. T., Wei, B. n., Dang, S. n., Li, Z. n., Nguyen, M. H.
2017
- **Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.** *The American journal of gastroenterology*
Nguyen, M. H., Trinh, H. n., Do, S. n., Nguyen, T. n., Nguyen, P. n., Henry, L. n.
2017
- **Editorial: hepatitis C virus (HCV) disease progression - HCV cure and the elimination of the "ethnic slope". Authors' reply.** *Alimentary pharmacology & therapeutics*
Le, A. K., Garcia, G. n., Nguyen, M. H.

2017; 46 (10): 1012–13

- **Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV cirrhosis with Normal Alanine Transaminase.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Yang, J. D., Dai, J. n., Singal, A. G., Gopal, P. n., Addissie, B. n., Nguyen, M. H., Befeler, A. S., Reddy, K. R., Schwartz, M. n., Harnois, D. M., Yamada, H. n., Gores, G. J., Feng, et al
2017
- **Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma? Authors' reply.** *Alimentary pharmacology & therapeutics*
Lin, D. n., Yang, H. I., Hoang, J. n., Nguyen, M. H.
2017; 45 (1): 182–83
- **Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease** *WORLD JOURNAL OF GASTROENTEROLOGY*
Wong, C. R., Nguyen, M. H., Lim, J. K.
2016; 22 (37): 8294-8303
- **Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.** *Alimentary pharmacology & therapeutics*
LIN, D., Yang, H., Nguyen, N., Hoang, J., Kim, Y., Vu, V., Le, A., Chaung, K., Nguyen, V., Trinh, H., Li, J., Zhang, J., Hsing, et al
2016; 44 (8): 846-855
- **The Effect of Gastric Acid Suppression on Ledipasvir-Sofosbuvir Effectiveness in Chronic Hepatitis C Infection**
Swanner, A., Kumari, R., Garcia, G., Daugherty, T., Nguyen, M. H., Ahmed, A., Kim, W., Lutchan, G. A.
WILEY.2016: 947A
- **High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals**
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I. M., Tran, T., Nahass, R., Hinestrosa, F., Herring, R., Bennett, M., Llewellyn, et al
NATURE PUBLISHING GROUP.2016: S380
- **Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B**
Fung, S., Yatsuhashi, H., Tak, W., Celen, M. K., Flaherty, J. F., Kim, K., Myers, R. P., Subramanian, M., Ryder, S. D., Sharma, M., Nguyen, M. H.
WILEY.2016: 914A–915A
- **Integrated Resistance Analyses of HCV-infected Patients treated with Sofosbuvir, Velpatasvir and Voxilaprevir for 8 and 12 weeks from Phase 2 Studies**
Reau, N., Nguyen, M. H., Kowdley, K. V., Gane, E. J., Dvory-Sobol, H., Svarovskaia, E. S., Yang, J. C., Stamm, L. M., Brainard, D. M., Miller, M. D., Mo, H., Lawitz, E., Kwo, et al
WILEY.2016: 415A–416A
- **High Frequency of Flares in Alanine Aminotransferase (ALT) And Hepatitis B Virus (HBV) DNA During Pregnancy And Postpartum in Women With Chronic Hepatitis B (CHB) Who Discontinued Therapy Prior to or During Early Pregnancy**
Chang, C. Y., Aziz, N., Poongkunran, M., Javaid, A., Trinh, H. N., Lau, D., Nguyen, M. H.
WILEY.2016: 920A
- **Higher Prevalence of Existing Comorbidities and Medication Use in Untreated Patients with Chronic Hepatitis C (CHC) compared to Treated Patients: A Population-Based Study in Post-Oral Direct-Acting Antivirals (DAAs) Era**
Vutien, P., Tran, N. Q., Cao, F., Peichel, V., Nguyen, M. H.
WILEY.2016: 413A–414A
- **Predictors of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis Stage 3-4 in Patients with NAFLD in the United States: Results of a Population Based Sample of 6,000 Patients**
Le, M. H., Devaki, P., Ha, N. B., Jun, D., Te, H. S., Cheung, R., Nguyen, M. H.
WILEY.2016: 535A
- **Nonalcoholic steatohepatitis (NASH) or high probability of fibrosis based on noninvasive marker panels (APRI, FIB-4, NFS) at disease presentation is associated with increased all-cause mortality in patients with nonalcoholic fatty liver disease (NAFLD)**
Ha, N. B., Le, R. H., Trinh, S., Nguyen, M. D., Yip, B., Hoang, J. K., Nguyen, M. H.
WILEY.2016: 592A

- **Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a US Cohort of 2376 Patients with Chronic Hepatitis C (CHC) and Cirrhosis**
Tran, S. A., Hoang, J. K., Le, A. K., Zhao, C., Yasukawa, L., Weber, S. C., Nguyen, M. H.
WILEY.2016: 30A
- **Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. *Alimentary pharmacology & therapeutics***
Lutchman, G., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Gupta, S., Doshi, D., Nguyen, M. H.
2016; 44 (7): 738-746
- **Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B. *American journal of gastroenterology***
Chang, C. Y., Aziz, N., Poongkunran, M., Javaid, A., Trinh, H. N., Lau, D., Nguyen, M. H.
2016; 111 (10): 1410-1415
- **Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. *Alimentary pharmacology & therapeutics***
Lutchman, G., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Gupta, S., Doshi, D., Nguyen, M. H.
2016; 44 (7): 738-746
- **Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B. *American journal of gastroenterology***
Chang, C. Y., Aziz, N., Poongkunran, M., Javaid, A., Trinh, H. N., Lau, D., Nguyen, M. H.
2016; 111 (10): 1410-1415
- **Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. *American journal of gastroenterology***
Ahn, J., Lim, J. K., Lee, H. M., Lok, A. S., Nguyen, M., Pan, C. Q., Mannalithara, A., Te, H., Reddy, K. R., Trinh, H., Chu, D., Tran, T., Lau, et al
2016; 111 (9): 1297-1304
- **Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study *AMERICAN JOURNAL OF GASTROENTEROLOGY***
Ahn, J., Lim, J. K., Lee, H. M., Lok, A. S., Mindie Nguyen, M., Pan, C. Q., Mannalithara, A., Te, H., Reddy, K. R., Huy Trinh, H., Chu, D., Tram Tran, T., Lau, et al
2016; 111 (9): 1297-1304
- **Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection *ALIMENTARY PHARMACOLOGY & THERAPEUTICS***
Nguyen, L. H., Hoang, J., Nguyen, N. H., Vu, V. D., Wang, C., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M. H.
2016; 44 (4): 390-399
- **Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. *Medicine***
Hoang, J. K., Yang, H., Le, A., Nguyen, N. H., Lin, D., Vu, V. D., Chaung, K., Nguyen, V., Trinh, H. N., Li, J., Zhang, J. Q., Chen, C., Nguyen, et al
2016; 95 (31)
- **Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. *Medicine***
Wang, C., Chen, V., Vu, V., Le, A., Nguyen, L., Zhao, C., Wong, C. R., Nguyen, N., Li, J., Zhang, J., Trinh, H., Nguyen, M. H.
2016; 95 (35)
- **Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY***
Chen, V. L., Le, A. K., Kim, N. G., Kim, L. H., Nguyen, N. H., Nguyen, P. P., Zhao, C., Nguyen, M. H.
2016; 14 (6): 887-?
- **Analysis of HCV-6 isolates among Asian-born immigrants in North America reveals their high genetic diversity and a new subtype *VIROLOGY***
Lu, L., Wu, T., Xiong, L., Li, C., Nguyen, M. H., Murphy, D. G.
2016; 492: 25-31
- **Racial Disparities in Treatment Rates for Chronic Hepatitis C Analysis of a Population-Based Cohort of 73,665 Patients in the United States *MEDICINE***

- Vutien, P., Hoang, J., Brooks, L., Nguyen, N. H., Nguyen, M. H.
2016; 95 (22)
- **Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.** *Journal of clinical gastroenterology*
Chung, K. T., O'Brien, C., Ha, N. B., Nguyen, N. H., Trinh, H. N., Nguyen, M. H.
2016; 50 (4): 338-344
 - **Letter: lessons from the "real-world" entecavir therapy in chronic hepatitis B patients - authors' reply** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Ahn, J., Nguyen, M. H., Lim, J. K., Lee, H. M., Pan, C. Q., Lok, A. S.
2016; 43 (7): 847-48
 - **Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation.** *Digestive diseases and sciences*
Uribe, L. A., Nguyen, N., Kim, L., Trinh, H. N., Wong, C., Wong, C., Nguyen, L. H., Nguyen, M. H.
2016; 61 (2): 618-625
 - **Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.** *Journal of clinical gastroenterology*
Ha, N. B., Trinh, H. N., Rosenblatt, L., Nghiem, D., Nguyen, M. H.
2016; 50 (2): 169-74
 - **Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Ha, N. B., Trinh, H. N., Rosenblatt, L., Nghiem, D., Nguyen, M. H.
2016; 50 (2): 169-174
 - **Hepatocellular Carcinoma Screening and Surveillance Practice Guidelines and Real-Life Practice** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Zhao, C., Nguyen, M. H.
2016; 50 (2): 120-133
 - **HCV Prevalence in Asian Americans in California.** *Journal of immigrant and minority health*
Lin, O. N., Chang, C., Lee, J., Do, A., Martin, M., Martin, A., Nguyen, M. H.
2016: -?
 - **Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.** *BMJ open gastroenterology*
Nguyen, N. H., Yee, B. E., Chang, C., Jin, M., Lutchman, G., Lim, J. K., Nguyen, M. H.
2016; 3 (1)
 - **SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS**
Gane, E. J., Nguyen, M., Kwo, P., Kowdley, K., Reau, N., Jacobson, I., Curry, M., Pearlman, B., Khalid, O., Everson, G., Gordon, S., Poulos, J., Sheikh, et al
ELSEVIER SCIENCE BV.2016: S758-S759
 - **RISING INPATIENT ENCOUNTERS AND HOSPITAL CHARGES FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES**
Nguyen, A. L., Nguyen, P., Sheen, E., Jin, M., Jin, M., Kim, Y., Nguyen, M. H.
ELSEVIER SCIENCE BV.2016: S472
 - **ANTIVIRAL THERAPY FOR THE PREVENTION OF LONG-TERM CIRRHOSIS RISK IN PATIENTS WITH CHRONIC HEPATITIS B**
Yang, H., Hoang, J., Lin, D., Liu, J., Hu, H., Lee, M., Nguyen, N. H., Kim, Y., Jen, C., Vu, V., Le, A., Chaung, K., Nguyen, et al
ELSEVIER SCIENCE BV.2016: S591
 - **DEVELOPMENT AND VALIDATION OF A RISK SCORE SYSTEM INCLUSIVE OF ANTIVIRAL THERAPY FOR PREDICTING LIVER CIRRHOSIS RISK IN DIVERSE PATIENTS WITH CHRONIC HEPATITIS B INFECTION**
Jin, M., Yang, H., Le, A. K., Lee, M., Hoang, J., Nguyen, N. H., Lin, D., Trinh, H., Li, J., Zhang, J., Chen, C., Nguyen, M.
ELSEVIER SCIENCE BV.2016: S372

- **THE APPLICABILITY OF HEPATOCELLULAR CARCINOMA RISK PREDICTION SCORING SYSTEM IN A US PATIENT COHORT WITH CHRONIC HEPATITIS C INFECTION**
Jin, M., Zhao, C., Lee, M., Le, A. K., Hoang, J., Ha, N. B., Trieu, V., Yang, H., Chen, C., Nguyen, M.
ELSEVIER SCIENCE BV.2016: S621–S622
- **HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV- INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS**
Lawitz, E., Kowdley, K., Curry, M., Reau, N., Nguyen, M., Kwo, P., Jacobson, I., Tran, T. T., Nahass, R., Hiestrosa, F., Herring, R., Bennet, M., Yang, et al
ELSEVIER SCIENCE BV.2016: S139–S140
- **VALIDATION OF THE GALAD SCORE FOR HEPATOCELLULAR CARCINOMA DIAGNOSIS IN A US COHORT**
Yang, J. D., Dai, J., Addissie, B., Nguyen, M. H., Befeler, A. S., Reddy, R., Schwartz, M. E., Harnois, D. M., Gores, G. J., Feng, Z., Marrero, J. A., Roberts, L. R.
ELSEVIER SCIENCE BV.2016: S330
- **ONLY ONE-THIRD OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WERE DIAGNOSED BY SCREENING, SURVEILLANCE, OR WITHOUT SYMPTOMS: A META-ANALYSIS OF 40 STUDIES AND 20,349 PATIENTS WITH DIVERSE UNDERLYING LIVER DISEASE AND WORLD REGIONS**
Jin, M. Q., Le, R. H., Jin, M., Zhao, C., Le, M. H., Nguyen, A., Kwan, B., Chen, V. L., Wong, V., Lim, Y., Chuang, W., Yu, M., Wong, et al
ELSEVIER SCIENCE BV.2016: S336
- **SOFOBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY)**
Asselah, T., Shafran, S., Bourgeois, S., Lai, C., Cramp, M., Mathurin, P., Willems, B., Nguyen, M. H., Davis, M. N., Huang, K. C., Svarovskaia, E., Osinusi, A., McNally, et al
ELSEVIER SCIENCE BV.2016: S827–S828
- **Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study.** *Alimentary pharmacology & therapeutics*
Ahn, J., Lee, H. M., Lim, J. K., Pan, C. Q., Nguyen, M. H., Ray Kim, W., Mannalithara, A., Trinh, H., Chu, D., Tran, T., Min, A., Do, S., Te, et al
2016; 43 (1): 134-44
- **The Cascade of Care in Chronic Hepatitis B** *Current Hepatitis Reports*
Liou, I. W., Nguyen, M. H.
2016; 15: 209-219
- **Antibody-dependent and -independent uptake of HBsAg across human leukocyte subsets is similar between individuals with chronic hepatitis B Virus infection and healthy donors.** *Journal of viral hepatitis*
Tharinger, H. n., Rebbapragada, I. n., Samuel, D. n., Novikov, N. n., Nguyen, M. n., Jordan, R. n., Frey, C. R., Pflanz, S. n.
2016
- **Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.** *BMJ open gastroenterology*
Kim, Y. A., Estevez, J. n., Le, A. n., Israelski, D. n., Baatarkhuu, O. n., Sarantuya, T. n., Narantsetseg, S. n., Nymadawa, P. n., H Le, R. n., Yuen, M. F., Dusheiko, G. n., Rizzetto, M. n., Nguyen, et al
2016; 3 (1): e000119
- **Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.** *Clinical and molecular hepatology*
Oh, H. n., Jun, D. W., Saeed, W. K., Nguyen, M. H.
2016; 22 (3): 327–35
- **Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study.** *BMJ open gastroenterology*
Ladenheim, M. R., Kim, N. G., Nguyen, P., Le, A., Stefanick, M. L., Garcia, G., Nguyen, M. H.
2016; 3 (1)
- **Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.** *Cancer*
Yang, J. D., Altekruse, S. F., Nguyen, M. H., Gores, G. J., Roberts, L. R.
2016

- **Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Ahn, J., Lee, H. M., Lim, J. K., Pan, C. Q., Nguyen, M. H., Kim, W. R., Mannalithara, A., Trinh, H., Chu, D., Tran, T., Min, A., Do, S., Te, et al
2016; 43 (1): 134-144
- **Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.** *BMJ open gastroenterology*
Yee, B. E., Nguyen, N. H., Jin, M., Lutchman, G., Lim, J. K., Nguyen, M. H.
2016; 3 (1)
- **Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited.** *World journal of clinical cases*
Leong, J. n., Lin, D. n., Nguyen, M. H.
2016; 4 (3): 71-75
- **Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.** *The New England journal of medicine*
Feld, J. J., Jacobson, I. M., Hézode, C., Asselah, T., Ruane, P. J., Gruener, N., Abergel, A., Mangia, A., Lai, C. L., Chan, H. L., Mazzotta, F., Moreno, C., Yoshida, et al
2015; 373 (27): 2599-607
- **Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.** *Gastroenterology clinics of North America*
Nguyen, N. H., Nguyen, M. H.
2015; 44 (4): 871-881
- **Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis** *BMJ OPEN GASTROENTEROLOGY*
Zhang, B., Nguyen, N. H., Yee, B. E., Yip, B., Nguyen, M. H.
2015; 2 (1): e000057
- **Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy A Matched Case-Cohort Study** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Ha, N. B., Ku, K., Ha, N. B., Chaung, K. T., Trinh, H. N., Nguyen, M. H.
2015; 49 (10): 873-877
- **A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Martin, P., Lau, D. T., Nguyen, M. H., Janssen, H. I., Dieterich, D. T., Peters, M. G., Jacobson, I. M.
2015; 13 (12): 2071-?
- **Antiviral Therapy, Treatment Eligibility, and Treatment Rates in Patients Meeting Treatment Criteria in Chronic Hepatitis B in Diverse Practice Settings: A Systematic Review and Meta-analysis of 9 Studies and 22,768 Patients**
Mahajan, V., Jin, M., Le, M., Nghia Nguyen, Wong, C., Leong, J., Nguyen, M. H.
NATURE PUBLISHING GROUP.2015: S959-S961
- **Low HCV Treatment for Chronic Hepatitis C (CHC) Patients in Pre-Protease Inhibitor (PI) and Post-PI/Pre-Direct Acting Antiviral (DAA) Eras Compared to Post-DAA Era, Especially in African Americans: Analysis of A Large Real-World Cohort of 7105 Patients**
Nguyen, P. T., Nguyen, N. H., Hoang, J. K., Zhao, C., Le, A. K., Chang, C. Y., Le, R. H., Nguyen, M. D., Jin, M., Weber, S. C., Yasukawa, L., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1094A
- **Characteristics and Clinical Outcomes of A Diverse Cohort of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease (NAFLD)**
Yip, B., Yee, B. E., Do, A., Nguyen, N. H., Hoang, J. K., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1303A
- **IFN and/or RBV-Free Therapy (Rx) with Simeprevir plus Sofosbuvir (SMV plus SOF) was Well-Tolerated and Effective for Chronic Hepatitis C Genotype 1 (CHC-1) Including Post-Liver Transplant (LT) and Decompensated Non-Liver Transplant (Non-LT) Patients: A Single-Center Experience**
Lutchman, G. A., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Kim, W., Gupta, S., Doshi, D., Nguyen, M. H.
WILEY-BLACKWELL.2015: 797A-798A
- **Similar Tolerability and Effectiveness with SMV plus SOF Therapy in Asians and Non-Asians with Chronic Hepatitis C Genotype 1 (CHC-1) but Anemia and Fatigue were Common with SOF plus RBV in Both Groups**

Chang, C. Y., Nguyen, N. H., Zhao, C., Lutchman, G. A., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Kim, W., Trinh, H. N., Vu, V. D., Ku, W., Nguyen, et al
WILEY-BLACKWELL.2015: 794A

- **Antiviral Therapy for Chronic Hepatitis B (CHB) Reduces the Incidence of Hepatocellular Carcinoma (HCC) Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score**
Lin, D., Yang, H., Nguyen, N. H., Hoang, J. K., Kim, Y., Vu, V. D., Le, A. K., Chaung, K. T., Nguyen, V. G., Trinh, H. N., Li, J., Zhang, J. Q., Hsing, et al
WILEY-BLACKWELL.2015: 315A
- **Differences in Presentation and Long-Term Survival of Patients with Hepatocellular Carcinoma (HCC) with Hepatitis B Virus (HBV) Compared to Hepatitis C Virus (HCV) or Non-Viral Etiology**
Chen, V. L., Kim, N. G., Le, A. K., Ladenheim, M. R., Nguyen, P., Zhao, C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 406A
- **A Single Center Experience with Hepatocellular Carcinoma (HCC): Shifts in Patient Ethnicity and HCC Etiology but No Improvement in Survival over Time**
Chen, V. L., Kim, N. G., Le, A. K., Ladenheim, M. R., Nguyen, P., Zhao, C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 425A
- **Regional and Etiological Differences in the Adherence to Hepatocellular Carcinoma (HCC) Surveillance among Patients of Chronic Hepatitis B (CHB) and Cirrhosis of All Etiologies: A Meta-Analysis of 15,429 Patients from 14 Individual Studies**
Zhao, C., Jin, M., Le, R. H., Le, M. H., Chen, V. L., Wong, G., Wong, V. W., Lim, Y., Chuang, W., Yu, M., Nguyen, M. H.
WILEY-BLACKWELL.2015: 440A–441A
- **Higher Incidence of Hepatocellular Carcinoma (HCC) in Patients with Hepatitis B Virus (HBV) -related Liver Cirrhosis (LC) Compared to Hepatitis C Virus (HCV)-LC and Non-Viral LC**
Zhao, C., Nguyen, N. H., Nguyen, M. D., Hoang, J. K., Nguyen, L. H., Le, R. H., Nguyen, P. T., Vu, V. D., Lin, D., Yasukawa, L., Weber, S. C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 440A
- **Lower Incidence of Hepatocellular Carcinoma (HCC) with Antiviral Therapy in Chronic Hepatitis B (CHB) Patients without Cirrhosis and Normal to Minimally Elevated Alanine Aminotransferase (ALT) Levels (< 2x upper limit of normal or ULN)**
Hoang, J. K., Nguyen, N. H., Yang, H., Lin, D., Vu, V. D., Chaung, K. T., Nguyen, V. G., Le, A. K., Trinh, H. N., Li, J., Zhang, J. Q., Chen, C., Nguyen, et al
WILEY-BLACKWELL.2015: 972A
- **Differential Serum Cytokine Profiles in Patients with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Non-Viral Non-Autoimmune Liver Disease, with or without Hepatocellular Carcinoma (HCC)**
Chen, V. L., Vutien, P., Li, B., Podlaha, O., Chang, E. T., Jiang, Z., Ge, D., Gaggar, A., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1022A
- **Progression to liver cirrhosis in patients with chronic hepatitis C (CHC) in a large United States cohort: a natural history study**
Nguyen, N. H., Hoang, J. K., Le, A. K., Zhao, C., Chang, C. Y., Le, R. H., Jin, M., Kutsenko, A., Yasukawa, L., Zhang, J. Q., Weber, S. C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1089A
- **Racial Differences in Socioeconomic Status (SES), Cirrhosis, and Treatment of Chronic Hepatitis C (CHC): Highest Treatment Rates in Caucasian Americans (CA), followed by Hispanic Americans (HA), African Americans (AFA) and Lowest in Asian Americans (AA)**
Vutien, P., Hoang, J. K., Brooks, L., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1088A–1089A
- **Low HCV Treatment for Chronic Hepatitis C (CHC) Patients in Pre-Protease Inhibitor (PI) and Post-PI/Pre-Direct Acting Antiviral (DAA) Eras Compared to Post-DAA Era, Especially in African Americans: Analysis of A Large Real-World Cohort of 7105 Patients**
Nguyen, P. T., Nguyen, N. H., Hoang, J. K., Zhao, C., Le, A. K., Chang, C. Y., Le, R. H., Nguyen, M. D., Jin, M., Weber, S. C., Yasukawa, L., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1094A
- **Characteristics and Clinical Outcomes of A Diverse Cohort of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease (NAFLD)**
Yip, B., Yee, B. E., Do, A., Nguyen, N. H., Hoang, J. K., Nguyen, M. H.
WILEY-BLACKWELL.2015: 1303A

- **IFN and/or RBV-Free Therapy (Rx) with Simeprevir plus Sofosbuvir (SMV plus SOF) was Well-Tolerated and Effective for Chronic Hepatitis C Genotype 1 (CHC-1) Including Post-Liver Transplant (LT) and Decompensated Non-Liver Transplant (Non-LT) Patients: A Single-Center Experience**
Lutchman, G. A., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Kim, W., Gupta, S., Doshi, D., Nguyen, M. H.
WILEY-BLACKWELL.2015: 797A–798A
- **Similar Tolerability and Effectiveness with SMV plus SOF Therapy in Asians and Non-Asians with Chronic Hepatitis C Genotype 1 (CHC-1) but Anemia and Fatigue were Common with SOF plus RBV in Both Groups**
Chang, C. Y., Nguyen, N. H., Zhao, C., Lutchman, G. A., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Kim, W., Trinh, H. N., Vu, V. D., Ku, W., Nguyen, et al
WILEY-BLACKWELL.2015: 794A
- **Antiviral Therapy for Chronic Hepatitis B (CHB) Reduces the Incidence of Hepatocellular Carcinoma (HCC) Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score**
Lin, D., Yang, H., Nguyen, N. H., Hoang, J. K., Kim, Y., Vu, V. D., Le, A. K., Chaung, K. T., Nguyen, V. G., Trinh, H. N., Li, J., Zhang, J. Q., Hsing, et al
WILEY-BLACKWELL.2015: 315A
- **Differences in Presentation and Long-Term Survival of Patients with Hepatocellular Carcinoma (HCC) with Hepatitis B Virus (HBV) Compared to Hepatitis C Virus (HCV) or Non-Viral Etiology**
Chen, V. L., Kim, N. G., Le, A. K., Ladenheim, M. R., Nguyen, P., Zhao, C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 406A
- **A Single Center Experience with Hepatocellular Carcinoma (HCC): Shifts in Patient Ethnicity and HCC Etiology but No Improvement in Survival over Time**
Chen, V. L., Kim, N. G., Le, A. K., Ladenheim, M. R., Nguyen, P., Zhao, C., Nguyen, M. H.
WILEY-BLACKWELL.2015: 425A
- **Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.** *European journal of gastroenterology & hepatology*
Kim, L. H., Chaung, K. T., Ha, N. B., Kin, K. C., Vu, V. D., Trinh, H. N., Nguyen, H. A., Nguyen, M. H.
2015; 27 (8): 871-876
- **Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.** *Journal of viral hepatitis*
Lu, L., Yip, B., Trinh, H., Pan, C. Q., Han, S. B., Wong, C. C., Li, J., Chan, S., Krishnan, G., Wong, C. C., Nguyen, M. H.
2015; 22 (8): 675-681
- **Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients** *HEPATOLOGY INTERNATIONAL*
Devaki, P., Jencks, D., Yee, B. E., Nguyen, M. H.
2015; 9 (3): 431-437
- **Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Ku, W., Wang, U., Nguyen, M. H.
2015; 15 (5): 665-677
- **Chrome-Colonoscopy (CC), in a Single Operator Community Practice, Significantly Increases Polyp Detection Rate: a Call for Wider Adoption.**
Balaa, M. A., Al-Manaseer, F., Lin, O. N., Vinh Vu, Syriani, L., Nguyen, M. H.
MOSBY-ELSEVIER.2015: AB209–AB210
- **Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir** *DIGESTIVE DISEASES AND SCIENCES*
Vo, K. P., Vutien, P., Akiyama, M. J., Vu, V. D., Ha, N. B., Piotrowski, J. I., Wantuck, J., Roytman, M. M., Tsai, N., Cheung, R., Li, J., Nguyen, M. H.
2015; 60 (4): 1045-1051
- **LOWER RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR: A REACH-B ANALYSIS OF THE ENUMERATE STUDY**
Ahn, J., Nguyen, M., Lee, H., Lim, J., Pan, C., Te, H., Tran, T., Trinh, H. N., Lau, D., Chu, D., Min, A., Leduc, T., Pillai, et al
ELSEVIER SCIENCE BV.2015: S562

- **DIAGNOSIS BY SCREENING RATHER THAN SYMPTOMS IN HBV-RELATED HCC IS ASSOCIATED WITH IMPROVED OUTCOMES, REGARDLESS OF CIRRHOSIS STATUS BUT SCREENING HISTORY WAS ONLY PRESENT IN ONE-HALF OF CIRRHOSIS AND ONE-THIRD OF NONCIRRHOSIS CASES**
Chen, V. L., Kim, L., Nguyen, P., Zhao, C., Nguyen, M. H.
ELSEVIER SCIENCE BV.2015: S548
- **GENDER DIFFERENCES IN HEPATOCELLULAR CARCINOMA (HCC) SURVEILLANCE ADHERENCE PATTERNS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN A MULTICENTER ACADEMIC AND COMMUNITY COHORT STUDY**
Nguyen, L., Wang, C., Hoang, J., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M.
ELSEVIER SCIENCE BV.2015: S535
- **OUTCOMES OF 12-WEEK THERAPY WITH SIMEPREVIR plus SOFOSBUVIR plus +/- RIBAVIRIN (SMV plus SOF +/- RBV): A META-ANALYSIS OF 7 STUDIES AND 715 HCV GENOTYPE 1 (HCV-1) PATIENTS**
Yee, B. E., Nguyen, N. H., Lutchman, G. A., Lim, J. K., Nguyen, M. H.
ELSEVIER SCIENCE BV.2015: S668–S669
- **META-ANALYSIS: SVR12 WITH SIMEPREVIR AND SOFOSBUVIR (SMV+SO) FOR 12 WEEKS IN 225 LIVER TRANSPLANT (LT) RECIPIENTS WITH HCV GENOTYPE 1 (HCV-1)**
Nguyen, N. H., Yee, B. E., Lutchman, G. A., Lim, J. K., Nguyen, M.
ELSEVIER SCIENCE BV.2015: S314
- **Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. *Expert opinion on pharmacotherapy***
Kumari, R., Nguyen, M. H.
2015; 16 (5): 739-748
- **Recurrent Hepatocellular Carcinoma and Poorer Overall Survival in Patients Undergoing Left-sided Compared With Right-sided Partial Hepatectomy. *Journal of clinical gastroenterology***
Valenzuela, A., Ha, N. B., Gallo, A., Bonham, C., Ahmed, A., Melcher, M., Kim, L. H., Esquivel, C., Concepcion, W., Ayoub, W. S., Lutchman, G. A., Daugherty, T., Nguyen, et al
2015; 49 (2): 158-164
- **Chronic Hepatitis B Treatment Eligibility and Actual Treatment Rates in Patients in Community Gastroenterology and Primary Care Settings *JOURNAL OF CLINICAL GASTROENTEROLOGY***
Nguyen, V. G., Wan, K., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M. H.
2015; 49 (2): 145-149
- **Safety and efficacy of entecavir in adefovir-experienced patients *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY***
Nguyen, N. H., Trinh, H. N., Nguyen, T. T., Do, S. T., Tran, P., Nguyen, H. A., Nguyen, K. K., Garcia, R. T., Lutchman, G. A., Nguyen, M. H.
2015; 30 (1): 43-50
- **Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis *INTERVIROLOGY***
Zhang, B., Nguyen, N. H., Yee, B. E., Yip, B., Ayoub, W. S., Lutchman, G. A., Nguyen, M. H.
2015; 58 (4): 242-249
- **Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. *BMJ open gastroenterology***
Yee, B. E., Nguyen, N. H., Zhang, B., Lin, D., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H.
2015; 2 (1)
- **Current Treatment Options in Patients with Hepatitis C Virus Genotype 6 *Gastroenterol Clin N Am***
Nguyen, N. H., Nguyen, M. H.
2015; 44: 871-881
- **Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. *BMJ open gastroenterology***
Vu, V. D., Do, A., Nguyen, N. H., Kim, L. H., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Nguyen, M., Huynh, A., Nguyen, M. H.
2015; 2 (1)
- **Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin *INTERVIROLOGY***

- Nguyen, N. H., McCormack, S. A., Vutien, P., Yee, B. E., Devaki, P., Jencks, D., Nguyen, M. H.
2015; 58 (1): 27-34
- **Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.** *European journal of gastroenterology & hepatology*
Yee, B. E., Nguyen, N. H., Zhang, B., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H.
2014; 26 (11): 1189-1201
 - **The genetic diversity and evolutionary history of hepatitis C virus in Vietnam** *VIROLOGY*
Li, C., Yuan, M., Lu, L., Lu, T., Xia, W., Pham, V. H., Vo, A. X., Nguyen, M. H., Abe, K.
2014; 468: 197-206
 - **Current treatment guidelines for chronic hepatitis B and their applications.** *Journal of clinical gastroenterology*
Uribe, L. A., O'Brien, C. G., Wong, R. J., Gish, R. R., Tsai, N., Nguyen, M. H.
2014; 48 (9): 773-783
 - **Retreatment of Patients With Chronic Hepatitis C Genotype 4 (HCV-4) Infection With Pegylated Interferon and Ribavirin (P/R): A Systematic Review and Meta-Analysis**
Zhang, B., Yee, B., Nguyen, N., Yip, B., Ayoub, W., Nguyen, M., Lutchman, G.
NATURE PUBLISHING GROUP.2014: S185
 - **Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks.** *Hepatology international*
Nguyen, N. H., McCormack, S. A., Yee, B. E., Devaki, P., Jencks, D., Chao, D. T., Nguyen, M. H.
2014; 8 (4): 540-549
 - **The genetic diversity and evolutionary history of hepatitis C virus in Vietnam.** *Virology*
Li, C., Yuan, M., Lu, L., Lu, T., Xia, W., Pham, V. H., Vo, A. X., Nguyen, M. H., Abe, K.
2014; 468-470C: 197-206
 - **Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score.** *Clinical gastroenterology and hepatology*
Wong, R. J., Devaki, P., Nguyen, L., Cheung, R., Cho-Phan, C., Nguyen, M. H.
2014; 12 (9): 1534-1540 e1
 - **Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Wong, R. J., Devaki, P., Long Nguyen, L., Cheung, R., Cho-Phan, C., Nguyen, M. H.
2014; 12 (9): 1534-U323
 - **Low Treatment Rates in Patients Meeting Guideline Criteria in Diverse Practice Settings** *DIGESTIVE DISEASES AND SCIENCES*
Kim, L. H., Nguyen, V. G., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M. H.
2014; 59 (9): 2091-2099
 - **Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients.** *Clinical gastroenterology and hepatology*
Vutien, P., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Levitt, B. S., Nguyen, K., da Silveira, E., Daugherty, T., Ahmed, A., Garcia, G., Lutchman, G. A., Nguyen, M. H.
2014; 12 (8): 1363-1370
 - **Mutations in HBV DNA Polymerase Associated With Nucleos(t)ide Resistance Are Rare in Treatment-naive Patients.** *Clinical gastroenterology and hepatology*
Vutien, P., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Levitt, B. S., Nguyen, K., da Silveira, E., Daugherty, T., Ahmed, A., Garcia, G., Lutchman, G. A., Nguyen, M. H.
2014; 12 (8): 1363-1370
 - **Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Do, A. L., Wong, C. R., Nguyen, L. H., Nguyen, V. G., Huy Trinh, H., Nguyen, M. H.
2014; 48 (7): 644-649

- **Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis and Systematic Review** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Nguyen, L. H., Chao, D., Lim, J. K., Ayoub, W., Nguyen, M. H.
2014; 12 (8): 1262-1266
- **Isoniazid hepatotoxicity requiring liver transplantation.** *Digestive diseases and sciences*
Sheen, E., Huang, R. J., Uribe, L. A., Nguyen, M. H.
2014; 59 (7): 1370-1374
- **Isoniazid Hepatotoxicity Requiring Liver Transplantation** *DIGESTIVE DISEASES AND SCIENCES*
Sheen, E., Huang, R. J., Uribe, L. A., Nguyen, M. H.
2014; 59 (7): 1370-1374
- **Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.** *Alimentary pharmacology & therapeutics*
Gao, L., Trinh, H. N., Li, J., Nguyen, M. H.
2014; 39 (11): 1339-1340
- **Letter: Response-guided treatment of hepatitis C virus genotype 5 may be feasible--authors' reply.** *Alimentary pharmacology & therapeutics*
Wantuck, J. M., Nguyen, M. H.
2014; 39 (11): 1338-?
- **Letter: Response-guided treatment of hepatitis C virus genotype 5 may be feasible--authors' reply.** *Alimentary pharmacology & therapeutics*
Wantuck, J. M., Nguyen, M. H.
2014; 39 (11): 1338-?
- **Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: Results from the surveillance, epidemiology, and end results registry** *LIVER TRANSPLANTATION*
Wong, R. J., Devaki, P., Long Nguyen, L., Cheung, R., Nguyen, M. H.
2014; 20 (5): 528-535
- **Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients - authors' reply** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Yaghoobi, M., Yuan, Y., Hunt, R. H.
2014; 39 (9): 993
- **Letter: gender-associated cell-free microRNA profiles in non-alcoholic fatty liver disease** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Chao, D., Nguyen, M. H.
2014; 39 (9): 997-998
- **POOR ADHERENCE TO HCV MEDICATION IN A MEDICAID POPULATION**
Kim, Y. A., Nguyen, M., Richards, K. M., Wilson, J. P., Rascati, K. L.
ELSEVIER SCIENCE INC.2014: A277
- **GENDER DISPARITY AND REAL-LIFE PRACTICE SETTING DIFFERENCES IN ACTUAL TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B MEETING CRITERIA FOR ANTIVIRAL THERAPY**
Kim, L. H., Nguyen, V. G., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M.
ELSEVIER SCIENCE BV.2014: S13-S14
- **Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Gao, L., Trinh, H. N., Li, J., Nguyen, M. H.
2014; 39 (6): 629-637
- **Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase <= 40 IU/L and significant hepatic fibrosis** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Chao, D. T., Lim, J. K., Ayoub, W. S., Nguyen, L. H., Nguyen, M. H.
2014; 39 (4): 349-358

- **Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients.** *Digestive diseases and sciences*
Wong, R. J., Wantuck, J., Valenzuela, A., Ahmed, A., Bonham, C., Gallo, A., Melcher, M. L., Lutchman, G., Concepcion, W., Esquivel, C., Garcia, G., Daugherty, T., Nguyen, et al
2014; 59 (1): 183-191
- **Incidence of Hepatocellular Carcinoma (HCC) in a US Cohort of Chronic Hepatitis B (CHB) Patients by Age, Gender, Cirrhosis and Antiviral Treatment Status**
Lin, D., Nguyen, N. H., Hoang, J., Vu, V. D., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, H. A., Nguyen, K., Nguyen, M. H.
WILEY-BLACKWELL.2014: 315A–316A
- **Incidence of Hepatocellular Carcinoma (HCC) in non-cirrhotic chronic hepatitis B (CHB) patients with low ALT levels in a multicenter US Cohort**
Hoang, J. K., Nguyen, N. H., Lin, D., Vu, V. D., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, H. A., Nguyen, K., Nguyen, M. H.
WILEY-BLACKWELL.2014: 1088A
- **Antiviral Therapy and the Development of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB) Patients with and without Cirrhosis in a US Population**
Lin, D., Nguyen, N. H., Hoang, J., Vu, V. D., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, H. A., Khanh Nguyen, Nguyen, M. H.
WILEY-BLACKWELL.2014: 988A
- **Long-term Follow-up and Treatment Rates of Treatment-Eligible Chronic Hepatitis B (CHB) Patients: A Multicenter Cohort Study**
Vu, V. D., Do, A., Nguyen, N. H., Kim, L. H., Trinh, H. N., Nguyen, H. A., Nguyen, K., Nguyen, M. H.
WILEY-BLACKWELL.2014: 1125A–1126A
- **Entecavir Safety and Effectiveness in a National Cohort of Chronic Hepatitis B Patients in the United States - the ENUMERATE study**
Ahn, J., Lee, H., Lim, J. K., Pan, C. Q., Nguyen, M. H., Kim, W., Trinh, H. N., Tran, T. T., Chu, D., Min, A., Do, S. T., Woog, J., Mannalithara, et al
WILEY-BLACKWELL.2014: 1100A
- **Incidence of Hepatocellular Carcinoma in a National Cohort of Chronic Hepatitis B Patients on Long Term Entecavir Treatment- the ENUMERATE study**
Ahn, J., Lim, J. K., Lee, H., Pan, C. Q., Nguyen, M. H., Trinh, H. N., Tran, T. T., Chu, D., Min, A., Do, S. T., Woog, J., Mannalithara, A., Lok, et al
WILEY-BLACKWELL.2014: 1099A
- **Poor Sustained Virologic Response (SVR) in a Multicenter Real-Life Cohort of Chronic Hepatitis C (CHC) Patients Treated with Pegylated Interferon (PEG IFN) and Ribavirin (RBV) plus Telaprevir (TVR) or Boceprevir (BOC)**
Vo, K. P., Vutien, P., Akiyama, M. J., Vu, V. D., Piotrowski, J. I., Ha, N. B., Wantuck, J. M., Roytman, M., Cheung, R., Li, J., Tsai, N., Nguyen, M. H.
WILEY-BLACKWELL.2014: 673A–674A
- **Higher sustained virologic response (SVR) in patients with early virologic response (EVR) and hepatitis C genotype 4 (HCV-4) compared to genotype 1 (HCV-1) with pegylated interferon and ribavirin (PEG IFN plus RBV): a comparative analysis from a meta-analysis**
Yee, B. E., Lin, D., Nguyen, N. H., Zhang, B., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H.
WILEY-BLACKWELL.2014: 686A
- **Meta-analysis: Predictors for response-guided therapy (RGT) in hepatitis C genotype 4 (HCV-4) patients treated with pegylated interferon and ribavirin (PEG IFN plus RBV)**
Yee, B. E., Nguyen, N. H., Zhang, B., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H.
WILEY-BLACKWELL.2014: 690A
- **Treatment of Acute Hepatitis C (HCV) Infection with Pegylated Interferon and Ribavirin (P/R) in Patients Co-infected with Human Immunodeficiency Virus (HIV): a systematic review and meta-analysis**
Zhang, B., Yip, B., Nguyen, N. H., Yee, B. E., Ayoub, W. S., Nguyen, M. H., Lutchman, G. A.
WILEY-BLACKWELL.2014: 706A
- **High Rates of Comorbidities and Polypharmacy in Patients with Chronic Hepatitis C (CHC) in a Real-World Setting: a Consequence of an Aging Population**
Vutien, P., Brooks, L., Livornese, R. C., Nguyen, M. H.
WILEY-BLACKWELL.2014: 910A–911A
- **Higher rates of hepatitis B surface antigen (HBsAg) seroclearance among males and non-Asian patients with chronic hepatitis B (CHB) in a large, multi-center US cohort study**

- Nguyen, L. H., Wang, C., Vu, V. D., Trinh, H. N., Li, J., Zhang, J. Q., Nguyen, M. H.
WILEY-BLACKWELL.2014: 1005A–1006A
- **Similar Renal Function Profile in Chronic Hepatitis B (CHB) Patients Treated with Tenofovir (TDF) vs. Entecavir (ETV) Monotherapy - A Multicenter Matched Case Cohort Study**
Ha, N. B., Ku, K., Ha, N. B., Chaung, K. T., Trinh, H. N., Nguyen, M. H.
WILEY-BLACKWELL.2014: 1124A
 - **Safety and Effectiveness of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) or Ribavirin (RBV) for the Treatment of Hepatitis C Virus (HCV) Recurrence after Liver Transplant (LT)**
Lutchman, G. A., Nguyen, N. H., Hsiao, T. I., Vu, V. D., Chen, V., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Kim, W., Nguyen, M. H.
WILEY-BLACKWELL.2014: 670A
 - **Management of Chronic hepatitis C among Asian Americans.** *North Am J Med Sci.*
Yip, B., Nguyen, L. H., Nguyen, M. H.
2014; 7: 38-45
 - **Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Na < ve Chronic Hepatitis B Patients: A Case-Control Study** *DIGESTIVE DISEASES AND SCIENCES*
Ha, N. B., Ha, N. B., Chaung, K. T., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Nguyen, M. H.
2014; 59 (1): 168-173
 - **Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Wantuck, J. M., Ahmed, A., Nguyen, M. H.
2014; 39 (2): 137-147
 - **Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma** *DIGESTIVE DISEASES AND SCIENCES*
Yip, B., Wantuck, J. M., Kim, L. H., Wong, R. J., Ahmed, A., Garcia, G., Nguyen, M. H.
2014; 59 (1): 192-200
 - **Both HCV and HBV are Major Causes of Liver Cancer in Southeast Asians.** *Journal of immigrant and minority health*
Lin, H., Ha, N. B., Ahmed, A., Ayoub, W., Daugherty, T. J., Lutchman, G. A., Garcia, G., Nguyen, M. H.
2013; 15 (6): 1023-1029
 - **Chronic Hepatitis B Management Based on Standard Guidelines in Community Primary Care and Specialty Clinics** *DIGESTIVE DISEASES AND SCIENCES*
Ku, K. C., Li, J., Ha, N. B., Martin, M., Nguyen, V. G., Nguyen, M. H.
2013; 58 (12): 3626-3633
 - **Hepatocellular Carcinoma Incidence in Noncirrhotic Patients With Chronic Hepatitis B and Patients With Cirrhosis of All Etiologies.** *Journal of clinical gastroenterology*
Do, A. L., Wong, C. R., Nguyen, L. H., Nguyen, V. G., Trinh, H., Nguyen, M. H.
2013
 - **Less-established risk factors are common in asian americans with hepatitis C virus: a case-controlled study.** *Digestive diseases and sciences*
Kin, K. C., Lin, B., Chaung, K. T., Ha, N. B., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Nguyen, K. K., Levitt, B. S., Da Silveira, E. B., Nguyen, M. H.
2013; 58 (11): 3342-3347
 - **Prevention of mother-to-child transmission of hepatitis B virus: is elective cesarean section in highly viremic mothers an appropriate adjunct to immunoprophylaxis?** *Clinical gastroenterology and hepatology*
Nguyen, L. H., Nguyen, M. H.
2013; 11 (10): 1356-1357
 - **Treatment Tolerability and Persistency Rate in Chronic Hepatitis C (CHC) Patients Treated with Pegylated Interferon (PEG IFN) and Ribavirin (RBV) plus Telaprevir (TVR) versus Boceprevir (BOC)**
Vo, K., Akiyama, M., Ha, N., Vutien, P., Piotrowski, J., Wantuck, J., Roytman, M., Tsai, N., Cheung, R., Li, J., Nguyen, M.
NATURE PUBLISHING GROUP.2013: S155–S156

- **Changes in Hepatitis B (HBV) Vaccination Rates and Differences in Various General Demographics across National Health and Nutrition Examination Surveys (NHANES) from 1999-2010**
Devaki, P., Nguyen, L. H., Wong, R., Sinha, S., Marupakula, V., Nangia, S., Ditah, I. C., Ehrinpreis, M. N., Nguyen, M. H.
WILEY-BLACKWELL.2013: 607A–608A
- **Suboptimal Vaccination Rates for Hepatitis B Virus (HBV) among U. S. Adults at High Risk for HBV Infection in National Health and Nutrition Examination Survey (NHANES) from 2001-2010**
Devaki, P., Wong, R., Nguyen, L. H., Nangia, S., Sinha, S., Marupakula, V., Ditah, I. C., Ehrinpreis, M. N., Nguyen, M. H.
WILEY-BLACKWELL.2013: 611A–612A
- **Significant Fibrosis Among Patients with Chronic Hepatitis B Infection and Only Normal Serum Alanine Transaminase Levels: A Systematic Review and Meta-Analysis**
Chao, D. T., Ayoub, W., Lim, J. K., Nguyen, L. H., Nguyen, M. H.
WILEY-BLACKWELL.2013: 646A
- **Tenofovir (TDF) Monotherapy Rescue Therapy is Comparable to Tenofovir and Entecavir (ETV) Combination Rescue Therapy in ETV Partial Responders**
Lu, L., Nguyen, V. G., Trinh, H. N., Li, J., Nguyen, M. H.
WILEY-BLACKWELL.2013: 704A
- **Ethnic Disparity and Liver Transplantation (LT) Rates in Hepatocellular Carcinoma (HCC) Patients in the Recent Era (2009-2010): Results from the Surveillance, Epidemiology, and End Results (SEER) Cancer Registry**
Wong, R., Devaki, P., Nguyen, L. H., Cheung, R., Ahmed, A., Nguyen, M. H.
WILEY-BLACKWELL.2013: 1191A–1192A
- **Suboptimal Treatment Rates and Treatment Completion Rates of Chronic Hepatitis C Virus Therapy in Patients with Comorbidities: Analysis of a Large Real-World US Cohort**
Nguyen, M. H., Brooks, L., Livornese, R. C.
WILEY-BLACKWELL.2013: 1194A–1195A
- **Significantly Higher Long-Term Survival in Hepatocellular Carcinoma (HCC) Patients in the Post-MELD Era: A Population-Based Cohort Study**
Wong, R., Devaki, P., Nguyen, L. H., Cheung, R., Cho, C., Nguyen, M. H.
WILEY-BLACKWELL.2013: 1232A–1233A
- **High Prevalence of Hepatitis C Virus in Asian-Americans: Results of Office-Based Primary Care Screening**
Lin, O., Chang, C. Y., Lee, J. Y., Do, A., Martin, M. H., Martin, A. B., Nguyen, M. H.
WILEY-BLACKWELL.2013: 1308A
- **Prevalence, Risk Factors, and Disease Knowledge of Chronic Hepatitis B Infection in Vietnamese Americans in California** *JOURNAL OF CANCER EDUCATION*
Ha, N. B., Trinh, H. N., Nguyen, T. T., Leduc, T., Bui, C., Ha, N. B., Wong, C. R., Anh Thu Tran, A. T., Nguyen, M. H.
2013; 28 (2): 319-324
- **Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy.** *Clinical gastroenterology and hepatology*
Nguyen, N. H., Nguyen, V., Trinh, H. N., Lin, B., Nguyen, M. H.
2013; 11 (5): 565-571
- **Systematic review: Asian patients with chronic hepatitis C infection.** *Alimentary pharmacology & therapeutics*
Nguyen, L. H., Nguyen, M. H.
2013; 37 (10): 921-936
- **Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.** *Journal of gastroenterology and hepatology*
Lin, B., Ha, N. B., Liu, A., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Ahmed, A., Keeffe, E. B., Garcia, R. T., Garcia, G., Nguyen, M. H.
2013; 28 (5): 855-860
- **Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Ha, N. B., Ha, N. B., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Nguyen, M. H.
2013; 47 (5): 461-465

- **High Proportion of Hepatitis C Virus in Community Asian American Patients With Non-Liver-related Complaints** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Kin, K. C., Lin, B., Ha, N. B., Chung, K. T., Trinh, H. N., Garcia, R. T., Nguyen, K. K., Nguyen, H. A., Da Silveira, E. B., Levitt, B. S., Nguyen, M. H.
2013; 47 (4): 367-371
- **A COMPARISON OF PRIMARY SURGICAL RESECTION TO LIVER TRANSPLANTATION (LT) AMONG TRANSPLANT-ELIGIBLE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS USING AN INTENTION-TO-TREAT MODEL**
Wong, R. J., Wantuck, J., Valenzuela, A., Ahmed, A., Bonham, C., Gallo, A., Melcher, M., Lutchman, G., Concepcion, W., Esquivel, C., Garcia, G., Daugherty, T., Nguyen, et al
ELSEVIER SCIENCE BV.2013: S117
- **LOW TREATMENT RATES AND SUBOPTIMAL TREATMENT COMPLETION RATES TO HEPATITIS C VIRUS (HCV) THERAPY: A REAL-WORLD ANALYSIS OF A LARGE US COHORT**
Brooks, L. H., Schwebke, K., Livornese, R., Van Caster, K., Nguyen, M. H.
ELSEVIER SCIENCE BV.2013: S363
- **Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice** *EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY*
Liu, A., Ha, N. B., Lin, B., Yip, B., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Ahmed, A., Garcia, G., Nguyen, M. H.
2013; 25 (3): 338-343
- **Precore and basal core promoter mutations in Asian American patients with hepatitis B e antigen-positive chronic hepatitis B** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
VuTien, P., Trinh, H. N., Nguyen, K., Garcia, R. T., Nguyen, H. A., Levitt, B. S., Nguyen, L., Ha, N. B., Ahmed, A., Daugherty, T., Garcia, G., Nguyen, M. H.
2013; 37 (4): 464-472
- **Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Mair, R. D., Valenzuela, A., Ha, N. B., Ayoub, W. S., Daugherty, T., Lutchman, G. A., Garcia, G., Ahmed, A., Nguyen, M. H.
2012; 10 (12): 1412-1417
- **High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Chung, K. T., Ha, N. B., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Nguyen, K. K., Garcia, G., Ahmed, A., Keeffe, E. B., Nguyen, M. H.
2012; 46 (10): 865-870
- **Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders** *DIGESTIVE DISEASES AND SCIENCES*
Yip, B., Chung, K., Wong, C. R., Trinh, H. N., Nguyen, H. A., Ahmed, A., Cheung, R., Nguyen, M. H.
2012; 57 (11): 3011-3016
- **Hepatocellular Carcinoma (HCC) Caused by Non-Viral Etiologies Is Associated with Higher Stage at Presentation**
Wantuck, J., Ha, N., Ahmed, A., Mindie Nguyen
NATURE PUBLISHING GROUP.2012: S189-S190
- **Clinical Characteristics and Treatment in Asian and Non-Asians with Hepatocellular Carcinoma (HCC)**
Wantuck, J. M., Ha, N. B., Ahmed, A., Yip, B., Nguyen, M. H.
WILEY-BLACKWELL.2012: 465A
- **Maintenance of Complete Viral Suppression (CVS) with Tenofovir (TDF) Monotherapy Following CVS with Entecavir (ETV) plus TDF Combination in Patients with Prior ETV Partial Response**
Chung, K., Ha, N., Kin, K., Huy Trinh, Huy Nguyen, Mindie Nguyen
NATURE PUBLISHING GROUP.2012: S187
- **Treatment Tolerability in Chronic Hepatitis C (CHC) Patients Treated with Pegylated Interferon (PEG IFN) and Ribavirin (RBV) Plus Telaprevir (TVR) versus Boceprevir (BOC)**
Ha, N., Vo, K., Wantuck, J., Ahmed, A., Mindie Nguyen
NATURE PUBLISHING GROUP.2012: S183-S184
- **Undertreatment of Asian Chronic Hepatitis B Patients on the Basis of Standard Guidelines: A Community-Based Study** *DIGESTIVE DISEASES AND SCIENCES*

- Zhang, S., Ristau, J. T., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Nguyen, M. H.
2012; 57 (5): 1373-1383
- **Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study** *CANCER CAUSES & CONTROL*
Ha, N. B., Ha, N. B., Ahmed, A., Ayoub, W., Daugherty, T. J., Chang, E. T., Lutchman, G. A., Garcia, G., Cooper, A. D., Keeffe, E. B., Nguyen, M. H.
2012; 23 (3): 455-462
 - **Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients** *JOURNAL OF VIRAL HEPATITIS*
Ho, E. Y., Ha, N. B., Ahmed, A., Ayoub, W., Daugherty, T., Garcia, G., Cooper, A., Keeffe, E. B., Nguyen, M. H.
2012; 19 (2): E105-E111
 - **Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection** *Hepatology*
Nguyen LH, Nguyen MH
2012; 55: 1640
 - **High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Wong, C. R., Trinh, H. N., Yip, B., Nguyen, H. A., Garcia, R. T., Ahmed, A., Keeffe, E. B., Nguyen, M. H.
2011; 45 (10): 900-905
 - **The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adefovir** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
SHEEN, E., Trinh, H. N., Nguyen, T. T., Do, S. T., Tran, P., Nguyen, H. A., Nguyen, K. K., Garcia, R. T., Nguyen, M. H.
2011; 34 (7): 767-774
 - **Adefovir (ADV) Partial Response in Patients with Chronic Hepatitis B (CHB): Switch Versus Add-On Therapy** *76th Annual Scientific Meeting of the American-College-of-Gastroenterology*
Yip, B., Huy Trinh, H., Khanh Nguyen, K., Huy Nguyen, H., Garcia, R., Keeffe, E., Ahmed, A., Mindie Nguyen, M.
NATURE PUBLISHING GROUP.2011: S108-S108
 - **Risk Factors for Hepatitis C Virus (HCV) Infection in Asian American Patients: A Case-Control Study** *76th Annual Scientific Meeting of the American-College-of-Gastroenterology*
Kin, K., Lin, B., Chaung, K., Nghiem Ha, N., Huy Trinh, H., Garcia, R., Huy Nguyen, H., Khanh Nguyen, K., Levitt, B., da Silveira, E., Mindie Nguyen, M.
NATURE PUBLISHING GROUP.2011: S104-S104
 - **Efficacy and Tolerability of Entecavir (ETV) after Liver Transplantation (LT) for Chronic Hepatitis B (CHB)**
Kin, K., Nghiem Ha, Ayoub, W., Daugherty, T., Keeffe, E., Mindie Nguyen, Ajjaz, A.
NATURE PUBLISHING GROUP.2011: S107-S108
 - **Incidence and Predictors of Recurrent Hepatocellular Carcinoma (HCC) Following Partial Hepatectomy** *76th Annual Scientific Meeting of the American-College-of-Gastroenterology*
Vergara, A. M., Gallo, A., Nghiem Ha, N., Bonham, C., Esquivel, C., Concepcion, W., Melcher, M., Daugherty, T., Ayoub, W., Lutchman, G., Ahmed, A., Mindie Nguyen, M.
NATURE PUBLISHING GROUP.2011: S103-S104
 - **Systematic review: epidemiology of hepatitis C genotype 6 and its management** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Chao, D. T., Abe, K., Nguyen, M. H.
2011; 34 (3): 286-296
 - **Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B** *DIGESTIVE DISEASES AND SCIENCES*
Ha, N. B., Ha, N. B., Garcia, R. T., Trinh, H. N., Chaung, K. T., Nguyen, H. A., Nguyen, K. K., Levitt, B. S., Nguyen, M. H.
2011; 56 (8): 2423-2431
 - **Ethnic Differences in Viral Dominance Patterns in Patients with Hepatitis B Virus and Hepatitis C Virus Dual Infection** *HEPATOLOGY*
Nguyen, L. H., Ko, S., Wong, S. S., Tran, P. S., Trinh, H. N., Garcia, R. T., Ahmed, A., Lutchman, G. A., Keeffe, E. B., Nguyen, M. H.
2011; 53 (6): 1839-1845
 - **The Importance of the Definition of Early Virological Response for Predicting Treatment Efficacy for Chronic Hepatitis C**
Reply *HEPATOLOGY*

- Nguyen, M., Lam, K.
2011; 53 (4): 1403
- **Relationship between HBsAg seroconversion and hepatocellular carcinoma** *J Clin Gastroenterol*
Lutchman G, Nguyen MH
2011; 45: 64-68
 - **Screening for Hepatocellular Carcinoma After HBsAg Clearance Age Before Cirrhosis?** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Lutchman, G. A., Nguyen, M. A.
2011; 45 (1): 4-5
 - **Early virologic response in HCV genotype 6** *Hepatology*
Lam KD, Nguyen MH
2011; 53: 1403
 - **The role of steatosis in HBV infection** *Curr Hepat Rep*
Lim JK, Nguyen MH
2011; 10: 134-141
 - **Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery** *ANTIVIRAL RESEARCH*
Rhee, S., Margeridon-Thermet, S., Nguyen, M. H., Liu, T. F., Kagan, R. M., Beggel, B., Verheyen, J., Kaiser, R., Shafer, R. W.
2010; 88 (3): 269-275
 - **Randomized Controlled Trial of Pegylated Interferon-Alfa 2a and Ribavirin in Treatment-Naive Chronic Hepatitis C Genotype 6** *HEPATOLOGY*
Lam, K. D., Trinh, H. N., Do, S. T., Nguyen, T. T., Garcia, R. T., Nguyen, T., Phan, Q. Q., Nguyen, H. A., Nguyen, K. K., Nguyen, L. H., Nguyen, M. H.
2010; 52 (5): 1573-1580
 - **Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6** *JOURNAL OF VIRAL HEPATITIS*
Nguyen, N. H., VuTien, P., Garcia, R. T., Trinh, H., Nguyen, H., Nguyen, K., Levitt, B., Nguyen, M. H.
2010; 17 (10): 691-697
 - **RESPONSE TO HIGHER DOSE OF ENTECAVIR (ETV) 1.0 MG DAILY IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND PARTIAL RESPONSE TO ETV 0.5 MG DAILY**
Ha, N. B., Trinh, H. N., Ha, N. B., Nguyen, H. A., Nguyen, K., Nguyen, M. H.
WILEY-BLACKWELL.2010: 535A
 - **Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans** *HEPATOLOGY INTERNATIONAL*
Nguyen, N. H., Vutien, P., Trinh, H. N., Garcia, R. T., Nguyen, L. H., Nguyen, H. A., Nguyen, K. K., Nguyen, M. H.
2010; 4 (2): 523-529
 - **Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Vutien, P., Nguyen, N. H., Trinh, H. N., Li, J., Garcia, R. T., Garcia, G., Nguyen, K. K., Nguyen, H. A., Levitt, B. S., Keeffe, E. B., Nguyen, M. H.
2010; 105 (5): 1110-1115
 - **Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels** *Curr Hepat Rep*
Lim JK, Ayoub WS, Nguyen MH
2010; 9: 65-74
 - **Hepatitis B virus reverse transcriptase mutation search engine for queries (HBVseq): an online database and program for sequence analysis and mutation discovery**
Rhee, S. Y., Margeridon-Thermet, S., Liu, T. F., Nguyen, M. H., Kagan, R. M., Shafer, R. W.
INT MEDICAL PRESS LTD.2010: A107
 - **Adherence to Screening for Hepatocellular Carcinoma Among Patients with Cirrhosis or Chronic Hepatitis B in a Community Setting** *DIGESTIVE DISEASES AND SCIENCES*
Wong, C. R., Garcia, R. T., Trinh, H. N., Lam, K. D., Ha, N. B., Nguyen, H. A., Nguyen, K. K., Levitt, B. S., Nguyen, M. H.
2009; 54 (12): 2712-2721

- **Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Nguyen, M. H., Garcia, R. T., Trinh, H. N., Nguyen, H. A., Nguyen, K. K., Nguyen, L. H., Levitt, B.
2009; 30 (11-12): 1150-1158
- **Combination of pharmacologic and endoscopic therapy for the secondary prevention of esophageal variceal bleeding** *GASTROINTESTINAL ENDOSCOPY*
Ayoub, W. S., Nguyen, M. H.
2009; 70 (4): 665-667
- **ALPHA-FETOPROTEIN AND DES-GAMMA CARBOXYPROTHROMBIN ARE INDEPENDENT PREDICTORS OF EARLY STAGE HEPATOCELLULAR CARCINOMA**
Marrero, J., Schwartz, M. E., Nguyen, M. H., Befeler, A., Reddy, K., Roberts, L. R., Harnois, D. M., Wang, Y., Wagner, P., Feng, Z.
JOHN WILEY & SONS INC.2009: 1091A–1092A
- **Histological Disease in Asian-Americans With Chronic Hepatitis B, High Hepatitis B Virus DNA, and Normal Alanine Aminotransferase Levels** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Nguyen, M. H., Garcia, R. T., Trinh, H. N., Lam, K. D., Weiss, G., Nguyen, H. A., Nguyen, K. K., Keeffe, E. B.
2009; 104 (9): 2206-2213
- **Renal Dysfunction in Chronic Hepatitis B Patients Treated with Adefovir Dipivoxil** *HEPATOLOGY*
Ha, N. B., Ha, N. B., Garcia, R. T., Trinh, H. N., Vu, A. A., Nguyen, H. A., Nguyen, K. K., Levitt, B. S., Nguyen, M. H.
2009; 50 (3): 727-734
- **Prevalence of hepatitis B virus genotype B in Vietnamese patients with chronic hepatitis B** *HEPATOLOGY INTERNATIONAL*
Nguyen, L. H., Ha, N. B., Vutien, P., Ha, N. B., Garcia, R. T., Trinh, H. N., Levitt, B. S., Nguyen, H. A., Nguyen, K. K., Keeffe, E. B., Nguyen, M. H.
2009; 3 (3): 461-467
- **alpha-Fetoprotein, Des-gamma Carboxyprothrombin, and Lectin-Bound alpha-Fetoprotein in Early Hepatocellular Carcinoma** *GASTROENTEROLOGY*
Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., Reddy, K. R., Harnois, D., Llovet, J. M., Normolle, D., Dalhgren, J., Chia, D., Lok, et al
2009; 137 (1): 110-118
- **Clinical course of hepatitis B virus infection during pregnancy** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Nguyen, G., Garcia, R. T., Nguyen, N., Trinh, H., Keeffe, E. B., Nguyen, M. H.
2009; 29 (7): 755-764
- **Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides** *JOURNAL OF VIRAL HEPATITIS*
Nguyen, M. H., Keeffe, E. B.
2009; 16 (3): 149-155
- **Hepatitis C virus and cancers: How strong are the relationships?** *Curr Hepat Rep*
Lutchman G, Nguyen MH
2009; 8: 141-147
- **Prevalence of Colorectal Neoplasms in Asian Americans** *DIGESTIVE DISEASES AND SCIENCES*
Lam, K. D., Garcia, R. T., Nguyen, L. H., Trinh, H., Triadafilopoulos, G., Phan, J. T., Nguyen, K., Nguyen, H., Ahmed, A., Nguyen, M. H.
2009; 54 (1): 160-167
- **Are Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B and HBeAg-Negative Chronic Hepatitis B Distinct Diseases?** *CLINICAL INFECTIOUS DISEASES*
Nguyen, M. H., Keeffe, E. B.
2008; 47 (10): 1312-1314
- **Long-term outcome of chronic hepatitis B patients initially treated with adefovir dipivoxil in a community practice**
Ha, N., Ha, N., Garcia, R., Trinh, H., Nguyen, H., Nguyen, K., Levitt, B., Nguyen, N., Nguyen, M.
NATURE PUBLISHING GROUP.2008: S151–S152
- **Risk factors (Rfs), novel genotypes, and treatment outcomes in Southeast Asians (Seas) with chronic hepatitis C**
Nguyen, N., Vutien, P., Trinh, H., Garcia, R., Nguyen, L., Nguyen, H., Nguyen, K., Levitt, B., Ha, N., Nguyen, M.

NATURE PUBLISHING GROUP.2008: S150

- **Low proportion of Barrett's esophagus in Asian Americans** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Lam, K. D., Phan, J. T., Garcia, R. T., Trinh, H., Nguyen, H., Nguyen, K., Triadafilopoulos, G., Vutien, P., Nguyen, L., Nguyen, M. H.
2008; 103 (7): 1625-1630
- **Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Nguyen, M. H., Trinh, H. N., Garcia, R., Nguyen, G., Lam, K. D., Keeffe, E. B.
2008; 103 (5): 1131-1135
- **Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Tsang, P. S., Trinh, H., Garcia, R. T., Phan, J. T., Ha, N. B., Nguyen, H., Nguyen, K., Keeffe, E. B., Nguyen, M. H.
2008; 6 (5): 569-574
- **Phase 2 validation of AFP, DCP and AFP-L3 in early stage hepatocellular carcinoma**
Marrero, J. A., Llovet, J. M., Nguyen, M., Befeler, A., Roberts, L. R., Reddy, R. R., Harnois, D., Normolle, D., Hui, Y., Dalhgren, J., Chia, D., Lok, A. S., Wagner, et al
IOS PRESS.2008: 183
- **High prevalence of significant histologic disease in patients with chronic hepatitis B (CHB) and normal ALT**
Nguyen, M. H., Trinh, H. N., Garcia, R. T., Phan, J., Nguyen, G. H., Weiss, G., Nguyen, H., Nguyen, K., Keeffe, E. B.
JOHN WILEY & SONS INC.2007: 680A
- **Very high prevalence of precore (preC) and/or basal core promoter (BCP) mutations (MUT) in HBeAg-positive (eAg plus) and negative (eAg-) chronic hepatitis B (CHB) especially among older patients**
Nguyen, M. H., Trinh, H. N., Garcia, R. T., Phan, J., Nguyen, G. H., Nguyen, K., Nguyen, H., Keeffe, E. B.
JOHN WILEY & SONS INC.2007: 674A
- **Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Ha, B. Y., Ahmed, A., Sze, D. Y., Razavi, M. K., Simpson, N., Keeffe, E. B., Nguyen, M. H.
2007; 26 (6): 839-846
- **Life-threatening hepatic failure associated with entecavir resistance mutations 1269I/T and T184L two years after discontinuation of lamivudine**
Morgan, M. E., Ayoub, W., Ahmed, A., Keeffe, E. B., Nguyen, M. H.
BLACKWELL PUBLISHING.2007: S322-S323
- **Chronic HBV infection and normal ALT levels: Underlying histological disease** *Curr Hepat Rep*
Hoda K, Nguyen MH
2007; 6: 24-29
- **Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.** *Clinical gastroenterology and hepatology*
Nguyen, M. H., Keeffe, E. B.
2005; 3 (10): S97-S101
- **Chronic hepatitis C: genotypes 4 to 9.** *Clinics in liver disease*
Nguyen, M. H., Keeffe, E. B.
2005; 9 (3): 411-?
- **The diagnosis and management of benign hepatic tumors** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Choi, B. Y., Nguyen, M. H.
2005; 39 (5): 401-412
- **General management** *BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY*
Nguyen, M. H., Keeffe, E. B.
2005; 19 (1): 161-174
- **Benign tumors and evaluation of liver masses** *In: Al Knawy B, Schiffman ML, and Wiesner R, eds. Hepatology: A Practical Approach, 1st ed. Amsterdam: Elsevier Science BV.*

Nguyen MH, Keeffe EB
2005

- **Lead poisoning as an etiology of abdominal pain and intestinal pseudo-obstruction in adults** *69th Annual Meeting of the American-College-of-Gastroenterology*
Tran, C. P., Garcia, R. T., Lam, V. T., Trong, T. H., Keeffe, E. B., Nguyen, M. H.
NATURE PUBLISHING GROUP.2004: S105–S105
- **Role of Ethnicity in Risk for Hepatocellular Carcinoma in Patients With Chronic Hepatitis C and Cirrhosis** *CLINICAL GASTROENTEROLOGY AND HEPATOLOGY*
Nguyen, M. H., Whittemore, A. S., Garcia, R. T., Tawfeek, S. A., Ning, J., Lam, S., Wright, T. L., Keeffe, E. B.
2004; 2 (9): 820-824
- **Use of endoclips in the treatment of massive colonic diverticular bleeding** *GASTROINTESTINAL ENDOSCOPY*
Simpson, P. W., Nguyen, M. H., Lim, J. K., Soetikno, R. M.
2004; 59 (3): 433-437
- **Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9.** *Reviews in gastroenterological disorders*
Nguyen, M. H., Keeffe, E. B.
2004; 4: S14-21
- **Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: A multicenter randomized trial** *GASTROENTEROLOGY*
Garcia, R. T., Cello, J. P., Nguyen, M. H., Rogers, S. J., Rodas, A., Trinh, H. N., Stollman, N. H., Schlueck, G., McQuaid, K. R.
2003; 125 (6): 1606-1612
- **Prophylactic clip application** *GASTROINTESTINAL ENDOSCOPY*
Nguyen, M. H., Soetikno, R.
2003; 58 (6): 941-941
- **Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine** *JOURNAL OF CLINICAL GASTROENTEROLOGY*
Simpson, N. D., Simpson, P. W., Ahmed, A. M., Nguyen, M. H., Garcia, G., Keeffe, E. B., Ahmed, A.
2003; 37 (1): 68-71
- **Chronic hepatitis B and hepatitis C in Asian Americans.** *Reviews in gastroenterological disorders*
Nguyen, M. H., Keeffe, E. B.
2003; 3 (3): 125-134
- **Treatment of Hepatocellular Carcinoma** *Rustgi AK and Crawford J, eds. Gastrointestinal Cancer: A companion to Sleisenger & Fordtran's GI and liver diseases. Philadelphia: WB Saunders*
Nguyen MH, Keeffe EB
2003; 1st ed: 605-622
- **Screening for hepatocellular carcinoma** *Yale-University Workshop on Hepatocellular Carcinoma*
Nguyen, M. H., Keeffe, E. B.
LIPPINCOTT WILLIAMS & WILKINS.2002: S86–S91
- **Unsedated ultrathin EGD is well accepted by most patients: A randomized trial of unsedated ultrathin EGD (UT-EGD) vs. sedated conventional EGD (C-EGD)**
Garcia, R. T., Cello, J. P., Rogers, S. J., Rodas, A., Nguyen, M. H., Trinh, H., Stollman, N. H., McQuaid, K. R.
NATURE PUBLISHING GROUP.2002: S306–S306
- **Does isoniazid cause more serious hepatotoxicity in hepatitis B virus carriers?** *AMERICAN JOURNAL OF GASTROENTEROLOGY*
Nguyen, M. H., Garcia, G.
2002; 97 (5): 1092-1093
- **Therapeutic advances in the management of hepatitis B and hepatitis C** *CURRENT OPINION IN INFECTIOUS DISEASES*
Nguyen, M. H., Wright, T. L.
2001; 14 (5): 593-601

- **Sensitivity and specificity of alpha-fetoprotein (AFP) in US patients with hepatitis C virus-related hepatocellular carcinoma (HCV/HCC).**
Nguyen, M. H., Keeffe, E. B., Wright, T. L.
W B SAUNDERS CO.2001: 663A
- **DIFFERENTIAL MIGRATION OF ASTROCYTES GRAFTED INTO THE DEVELOPING RAT-BRAIN *GLIA***
Hatton, J. D., Nguyen, M. H., U, H. S.
1993; 9 (2): 113-119

PRESENTATIONS

- HBV Diagnosis Challenges and Prevention Gaps: The AASLD Perspective - Latin American Association for the Study of the Liver (11/1/2021)
- HBV Novel Therapies - International Association for the Study of Liver Disease (7/1/2021)
- HCC Surveillance and Diagnosis, 2021 Update - Korean Liver Cancer Association/International Association for the Study of the Liver (7/2021)
- HBV Reactivation - International Association for the Study the Liver; Egyptian Association for Research and Training in Hepato-Gastroenterology (6/2021)
- Landscape of HCC epidemiology in Asia - Singapore Hepatology Conference, Prof. SG Lim, National Singapore University. (6/2021)
- Strategies to minimize the consequences of late diagnosis: HBV. Health Systems Research Session – Health system, burden of care - Seizing Opportunities: Prevention of Late Diagnosis - Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CanHepC), the Canadian Association of Hepatology Nurses (CAHN) and the American Association for the Study of Liver Diseases (AASLD), Virtual.
- Antiviral therapy and risk of hepatocellular carcinoma in chronic hepatitis B - The Annual Congress of Gastroenterological Society of Taiwan (GEST); the Digestive Endoscopic Society of Taiwan (DEST) (3/2021)
- Annual Meeting of the Chinese Alliance for the Study of Liver Diseases - Annual Meeting of the Chinese Alliance for the Study of Liver Diseases (12/2020)
- "Editor's Choice", Best Publications in "Hepatology" - APASL-AASLD Webinar (12/2020)
- Nonviral Liver cancer - International Association of the Study of Liver Disease (IASL)/Taiwan Liver Research Foundation (TLRF) (August 6, 2022)
- HCV Care after SVR - Gastroenterological Society of Singapore (7/16/2022)